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General introduction and outline 11
1.1 GENEral iNTroduCTioN
Cardiovascular disease (CVD) is the leading cause of death and illness in the Western 
world. In the Netherlands one out of four people dies from CVD (1) that includes myo-
cardial infarction, congestive heart failure, stroke and peripheral artery disease. The 
major underlying pathogenic process of CVD is atherosclerosis, a progressive disease 
characterized by the accumulation of immune cells, lipids and fibrous elements in the 
large arteries (2,3). Advances in research suggest that the initiation and continuation 
of atherosclerotic diseases includes oxidative stress, endothelial dysfunction, inflamma-
tory processes and vascular remodeling (4). 
The increasing burden of CVD is in part driven by obesity. Obesity is defined as a body 
mass index [BMI; calculated as a person’s bodyweight in kilograms divided by the square 
of his height in meters (kg/m2)] as a BMI over 30. Worldwide the prevalence of obesity 
has more than doubled since 1980 and nowadays obesity-related mortality exceeds that 
caused by underweight (5). In the Netherlands half of the adults are overweight (6), 
which is defined as a BMI between 25 and 30. Large epidemiological studies show that 
the risk of coronary heart disease, ischemic stroke and type 2 diabetes mellitus increase 
steadily with an increasing body mass index (7). Especially the increase in visceral obesity 
as reflected by an increase in waist circumference seems to add to the cardiovascular risk 
(8,9) and correlates directly with metabolic dysfunction in epidemiological studies (10).
CVd in obesity
The mechanisms underlying CVD in obesity are complex and related to inflammation, 
insulin resistance, dyslipidemia, and hypertension which are closely interconnected. 
The clustering of these phenomena is called the metabolic syndrome. Despite the 
continuing debate regarding metabolic syndrome as a distinct disorder, it is a widely 
used term, as the clustering of abnormalities seems helpful in predicting CVD risk. The 
definition of the metabolic syndrome according to the International Diabetes Federa-
tion (IDF) criteria (11) includes two or more of the following criteria present in addition 
to increased abdominal obesity (waist circumference in males ≥ 94 cm, females ≥ 80 
cm): hypertriglyceridemia (triglycerides (TG) ≥ 1.7 mmol/l or the use of lipid lowering 
medication); low levels of HDL-cholesterol (< 1.03 mmol/l in males and < 1.29 mmol/l 
in females); hyperglycemia (fasting glucose ≥ 5.6 mmol/l) or elevated blood pressure 
(systolic/diastolic blood pressure ≥130/≥85 mmHg or the use of blood pressure lower-
ing medication). Prevalence of the metabolic syndrome ranges from 20 to 30% of the 
adult population in Europe and varies somewhat depending on the age, geographic 
location or population studies (12).
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Inflammation
Inflammation is considered a major pathogenic phenomenon in obesity related disor-
ders. Indeed, inflammation is tightly connected to other phenomena of the metabolic 
syndrome as it may contribute to the pathogenesis of insulin resistance and dyslip-
idemia on the one hand, and plays a role in the adverse effects of insulin resistance, 
hyperglycemia and dyslipidemia on the other hand (13).
Inflammation in vascular injury and atherosclerosis 
Atherosclerosis is a chronic inflammatory condition that involves infiltration and ac-
cumulation of cholesterol-rich atherogenic lipoproteins from the plasma into the intima 
of the vessel wall. This infiltration and accumulation of lipoproteins initiates a local 
inflammatory response (2,3) resulting in the activation of endothelial cells (14). In turn 
adhesion molecules such as vascular cell adhesion molecule (VCAM)-1, intercellular ad-
hesion molecule (ICAM)-1 and E selectin are expressed. Adhesion molecules mediate the 
binding of circulating leukocytes to endothelial cells and their subsequent migration 
into the blood vessel wall, which is an important step in the initiation of atherosclerotic 
lesions (15). As monocytes migrate into the intima they proliferate and differentiate into 
macrophages that take up modified (e.g. oxidized) lipoproteins forming foam cells (16). 
These fat laden immune cells in the vascular wall excrete cytokines and chemokines that 
attract and activate additional immune cells. 
Inflammation of adipose tissue and liver
In the metabolic syndrome, visceral adipose tissue is actively involved in inflammation. 
Lipid accumulation in adipocytes initiates a state of cellular stress and activation of the 
JNK(c-Jun N-terminal kinase) and IKKβ(IkB kinase beta)/NF-kB(nuclear factor kappa B) 
pathways. Macrophages are recruited and infiltrate the adipose tissue where they are 
the major source of several pro-inflammatory cytokines such as tumor necrosis factor 
(TNF)-α and interleukin (IL)-6 (17). Both JNK and IKKB/NF-kB activated pathways in 
adipocytes and macrophages play important roles in inflammation-induced insulin 
resistance through inhibition of the insulin receptor signaling.
Cytokines as TNF-α and IL-6 stimulate the production of inflammatory acute-phase 
proteins by the liver such as C-reactive protein (CRP), a marker of inflammation and 
predictor of cardiovascular events (18,19). Similarly plasminogen activator inhibitor-1 
(PAI-1) and fibrogen originate from hepatic tissue and are activators of the coagulation 
system, enhancing atherothrombosis (20-22).
In addition, the hepatocellular transcription factor NF-kB, is activated in liver by high-
fat diet, obesity and liver steatosis. NF-kB activation results in hepatic production of 
pro-inflammatory cytokines (IL-6, IL-1β and TNF-α as well as activation of Kupffer cells 
and macrophages) thereby contributing to a low grade  systemic inflammatory state 
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(23). NF-kB activation also results in hepatic and skeletal muscle insulin resistance. The 
concept that non-alcoholic fatty liver disease (NAFLD) may also drive the inflammatory 
cascade of atherosclerosis is now gaining acceptance (24). 
Furthermore an increasing number of studies emphasize the central role of macro-
phage infiltration and foam cell formation in the pathogenesis of NASH, similar to the 
pathogenesis of atherosclerosis (25). The liver is thus a generator as well as a target of 
inflammatory factors. Increasing severity of NAFLD represents worsening of inflamma-
tory and insulin resistant states with adverse cardiovascular outcomes. 
Systemic inflammation 
Countless epidemiologic studies have shown that low grade systemic inflammation, 
mostly reflected as elevated levels of CRP, is associated with metabolic syndrome, cor-
relates with subclinical markers of atherosclerosis (26,27) and predicts future cardiovas-
cular risk. This is generally attributed to the role of inflammation in plaque instability. 
Ridker et al. (28) were the first to report that elevated CRP levels predict future myocar-
dial infarction and stroke. Although experimental studies have demonstrated that CRP 
is able to induce the expression of adhesion molecules, to activate endothelial cells and 
the complement system, CRP is generally regarded as a marker of inflammation that 
reflects the inflammatory status of the body, rather than an inflammatory mediator (29). 
In this view, the release of IL-1ß, IL-6 and TNFα, can stimulate the liver to produce CRP.
An important role for the innate immune system in the underlying mechanisms of 
systemic inflammation is suggested. Free fatty acids (FFAs) activate pattern recognition 
receptors (PRR) such as Toll-like receptor 4 (TLR4) that is predominantly expressed on 
immune cells like macrophages but have also been found in adipocytes (30,31) that 
are associated with inflammation. PRR induces NF-kB and subsequently the secretion of 
pro-inflammatory cytokines. 
Angiopoietin-like protein 4 
Angiopoietin-like protein 4 (ANGPTL4) is a protein involved in a variety of functions 
including angiogenesis and energy metabolism. ANGPTL4 plays a role in plasma lipid 
metabolism by inhibiting the enzyme lipoprotein lipase (LPL). This results in suppression 
of the release of plasma TG-derived fatty acids and their subsequent uptake by tissues 
including adipose and skeletal muscle tissue. Recent studies suggest an additional role 
in inflammation. It was shown that the expression of ANGPTL4 is governed by the lipid-
sensing peroxisome proliferator-activated receptors (PPARs) and is in vitro stimulated 
by FFAs (32-38). Because FFAs also activate PRR such as TLR4 in adipocytes and mac-
rophages (39,40) it is likely that induction of inflammation (e.g. via TLR4 agonism) also 
increases ANGPTL4 expression.  
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ANGPTL4 as well as LPL are expressed at high levels in macrophages (41). Since 
foam cells are important in atherosclerosis (42) and given the facilitating role of LPL in 
macrophage foam cell formation (43,44), changes in ANGPTL4 expression may influence 
atherosclerosis development. 
Insulin resistance
Development of decreased insulin sensitivity or insulin resistance is prevalent in obesity 
and overweight. Insulin resistance is characterized by reduced responsiveness of tissues 
to the effect of insulin. Insulin resistance often goes unnoticed and can be present many 
years before ultimately type 2 diabetes mellitus is diagnosed. Although often unnoticed 
the presence of insulin resistance independently predicts diabetes, hypertension and 
CVD. A validated and frequently used marker of insulin resistance is the Homeostasis 
Model Assessment Insulin Resistance (HOMA-IR). HOMA-IR is a model for assessing beta-
cell function and incorporates both glucose and insulin concentrations and is calculated 
by the formula: (fasting insulin x fasting glucose)/22.5 or by the more recently updated 
computer model with normal insulin sensitivity defined as one (45). However no com-
parative data exist on the predictive effect of fasting plasma glucose levels, insulin levels 
and HOMA-IR on CVD. 
High levels of insulin may independently contribute to CVD by stimulating prolifera-
tion of smooth muscle cells (46,47). However studies showing that insulin treatment is 
associated with a reduction of CVD events provide strong evidence against a direct 
atherogenic effect of insulin per se (48,49). This may be related to suppressed synthesis 
of proinflammatory cytokines in endothelial cells via nitric oxide mediated mechanisms. 
This beneficial effect may be decreased in insulin resistance (50). Furthermore insulin 
itself has an important role in hemodynamic regulation by modulating vascular tone 
probably also mediated by nitric oxide. 
Insulin resistance may lead to hyperglycemia when pancreatic beta cells are no longer 
capable to compensate the increased hepatic glucose production and diminished up-
take of glucose in peripheral tissues. Hyperglycemia in the context of insulin resistance 
may be directly atherogenic because it increases oxidative stress, thereby impairing 
endothelial function, which is implicated as one of the first steps in atherosclerosis. 
Moreover, during the exposure to hyperglycemia advanced glycation end products 
(AGES) are formed, resulting from advanced glycation of proteins and lipids, which 
contribute to a variety of microvascular and macrovascular complications through the 
creation of cross-links of collagen and by engaging the receptor for AGES in the vascular 
wall (51,52). Insulin resistance and the associated hyperglycemia thus may alter the 
mechanical properties of the arterial wall and on the long term cause increased arterial 
stiffness. Howeverthe effects of glucose and insulin on the arterial wall on the short term 
are unclear.
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A third, possibly, most plausible way by which insulin resistance leads to CVD is via 
induction of dyslipidemia. 
Dyslipidemia
When insulin resistance develops as a result of obesity, enlarged adipocytes of visceral 
adipose tissue release FFAs in the circulation due to increased lipolysis. These FFAs are 
subsequently transported to the liver, which leads to increased hepatic TG-rich very low-
density lipoprotein (VLDL) production, one cause of the hypertriglyceridemia seen in 
insulin resistance. Besides the increased VLDL synthesis there is a decreased clearance of 
TG-rich lipoproteins in the circulation due to decreased lipoprotein lipase (LPL) activity. 
LPL is expressed by metabolic organs including the heart, skeletal muscle, white adipose 
tissue and brown adipose tissue. The enzyme is responsible for the hydrolysis of the TG 
from the core of VLDL into glycerol and fatty acids (53). Insulin is a potent stimulator of 
LPL but the responsiveness of LPL to insulin in obesity is diminished which is another 
cause of the hypertriglyceridemia found in insulin resistance. 
The depletion of TG from VLDL particles by LPL results in the formation of VLDL 
remnants that are partly cleared by the liver. The remaining particles undergo further 
lipolysis to form low-density lipoproteins (LDL). In addition, both VLDL and LDL undergo 
exchange of TG for cholesteryl esters derived from high-density lipoprotein (HDL), a 
process mediated by cholesteryl ester transfer protein (CETP). CETP thus plays a pivotal 
role in the metabolism of VLDL and HDL by mediating the heteroexchange of choles-
teryl esters in exchange for TG between HDL and (V)LDL. CETP activity is elevated in 
insulin resistance and thus further aggravates the dyslipidemia. The consequence of 
the action of CETP is the formation of small (dense) LDL particles and TG-enriched less 
stable HDL particles that are more rapidly catabolized by hepatic lipase, resulting in 
reduced HDL levels. HDL is generally believed to have anti-atherogenic properties due 
to its involvement in reverse cholesterol transport, its provision of antioxidant enzymes 
and its anti-inflammatory properties (21). Although liver and adipose tissue are the two 
major sources of circulating CETP in several mammalian species, the cellular origin of 
CETP is still uncertain. 
Intracellular lipolysis also limits the capacity of adipose tissue to store TG. As a result 
transportation of FFAs towards other tissues that normally do not store lipids results in 
ectopic fat accumulation. Ectopic fat is associated with the generation of toxic inter-
mediates of lipid oxygenation, mitochondrial dysfunction, activation of inflammatory 
pathways and may lead to cell death (54). Deposition of fat in the liver in the absence of 
alcohol intake or NAFLD aggravates hepatic insulin resistance due to decreased glucose 
uptake and decreased suppression of glucose production in the liver. NAFLD is the lead-
ing cause of chronic liver disease in the Western world and is present when there is 
evidence of hepatic steatosis either by imaging or by histology and there are no causes 
Nathanja Tjeerderma - binnenwerk v7b.indd   15 08-09-15   11:35
16 Chapter 1
for secondary hepatic fat accumulation (55). The estimated prevalence ranges from 30 
to more than 60% in the metabolic syndrome (56,57). NAFLD represents a spectrum 
of liver disease ranging from steatosis through non-alcoholic steatohepatitis (NASH), 
characterized by a combination of fat accumulation and hepatic inflammation, and 
even further to fibrosis and cirrhosis. Interestingly, recent studies link NAFLD to CVD. In 
several studies NAFLD was strongly associated with high risk for atherosclerosis regard-
less of classical cardiovascular risk factors (24,58). 
Hypertension
Besides insulin resistance, dyslipidemia and inflammation, overweight and obesity are 
often accompanied by high blood pressure. Hypertension is, in addition to aging, the 
major risk factor for CVD (59). Clinical studies have documented that weight gain can 
raise arterial pressure whereas weight loss has been shown successful in lowering blood 
pressure (60-62). Systematic reviews consistently report a decrease in systolic blood 
pressure of about 1 mmHg per kg weight loss (63). Elevated blood pressure is partly 
mediated through obesity-induced processes such as increased circulating plasma 
volume, activated rennin angiotensin system and increased sympathetic activity (64). 
The above described processes such as cross linking of collagen in insulin resistance and 
atherosclerotic plaque formation, lead to decreased arterial compliance and contribute 
to hypertension. In turn sustained high blood pressure itself gives continuous stress at 
the aortic wall which causes greater recruitment of inelastic collagen fibers and thereby 
a reduction in elasticity. In accordance studies show accelerated progression of arterial 
stiffness in (untreated) hypertension (65,66).
End organ damage 
Cardiovascular complications are late events in a pathogenic process starting with 
endothelial dysfunction, oxidative stress and manifest atherosclerotic lesions which 
progress to organ damage and eventually result in organ failure. As CVD takes years 
to develop this allows time to early intervention in the chain of events precipitated by 
several risk factors. Generally adverse effects on the vascular tree are classified into mac-
rovascular complications (coronary artery disease, peripheral arterial disease, stroke) 
and microvascular complications (nephropathy, neuropathy, retinopathy). A fifth of all 
cardiovascular events occur among individuals in whom traditional risk factors have 
not been identified (67,68). It is therefore important to search for asymptomatic organ 
damage before overt vascular complications develop. Biomarkers of end organ damage 
are characteristics that are objectively measured and evaluated as indicators of end 
organ damage. They may be either circulating substances, or characteristic alterations 
observed by imaging. Biomarkers may indicate underlying (subclinical) disease and/or 
predict future events beyond established major risk factors. 
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Arterial stiffness 
Arterial stiffness in general, and aortic stiffness in particular, have become established as 
important biomarkers for CVD (69) and end organ damage as renal dysfunction, retinal 
damage and brain white matter injury (70,71). Most of the above described factors in the 
metabolic syndrome and diabetes directly or indirectly influence vascular wall proper-
ties leading to decreased arterial compliance. 
Increased arterial stiffness has been found in the metabolic syndrome and diabetes 
and may be an important phenomenon linking obesity to increased cardiovascular 
risk. Large arteries play a key role in converting the pulsatile cardiac outflow produced 
during the ejection phase, into continuous blood flow throughout the arterial tree. By 
stretching the arterial wall, elastic energy accumulates that maintains the blood flow 
during diastole (Windkessel effect).
The damaging effect of high pulse pressure on kidney and brain is because cells de-
pends on their resilience and are not protected by vasoconstricted arteries upstream as 
in the systemic circulation (72). Stiffness of the aorta may contribute to end-organ injury 
of the brain and kidney by exposing the small vessels to high pressure fluctuations and 
flow in the circulation (73). In addition arterial stiffening from aging or hypertension 
varies along the arterial tree, with increased stiffening of the central elastic arteries com-
pared to more muscular distal arteries. Disproportional arterial stiffening may accelerate 
the transmission of excessive pulsatile energy toward the microcirculation. 
Brain
Most studies regarding the brain are performed in type 2 diabetes and associations 
with cognitive dysfunction and structural brain changes (e.g. global brain atrophy and 
small-vessel disease) have been shown (74). In the last decades it has become increas-
ingly clear that type 1 diabetes (T1DM) also affects the brain (75,76). Although adverse 
effects of diabetes on the brain have been reported as early as in the 1920’s, for long 
research has mainly focused on cognitive function. More recently the application of 
magnetic resonance imaging of the brain has provided evidence for volume loss and 
subtle brain damage in T1DM. The high prevalence of white matter lesions, silent in-
farctions, microbleeds and early brain atrophy in T1DM (77-80) are related to cognitive 
decline and dementia. Although loss of cortical tissue has been demonstrated, less is 
known about possible atrophy of the subcortical grey matter structures. Volume loss of 
the hippocampus and left thalamus were only observed in small studies (81-84) and no 
data exist on subcortical structures. In addition to regional distribution of brain atrophy, 
connectivity between multiple brain areas is of interest as this is an important aspect of 
brain function related to cognitive function.
In addition to abnormalities in glucose metabolism a proposed underlying mecha-
nism in the relationship between T1DM and the brain includes vascular disease. Arterial 
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stiffness in diabetes mellitus is increased and therefore it is an interesting marker with 
regard to brain injury as it reflects the cumulative influence of vascular risk factors with 
aging of the arterial wall.
Kidney 
Renal function can be defined by estimated glomerular filtration rate (eGFR). Decreased 
eGFR, proteinuria and microalbuminuria are important markers of progressive chronic 
kidney disease and CVD. Hypertension is often accompanied with deterioration in 
renal function. Damage to the kidney due to chronic high blood pressure results from 
nephrosclerosis (thickening of the wall and the narrowing of the lumina of small arteries 
and arterioles). The severity of hypertensive renal damage depends on the degree to 
which renal autoregulatory mechanisms fail to prevent the blood pressure elevations 
from being transmitted to the vascular bed as is seen in diabetes. 
Declined renal function in turn can lead to atherosclerosis and occurrence of vascular 
events via retention of sodium and water, increased levels of various atherogenic factors 
(enhanced oxidative stress and inflammation) and metabolic changes such as anaemia, 
hypocalcaemia, hypophosphatemia, hyperparathyroidism and vitamin D deficiency. 
Shared risk factors of declined renal function and hypertension including diabetes are 
often present. Both hypertension and chronic kidney disease can lead to arterial stiff-
ness, however limited data are available on aortic stiffness in hypertension with normal 
renal function.  
Mr assessment of end organ damage
Advances in imaging techniques have resulted in imaging modalities for assessment 
of atherosclerosis and end organ damage at early stages of disease. Aortic stiffness can 
be accurately assessed by means of pulse wave velocity (PWV), which is considered the 
gold standard marker for vascular stiffness (85). In contrast to Doppler ultrasound, MRI 
enables regional assessment of PWV in multiple locations in the aorta and therefore 
allows the measurement of site-specific changes. 
Furthermore MRI has been used to study the brain. Voxel based morphometry (VBM) 
is a novel and sophisticated analysis technique which allows testing for regional differ-
ences in grey and white matter density (86). Diffusion tensor imaging (DTI) is used for 
the measurement of structural connectivity (75). Based on difference in diffusivity, the 
integrity of white matter tracts can be assessed. White matter tracts provide connectiv-
ity between cortical areas and allow for communication between different brain regions. 
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1.2 ouTliNE of ThE ThEsis
The studies in this thesis focus on biomarkers of cardiovascular end organ damage in the 
metabolic syndrome and diabetes. 
The epidemic rise in overweight and obesity explains most of the increase in prevalence 
of type 2 diabetes thereby increasing the risk of CVD. Before diabetes is diagnosed, insu-
lin resistance can be present for many years. As no comparative data exist on the effect 
of different components of insulin-resistance on cardiovascular events we performed a 
systematic review in Chapter 2 and compared the associations of fasting glucose, fast-
ing insulin and HOMA-IR with incident cardiovascular disease in adults without diabetes. 
In Chapter 3, we investigated whether systemic inflammation is a determinant for 
plasma ANGPTL4 levels in patients with the metabolic syndrome and type 2 diabetes. 
To get more insight into the causal relationship between inflammation and ANGPTL4 
expression we also assessed the effect of inflammatory stimuli on ANGPTL4 expression 
in vitro. 
Aortic stiffness is a commonly used marker of vascular damage and can be assessed by 
means of pulse wave velocity (PWV). In Chapter 4 we assessed the short-term effects 
of an oral glucose load on PWV. As the effect of insulin on vascular tone may be region-
specific for various vascular beds and locations we developed an MRI protocol enabling 
regional assessment of the PWV in multiple locations or the aorta. 
In Chapter 5 we focused on the impact of type 1 diabetes mellitus on regional brain grey 
matter volume using voxel-based morphometry (VBM). Besides regional differences in 
brain volume, early detection of subtle deficits in microstructure by diffusion tensor 
imaging (DTI) (75) with MRI has become recently feasible. In Chapter 6, we assessed the 
possible association between aortic PWV and markers of microstructural brain damage 
i.e. brain white matter integrity in type 1 diabetes. 
In Chapter 7 we investigated the relation between aortic PWV and renal function in 
patients with hypertension. As arterial stiffening as well as impaired renal function often 
co-exist, it is not known whether increased PWV in patients with hypertension is directly 
related to high blood pressure or depends on co-existing renal dysfunction. Moreover 
no previous publications explored the possible relation with regional aortic stiffening. 
Therefore we assessed the relation between regional aortic PWV and  performed this 
study in hypertensive patients with renal function in the normal range and compared 
them with healthy controls. 
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In addition to these studies on biomarkers of end organ damage, Chapter 8 describes 
the result of an intervention study in a primary health care setting. Once subjects at 
high risk for cardiovascular disease are identified, adequate changes in lifestyle such as 
a more healthy diet, smoking prevention, increased physical activity and weight control 
can avoid over 75% of deaths (87). However changes in lifestyle are difficult to achieve 
and data on the large scale implementation in primary care are lacking. We therefore 
evaluated the feasibility and the effect of the implementation of a lifestyle intervention 
in subjects with the metabolic syndrome in a primary health care setting.
In Chapter 9 the results of the studies described in this thesis are summarized and 
discussed.
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Glucose, insulin and Homeostasis Model Assessment Insulin Resistance (HOMA-IR) are 
markers of insulin resistance. The objective of this study is to compare fasting glucose, 
fasting insulin concentrations and HOMA-IR in strength of association with incident 
cardiovascular disease.
Methods
We searched the PubMed, MEDLINE, EMBASE, Web of Science, ScienceDirect and Co-
chrane Library databases from inception to March, 2011 and screened reference lists. 
Cohort studies or nested case-control studies that investigated the association between 
fasting glucose, fasting insulin or HOMA-IR and incident cardiovascular disease, were 
eligible. Two investigators independently performed the article selection, data extrac-
tion and risk of bias assessment. Cardiovascular endpoints were coronary heart disease 
(CHD), stroke or combined cardiovascular disease. We used fixed and random-effect 
meta-analyses to calculate the pooled relative risk for CHD, stroke and combined cardio-
vascular disease, comparing high to low concentrations of glucose, insulin or HOMA-IR. 
Study heterogeneity was calculated with the I2 statistic. To enable a comparison between 
cardiovascular disease risks for glucose, insulin and HOMA-IR, we calculated pooled rela-
tive risks per increase of one standard deviation. 
results
We included 65 studies (involving 516,325 participants) in this meta-analysis. In a 
random-effect meta-analysis the pooled relative risk of CHD (95% CI; I2) comparing high 
to low concentrations was 1.52 (1.31, 1.76; 62.4%) for glucose, 1.12 (0.92, 1.37; 41.0%) 
for insulin and 1.64 (1.35, 2.00; 0%) for HOMA-IR. The pooled relative risk of CHD per 
one standard deviation increase was 1.21 (1.13, 1.30; 64.9%) for glucose, 1.04 (0.96, 1.12; 
43.0%) for insulin and 1.46 (1.26, 1.69; 0.0%) for HOMA-IR. 
Conclusions
The relative risk of cardiovascular disease was higher for an increase of one standard 
deviation in HOMA-IR compared to an increase of one standard deviation in fasting 
glucose or fasting insulin concentration. It may be useful to add HOMA-IR to a cardio-
vascular risk prediction model.
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iNTroduCTioN
Cardiovascular disease is worldwide the leading cause of death [1]. Type 2 diabetes 
contributes importantly to cardiovascular disease, because it is highly prevalent and 
doubles cardiovascular disease risk [2,3]. Before type 2 diabetes is diagnosed, insulin 
resistance can be present for years, thereby increasing insulin and glucose concentra-
tions [4,5]. 
Recent meta-analyses have shown that elevated insulin and glucose concentrations in 
persons without diabetes were associated with an increased cardiovascular disease risk 
[3,6]. In accordance, mechanistic studies have shown that elevated glucose and insulin 
concentrations can be pro-atherogenic [7,8]. Elevated insulin and glucose concentra-
tions are direct consequences of insulin resistance. Insulin resistance can promote the 
development of atherosclerosis through elevated glucose and insulin concentrations, 
but also through mechanisms that involve dyslipidemia, hypertension, and inflamma-
tion [7,9]. Therefore, cardiovascular disease may be caused by insulin resistance rather 
than being a consequence of the toxic effects of elevated insulin or glucose concentra-
tions. A validated and frequently used marker of insulin resistance is the Homeostasis 
Model Assessment Insulin Resistance (HOMA-IR). Since, HOMA-IR incorporates both 
glucose and insulin concentrations and represents insulin resistance, which can pro-
mote atherosclerosis trough several mechanisms [7,9], it might be more strongly as-
sociated with cardiovascular disease than individual glucose or insulin concentrations. 
No meta-analysis thus far, has compared the strength of association between HOMA-IR 
and cardiovascular disease to associations between fasting glucose, fasting insulin and 
cardiovascular disease. 
Our aim was to perform a systematic review and meta-analysis on the association 
between fasting glucose, fasting insulin, HOMA-IR and incident cardiovascular disease 
in individuals without diabetes. Our second aim was to compare fasting glucose, fasting 
insulin and HOMA-IR in strength of association with incident cardiovascular disease. We 
hypothesized that HOMA-IR is more strongly associated with incident cardiovascular 
disease than fasting glucose or fasting insulin.
METhods
data sources and searches
We searched the following databases from their inception to February 23, 2010: PubMed, 
MEDLINE, EMBASE, Web of Science, ScienceDirect and Cochrane Library. We updated 
the search to February 29th, 2011 for the MEDLINE and PubMed databases. The search 
strategy was optimized for all consulted databases, taking into account the differences 
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of the various controlled vocabularies as well as the differences of database-specific 
technical variations (e.g. the use of quotation marks). The reference lists of all potentially 
relevant articles were screened for additional publications. Detailed and database spe-
cific information about the search strategy is shown in Table s1. 
study selection 
The aim of our meta-analysis was to investigate the association between fasting glu-
cose, fasting insulin, HOMA-IR and incident cardiovascular disease in individuals without 
diabetes at baseline. Cohort studies that measured glucose, insulin or HOMA-IR and 
reported original data on their association with cardiovascular disease, were eligible. 
We considered only cohort studies or nested case-control studies that measured glu-
cose or insulin concentrations prior to the assessment of cardiovascular disease with a 
subsequent follow-up of minimally one year. No cross-sectional studies were eligible. In 
addition, articles in other languages than English were not eligible.
Since anti-diabetic drugs influence insulin and glucose concentrations, study popu-
lations should preferably have excluded participants with overt diabetes at baseline. 
However, population based studies that did not exclude participants with overt diabe-
tes at baseline were eligible for inclusion. We excluded studies performed in populations 
exclusively consisting of persons with known diabetes or cohorts restricted to specific 
populations such as intensive care or transplant patients. 
Studies that measured glucose or insulin concentrations in the fasting state were 
eligible for inclusion. Unfortunately, no uniform definition of fasting exists and many 
different definitions are being used [10]. Concentrations were considered to be fasting 
if study participants abstained from food for at least eight hours. Studies that reported 
the glucose or insulin concentrations to be fasting or measured after an overnight fast, 
but did not report the time span of fasting, were not excluded. 
Studies reporting on at least one of the following endpoints were eligible: myocardial 
infarction, angina pectoris, stroke (ischemic or hemorrhagic), arrhythmias, congestive 
heart failure or sudden cardiac death separately or combinations. Studies that combined 
these endpoints with peripheral arterial disease, arterial aneurysm or arterial dissection 
in a composite endpoint were not excluded. 
Furthermore, to be included studies should (1) report the association by comparing 
categories (percentiles or cut-off values), (2) express the association as relative risks 
(hazard ratios, rate ratios, risk ratios or odds ratios) with corresponding standard errors, 
confidence intervals or exact p-values and (3) adjust effect estimates at least for age and 
sex. In case of multiple publications arising from the same study population we included 
the study with the highest number of participants or the longest follow-up.
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data Extraction and Quality assessment
Two investigators (K.G. and N.T.) independently performed the article selection based 
on titles and abstracts, data extraction and risk of bias assessment using a standard data 
sheet. Disagreement was resolved by consensus or by a third party (O.D.). 
If necessary, glucose and insulin concentrations were recalculated to the international 
system of units (i.e. mmol/L for glucose and pmol/L for insulin) [11]. Values for HOMA-IR 
were based on values provided by the authors of included studies. In general, HOMA-
IR is calculated by the formula: (fasting insulin x fasting glucose)/ 22.5 or by the more 
recently updated computer model [12]. We recalculated HOMA-IR values for studies that 
reported HOMA insulin sensitivity, which is the reciprocal of HOMA-IR. 
We categorized study endpoints as (fatal or non-fatal): (1) coronary heart disease 
(CHD), (2) stroke and as (3) combined cardiovascular disease outcome (CVD), includ-
ing studies contributing to 1 or 2. CHD was defined as myocardial infarction or angina 
pectoris; stroke consisted of hemorrhagic or ischemic stroke and CVD consisted of myo-
cardial infarction, angina pectoris, hemorrhagic stroke, ischemic stroke, arrhythmias, 
congestive heart failure or sudden cardiac death. 
Risk of bias assessment was based on design elements of cohort studies and nested 
case-control studies that could potentially bias the association between fasting glucose, 
fasting insulin, HOMA-IR and cardiovascular disease. Potential sources of bias were as-
sessed by using a predefined assessment form. Dimensions considered for both cohort 
and nested case-control studies were (1) presence of overt diabetes at baseline, (2) 
presence of cardiovascular disease at baseline, (3) adequacy of exposure measurement, 
(4) missing glucose, insulin or HOMA-IR data, (5) adequacy of endpoint ascertainment. 
Bias was considered to be likely present when: (1) study populations had overt diabetes 
prevalence of twice their country specific diabetes prevalence estimates of 2011 [13]; 
indicating that studies have selected their study population based on high glucose 
concentrations (selection bias), (2) persons with prevalent cardiovascular disease ac-
cording to their outcome definition were not excluded; (3) the time span of fasting was 
not reported, (4) ≥10% missing data of the exposure except when data was missing 
completely at random (e.g. in the case of later introduction of the measurement), (5) 
outcome classification was based on self- or family reports, (6) there was ≥10% loss 
to follow-up. Reliable methods of outcome assessment were assessment by medical 
records, death certificates or hospital discharge records. Diagnosis of myocardial in-
farction was considered reliable when WHO MONICA criteria or Minnesota coding of 
electrocardiograms during follow-up visits were used [14–16]. 
data synthesis and analysis
Hazard ratios, rate ratios, risk ratios or odds ratios (relative risks) of cardiovascular dis-
ease comparing high to low concentrations of glucose, insulin or HOMA-IR values were 
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extracted. If necessary, we recalculated these relative risks in a way that the lowest cat-
egory (percentile or cut-off value) comprised the reference category. Our first aim was to 
estimate the pooled relative risk for cardiovascular disease, when comparing categories 
(based on either percentiles or cut-offs) of high concentrations of glucose, insulin or 
HOMA-IR to categories of lower concentrations. We pooled maximally adjusted effect 
measures of studies with corresponding 95% confidence intervals (CI). For all analyses, 
both a fixed and a random-effect meta-analysis were performed. Study heterogeneity 
was calculated with the I2 statistic. Elements of the risk of bias assessment were used 
to explore potential heterogeneity in sensitivity analyses. We assessed the presence of 
funnel plot asymmetry by calculating Egger’s test [17].
Our second aim was to compare fasting glucose, fasting insulin and HOMA-IR in strength 
of association with cardiovascular disease by comparing pooled standardized relative 
risks (i.e. risk increase per increase of one standard deviation). First, we calculated the 
standard deviation per exposure by pooling reported standard deviations with a weight 
factor based on study size. Secondly, we applied the method of Hartemink et al. [18] to 
calculate an overall relative risk per one unit increase of the exposure. Then, we multiplied 
the logarithm of the relative risks by the pooled standard deviation of the exposure. In 
short, the method of Hartemink et al. [18] assumes a log-linear relation between the risk 
and the exposure. The input of the algorithm consists of the means and variances of the 
exposure within each category of the exposure, the log relative risks of the categories 
with respect to a reference category, and the number of cases within each category. To 
determine the category means and variances we applied various methods, depending 
on the kind of data reported in the article. We assumed a lognormal distribution for the 
exposures. Finally, we tested differences in pooled relative risks between the three expo-
sures by using multivariate meta-analysis. Relative risks obtained from the same study 
(i.e. for studies that reported relative risks for more than one exposure) are likely to be 
correlated and this correlation is taken into account by multivariate meta-analysis.
We investigated sex differences in studies that presented sex-specific relative risks of 
cardiovascular disease by performing meta-analyses stratified by sex. Statistical analyses 
were performed with STATA Statistical Software (Statacorp, College Station, Texas, USA), 
version 11.2 and SAS software (SAS Institute Inc., Cary, NC, USA), version 9.2. 
rEsulTs
search results
We identified 4,792 unique publications by database search (MEDLINE: n = 2,095, PubMed: 
n = 1,480, EMBASE n = 852, Cochrane: n = 112, ScienceDirect: n = 103, Web of Science: n = 
86) and by screening reference lists of potentially relevant articles (n = 64). After exclusion 
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of 4,469 publications by screening title and abstract, 323 publications were retrieved for 
detailed assessment of which 184 fulfilled inclusion criteria and were assessed in dupli-
cate. To avoid multiple inclusions of the same study participants, we excluded 32 publica-
tions originating from the same study populations and included the publication with the 
largest population or the longest follow-up. Sixty-five studies (from 64 publications) were 
included. Forty-five studies presented data on fasting glucose, 17 studies presented data 
on fasting insulin and 16 studies presented data on HOMA-IR (figure 1).
4,792 Unique publications retrieved
4,469 Publications excluded by 
screening title and abstract
323 Publications retrieved for detailed assessment
139 Publications did not fulfill 
inclusion criteria:
84 no relevant or original data
17 no relative risk
15 cross-sectional
13 specific study population
8 duplicates
2 not English184 Publications assessed in duplicate
Glucose:140 publications excluded:
90 no fasting glucose data
22 no categories
21 duplicates
5 no relative risk
1 reference category unclear
1 not adjusted for age or sex
HOMA-IR: 17 studies included
4,728 Publications 
retrieved through database 
searching
Insulin: 168 publications excluded:
145 no fasting insulin data
16 no categories
6 duplicates
1 no relative risk
HOMA-IR:167 publications exlcuded:
157 no HOMA-IR data
5 no categories
5 duplicates
65 Unique studiesa included
Insulin: 16 studies included




figure 1. Summary of search results. a One publication consisted of two studies. HOMA-IR, Homeostasis 
Model Assessment insulin resistance
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study characteristics
Study characteristics of the included studies are summarized in Table 1. Sixty-four 
cohort studies and 1 nested case-control study were included. The controls in this 
case-cohort study were matched on time and therefore the odds ratio corresponds to a 
rate ratio [19]. Fifty-six studies presented a hazard ratio and nine studies presented an 
odds ratio. Most study populations consisted of both men and women. Individual study 
characteristics of included studies are shown in Table s2.
risk of bias
The risk of bias assessment is summarized in Table s3 and shown per study in Table 
s4. Most studies excluded persons with overt diabetes at baseline. One study included 
persons with prevalent cardiovascular disease and this was unclear in 20 studies. 
Twenty-two studies did not specify the time span of fasting or whether participants had 









Total participants 450,487 46,236 51,161
Participants per study (range) 541-63,443  541-13,446  839-6,942
Year of publication 1983-2010 1992-2010 2001-2010
Mean follow-up (years, range) 3.2-23.5 5.0-22.3a 2.2-30
Study design
Cohort 45  15 17
Nested case-control 0 1 0
CHD endpoint
Number of studies 23 9 7
Events per study 23-4,490b 16-677 33-169b
Total events 10,884b 2,149 441b
Stroke endpoint
Number of studies 14 2 4
Events per study 13-405c 25-70 23-70b
Total events 1,936c 95 164b
Combined CVD endpoint
Number of studies 45 16 17
Events per study 23-4,490b 16-492 58-340
Total events 19,993b 3,329 3,035
Data are presented as number or range. a Three studies did not report follow-up time b Two studies did not 
report the number of participants who encountered the outcome of interest. c One study did not report the 
number of participants who encountered the outcome of interest. HOMA-IR, Homeostasis Model Assess-
ment Insulin Resistance; CHD, coronary heart disease; CVD, cardiovascular disease
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figure 2. Random-effect meta-analyses of coronary heart disease risk for the highest category of glucose, 
insulin or HOMA-IR compared to the lowest category. a Or known diabetes was used to define the highest 
category. b Paris Prospective Study. c Helsinki Policemen Study. d Men. e Women. f Glomerular Filtration Rate 
≥ 60 ml/min/1.73 m2. g Glomerular Filtration Rate < 60 ml/min/1.73 m2. 95 % CI, 95% confidence interval; vs, 
versus; I-squared, measure of heterogeneity; HOMA-IR, Homeostasis Model Assessment Insulin Resistance 
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an overnight fast.  Five studies had more than 10% missing data for glucose, four studies 
for insulin and three studies for HOMA-IR which was not reported to be completely at 
random. In 13 studies we considered bias to be likely present due to inadequate out-
come assessment. The percentage of participants that were loss to follow-up ranged 
from 0% to 42%. Seven studies had a loss to follow-up of more than 10% and this was 
unclear in most studies. The p-values of Egger’s test were 0.08 for glucose, <0.01 for 
insulin and <0.01 for HOMA-IR.
Comparison between glucose, insulin and hoMa-ir
In a random-effect meta-analysis the pooled relative risk of CHD comparing the high-
est versus the lowest category was 1.52 (95% CI: 1.31, 1.76; I2: 62.4%) for glucose, 1.12 
(95% CI: 0.92, 1.37; I2: 41.0%) for insulin and 1.64 (95% CI: 1.35, 2.00; I2: 0%) for HOMA-IR 
(figure 2 and figure s1). The pooled relative risks for the association with stroke and 
CVD, and meta-analyses stratified by sex for studies that provided sex-specific relative 
risks are summarized in figure s1.
To enable a direct comparison between CHD and CVD risks for glucose, insulin and 
HOMA-IR we calculated pooled relative risks for an increase of one standard deviation 
[18]. We did not investigate the endpoint stroke, because only two studies investigated 
the association between insulin and stroke. The relative risks per increase of one standard 
deviation for glucose (1.05 mmol/L), insulin (43.53 pmol/L) and HOMA-IR (2.23 units) are 
shown in figure 3. The pooled relative risk of CHD per one standard deviation increase 
was 1.21 (95% CI: 1.13, 1.30; I2: 64.9%) for glucose, 1.04 (95% CI: 0.96, 1.12; I2: 43.0%) for 
insulin and 1.46 (95% CI: 1.26, 1.69; I2: 0.0%) for HOMA-IR. The pooled relative risks of 
CHD for glucose, insulin, and HOMA-IR were all statistically different from each other 
(p-values: <0.05). The pooled relative risks of CVD for glucose, insulin, and HOMA-IR were 
not statistically different (p-value: 0.27).
Thirty-three studies provided sex-specific relative risks of CVD. Few studies provided 
relative risks of CHD or stroke for women and therefore we only investigated sex dif-
ferences for incident CVD. Women had higher relative risks of CVD per one standard 
deviation increase of glucose (1.25 (95% CI: 1.11, 1.41; I2: 65.0%) versus 1.13 (95% CI: 
1.08, 1.18; I2: 29.3%); p-value: 0.01) and insulin (1.24 (95% CI: 1.08, 1.44; I2: 18.5%) versus 
1.06 (95% CI: 0.97, 1.16; I2: 60.4%); p-value: 0.03) and lower relative risk of CVD per one 
standard deviation increase of HOMA-IR (1.37 (95% CI: 1.05, 1.80; I2 33.6%) versus 1.41 
(95% CI: 1.12, 1.77; I2 66.5%); p-value: 0.73) (figure 3). In sensitivity analyses we excluded 
studies which had a high risk of bias based on items of the risk of bias assessment. The 
results of the meta-analyses were materially unchanged.
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disCussioN
The present meta-analyses showed that fasting glucose, fasting insulin and HOMA-IR 
were all associated with incident cardiovascular disease in individuals without diabetes. 
In a standardized meta-analysis we found that coronary heart disease risk increased with 
46% for an increase of one standard deviation in HOMA-IR concentration compared to 
an increase of 21% for fasting glucose concentration and an increase of 4% for fasting 
insulin concentration. 
To our knowledge, this was the first meta-analysis that directly compared fasting glu-
cose, fasting insulin and HOMA-IR in strength of association with cardiovascular disease.
A number of previous meta-analyses have investigated the association between fast-
ing glucose, fasting insulin or HOMA-IR concentrations and cardiovascular disease by 
comparing high to low concentrations. Our pooled relative risks of cardiovascular dis-
ease (glucose: 1.44, insulin: 1.28, HOMA-IR: 1.44) are within the range of pooled relative 
risks reported in previous meta-analyses [6,20–22]. Differences in pooled relative risks 
between meta-analyses may be, for a large part attributed to different cut-off levels of 
figure 3. Results of random-effect meta-analyses comparing cardiovascular disease risk for an increase of 
one standard deviation. a 1 study did not specify sex-specific numbers. SD, standard deviation; 95% CI, 95% 
confidence interval; I2, measure of heterogeneity; CHD, coronary heart disease and is defined as fatal or 
non-fatal myocardial infarction or angina pectoris; CVD, cardiovascular disease and is defined as myocardial 
infarction, angina pectoris, hemorrhagic stroke, ischemic stroke, arrhythmias, congestive heart failure or 
sudden cardiac death; HOMA-IR, Homeostasis Model Assessment Insulin Resistance
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the exposure, leading to different causal contrasts. Further, differences in design aspects 
of meta-analyses may explain different pooled relative risks. For example, including 
studies with only fatal events versus studies with fatal and non-fatal events can result in 
different pooled RR for glucose, since diabetes seems to be a stronger risk factor for fatal 
than for non-fatal events [23]. Previous studies that investigated sex differences in the as-
sociation between diabetes and cardiovascular disease found that women with diabetes 
had a higher relative risk than men with diabetes [3,24,25]. The pooled relative risks for 
an increase of one standard deviation in glucose and insulin were somewhat higher for 
women than for men, whereas there was less difference in relative risks between sexes 
for HOMA-IR. It has been proposed that diabetes may induce a more unfavorable cardio-
vascular risk profile in women than in men and thereby increases cardiovascular disease 
risk more in women [24,25]. Another explanation could be that these cardiovascular risk 
factors are not intermediates, but common causes of both diabetes and cardiovascular 
disease which may have a stronger effect in women than in men. However, most indi-
vidual relative risks in this analysis were adjusted for cardiovascular risk factors. Leav-
ing the possibility that there could still be residual confounding, for example by body 
composition and insulin resistance which are known to differ between men and women 
[26,27]. Even if relative risks are truly higher in women than in men, it is important to 
consider that absolute cardiovascular disease risk are lower [24]. In this meta-analysis, 
the relative risk of cardiovascular disease was higher for an increase of one standard 
deviation in HOMA-IR compared to an increase of one standard deviation in glucose or 
insulin. Animal studies have shown that insulin resistance plays an important role in the 
early and advanced stages of atherosclerosis, whereas hyperglycemia seems exclusively 
to be involved in early stages of atherosclerosis [9]. In addition, insulin resistance seems 
to modify the effect of insulin on the vascular wall; anti-atherogenic in the insulin sensi-
tive state and  pro-atherogenic in the insulin resistant state [8]. Unfortunately, it is not 
clear to what extent these pro-atherogenic mechanism contribute to the development 
of cardiovascular disease in humans. 
A strength of this study is the large number of included studies comprising more than 
500,000 participants. Therefore, the pooled effect estimates were not influenced largely 
by random error and it was possible to investigate different cardiovascular endpoints 
and sex differences. Secondly, in most studies we were able to calculate the relative risk 
for an increase of one standard deviation in the exposure. In this way, we adjusted for 
differences in assays and used cut-off points between studies and could compare the 
three exposures. Thirdly, we investigate the risk of incident coronary heart disease which 
is considered to be a homogeneous well-defined cardiovascular disease endpoint [28].
A general limitation of meta-analyses of observational studies is that the result may be 
a precise, but biased estimate. We assessed the risk of bias per study and performed sen-
sitivity analyses excluding studies with a high risk of bias in a sensitivity analysis. This did 
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not change our results materially. We showed the presence of funnel-plot asymmetry by 
Egger’s test. Sources of funnel plot asymmetry are publication bias, true heterogeneity 
of study effects or differences in study quality [17]. Since funnel-plot asymmetry was 
present for all three exposures, comparing three exposures still seems valid. Most stud-
ies included in our meta-analysis measured concentrations only once and are thereby 
susceptible to random measurement error. Random measurement error of the exposure 
leads to an attenuation of estimated effects [29]. Moreover, most studies only reported 
composite cardiovascular disease outcomes which may hamper a causal interpretation 
of reported risks if the exposure has no uniform effect on the different endpoints [30]. 
For example, elevated cholesterol concentration is a risk factor for coronary heart dis-
ease, but not for stroke [31,32]. Few studies reported stroke endpoints and associations 
in women; as a consequence the pooled relative risk of stroke for insulin was based on 
two studies and the pooled relative risk for HOMA-IR was based on four studies. Finally, 
we only included studies that measured HOMA-IR, which is a surrogate measure of 
insulin resistance and mainly reflects hepatic insulin resistance [12]. Therefore, it may 
not account for the total effect of insulin resistance. However, the application of the gold 
standard measurement, i.e. the euglycemic hyperinsulinemic clamp which is a measure 
of peripheral insulin resistance is often not feasible in large epidemiological studies.  
More knowledge in the pathofysiology of atherosclerosis should guide type and initia-
tion of treatment. For example, shifting the glucose distribution curve leftwards for the 
entire population as was postulated previously [33], is only effective when glucose itself 
is involved in atherosclerosis pathofysiology and when the intervention has a uniform 
effect in the entire population. However, the addition of HOMA-IR, a marker of insulin 
resistance to a risk prediction model may improve cardiovascular risk prediction. The 
addition of a fasting glucose measurement to the Framingham risk score resulted in a 
slight net reclassification improvement of 1.8% [34]. Whether the addition of HOMA-IR 
to a risk prediction model, on top of glucose, results in a more accurate reclassification 
of cardiovascular risk is unknown. Furthermore, this possible benefit should be carefully 
weighted against the extra costs involved with measuring both glucose and insulin. 
However, considering the addition of HOMA-IR to a prediction model is important, since 
many current models aiming to predict cardiovascular events are still not optimal to 
define high risk groups. 
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Table s3. Risk of bias assessment summarized for three exposures 
Exposure
















































































HOMA-IR: Homeostasis Model Assessment Insulin Resistance
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Chapter 3
Inflammation increases plasma 
angiopoietin-like protein 4 in subjects 
with the metabolic syndrome and  
type 2 diabetes
Nathanja Tjeerdema, Anastasia Georgiadi, Jacqueline T. Jonker,  
Marjolijn van Glabbeek, Reza Alizadeh Dehnavi, Jouke T. Tamsma,  
Johannes W.A. Smit, Sander Kersten, Patrick C.N. Rensen
bMJ open diabetes research & Care2014;2:e000034




Angiopoietin-like protein 4 (ANGPTL4) inhibits lipoprotein lipase and associates with 
dyslipidemia. The expression of ANGPTL4 is regulated by free fatty acids (FFA) that 
activate lipid-sensing peroxisome proliferator-activated receptors (PPARs), but FFA 
can also activate pattern recognition receptors including Toll-like receptor 4 (TLR4) in 
macrophages.
objective
To assess whether systemic low grade inflammation is a determinant for plasma ANG-
PTL4 levels in patients with the metabolic syndrome (MetS) and type 2 diabetes mellitus 
(T2DM).
design
We studied 335 male subjects: healthy controls (Controls), subjects with the metabolic 
syndrome without inflammation (MetS-I) and with low grade inflammation (MetS+I), 
and T2DM patients. All non-diabetic subjects included in the present study were initially 
matched for waist circumference. In plasma, ANGPTL4, C-reactive protein (CRP) and 
metabolic parameters were determined. Underlying mechanisms were examined using 
human macrophages in vitro.
results
As compared to Controls, plasma ANGPTL4 levels were increased in subjects with MetS-I, 
MetS+I and T2DM. Furthermore ANGPTL4 was increased in T2DM compared to MetS-I. 
In fact, plasma CRP correlated positively with plasma ANGPTL4. In vitro studies showed 
that Toll-like receptor 3/4 activation largely increased the expression and release of 
ANGPTL4 by macrophages.
Conclusions
Plasma ANGPTL4 levels in humans are predicted by CRP, a marker of inflammation, and 
ANGPTL4 expression by macrophages is increased by inflammatory stimuli.
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iNTroduCTioN
The angiopoietin-like proteins are a family of secreted proteins that play an important 
role in energy metabolism. Angiopoietin-like protein 4 (ANGPTL4) is expressed in nu-
merous cell types including adipocytes, hepatocytes, (cardio)myocytes, endothelial cells 
and macrophages (1,2). ANGPTL4 plays a role in plasma lipid metabolism by inhibiting 
the enzyme lipoprotein lipase (LPL). This action of ANGPTL4 results in suppression of 
the release of plasma triglyceride-derived fatty acids and their subsequent uptake by 
underlying metabolic tissues including adipose tissue, skeletal muscle and the heart, 
with concomitant hypertriglyceridemia (3-5).
Expression of ANGPTL4 in a variety of tissues, including adipose tissue and liver, is 
governed by the lipid-sensing peroxisome proliferator-activated receptors (PPARs) α, 
ß and γ, and is stimulated in vitro by free fatty acids (FFA) (1,6-8). Accordingly, dietary 
modulations that increase plasma FFA levels, including prolonged fasting, very-low 
calorie diet, and high-fat, high-energy diet, also increase plasma ANGPTL4 levels, most 
likely via activation of PPARs in tissues such as adipose tissue and liver (9,10). Besides 
activating PPARs, there is compelling evidence that FFA also activate pattern recogni-
tion receptors (PRRs) in adipocytes and macrophages, including the Toll-like receptor 
4 (TLR4) (11,12). Accordingly, it is of interest to study the impact of inflammation and 
(associated) TLR activation on ANGPTL4 expression.
The metabolic syndrome is a progressive inflammatory disease, ranging from mild 
dyslipidemia and impaired fasting glucose levels to full blown type 2 diabetes mellitus 
(T2DM) (13,14). Interestingly, the progression of metabolic syndrome (MetS) towards 
T2DM is accompanied by progressive inflammation, which may result in increased 
plasma levels of ANGPTL4 that, in its turn, could aggravate dyslipidemia. Therefore, the 
aim of the present study was to assess whether systemic low grade inflammation is a de-
terminant for plasma ANGPTL4 levels in patients with the MetS and T2DM. To get more 
insight into the causal relationship between inflammation and ANGPTL4 expression we 
assessed whether inflammatory stimuli increase ANGPTL4 expression in vitro.
rEsEarCh dEsiGN aNd METhods 
human studies
Subjects 
To assess the effects of low grade systemic inflammation on plasma ANGPTL4 levels we 
studied four groups of human subjects: healthy controls (Controls, n=95), subjects with 
metabolic syndrome but without systemic inflammation (MetS-I, n=106), subjects with 
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metabolic syndrome accompanied by low grade systemic inflammation (MetS+I, n=66), 
and patients with T2DM (T2DM, n=68). All non-diabetic subjects included in the present 
study were initially matched for waist circumference (maximum difference 17 cm) and 
age (maximum difference 19 years). The metabolic syndrome was defined according 
to the IDF criteria (15) i.e. two or more of the following criteria present in addition to 
increased waist circumference (male ≥ 94): triglycerides ≥ 1.7 mmol/l (≥150 mg/dl) / the 
use of lipid lowering medication, HDL cholesterol < 1.03 mmol/l (<40 mg/dl) in men and 
< 1.29 mmol/l (<50 mg/dl) in women, fasting glucose ≥ 5.6 mmol/l (100 mg/dl) or BP 
≥130/≥85 mmHg / the use of blood pressure lowering medication. Low grade inflamma-
tion was defined as moderately elevated CRP: 3.0 mg/l ≤ CRP < 15.0 mg/l.
Controls (n=95), subjects with MetS-I (n=66; 62% of all included subjects with MetS-I) 
and subjects with MetS+I (n=33; 50% of all included subjects with MetS+I) were selected 
from a survey in the general population in the city of Rijswijk, The Netherlands. For this 
survey, all non-diabetic subjects between 40-70 years of age of four general practitio-
ners were invited for a cardiovascular risk screening (n=2942). Subjects with diagnosed 
diabetes, known terminal disease and a history of psychiatric disorders or substance 
abuse were excluded. Screening was performed on 2079 subjects (response rate of 71%) 
and CRP was determined for 1515 subjects. After excluding subjects with high CRP (de-
fined as > 15 mg/l, n=45), subjects with missing values (n=13), female subjects (n=792) 
and subjects with cardiovascular disease (n=55), 610 male subjects were eligible.  Only 
male subjects were selected to avoid the potential interference of sex steroid hormones 
on study parameters. The metabolic syndrome was present in 44% (n=268) of the 610 
males. A total of 98 controls and 102 subjects with metabolic syndrome were selected 
for the current study. In addition 1 subject with new diagnosed diabetes, 1 subject with 
a very high level of ANGPTL4 and four subjects with missing data (n=3 Control and n=1 
MetS) were excluded therefore leading to 95 controls and 99 MetS subjects. Subjects 
with metabolic syndrome were divided in MetS-I (n=66) and MetS+I (n=33). 
Subjects with MetS-I (n=40) and MetS+I (n=33) were also selected from a previ-
ously published study on the effect of lifestyle in combination with rosiglitazone versus 
placebo on atherosclerosis in subjects with the metabolic syndrome [RUBENS study, 
(16)]. These subjects (n=73) were matched on waist and age with the subjects from the 
PIRAMID study (see below). For this study male subjects with increased waist circumfer-
ence (≥ 94 cm) and elevated CRP levels (≥ 1.8 mg/l) and two other metabolic syndrome 
criteria were included. Exclusion criteria for this study were type 2 diabetes (fasting 
blood glucose ≥ 7 mmol/l), manifest cardiovascular disease, use of statins, steroids or 
non-steroidal anti-inflammatory drugs at baseline, heart failure, QTc time interval of 450 
ms or longer on baseline electrocardiogram (ECG), primary dyslipidemias, presence of 
potential hepatic disease (i.e. subjects with alanine aminotransferase, total bilirubin, or 
alkaline phosphatase levels exceeding 2.5 times the upper limit of the normal labora-
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tory values), alcohol abuse (> 30 units/week) and cardiovascular magnetic resonance 
contraindications.
Subjects with T2DM (n=68) were selected from a recently published study on the 
effects of pioglitazone versus placebo on cardiovascular parameters in uncomplicated 
T2DM (PIRAMID) study. For detailed inclusion criteria, see (17). In short, the study in-
cluded male patients with T2DM without cardiovascular disease or diabetes-related 
complications, BMI 25-32 kg/m2, age 45-65 years and well-controlled type 2 diabetes 
with oral antidiabetic medication (HbA1c 6.5-8.5%). A total of n=73 subjects from the 
PIRAMID were matched on waist circumference and age with n=73 subjects from the 
RUBENS. A total of 5 subjects were excluded due to CRP levels > 15 (n=4) and missing 
data (n=1). 
The studies were executed in accordance with the principles of the Declaration of 
Helsinki and were approved by the local medical ethics committee. All volunteers in 
these studies signed informed consent.
Analysis of CRP and ANGPTL4 
CRP was determined by the Tina Quant C-reactive protein (latex) high sensitive assay 
according to the manufacturer’s instructions (Roche, Basel, Switzerland). ANGPTL4 
was measured by ELISA as detailed previously (9). Briefly, 96-well plates were coated 
with anti-human ANGPTL4 polyclonal goat IgG antibody (AF3485, R&D Systems) and 
incubated overnight at 4°C. Plates were washed extensively between each step. After 
blocking, 100 µl of undiluted medium or 20-fold diluted human plasma was added, 
followed by 2 h incubation at room temperature. A standard curve was prepared using 
recombinant human ANGPTL4 (3485-AN, R&D Systems) at 0.3 to 2.1 ng/well. Next, 100 
µl of diluted biotinylated anti-human ANGPTL4 polyclonal goat IgG antibody (BAF3485, 
R&D Systems) was added for 2 h, followed by addition of streptavidin-conjugated horse-
radish peroxidase for 20 min, and tetramethyl benzidine substrate reagent for 6 min. 
The reaction was stopped by addition of 50 µl of 10% H2SO4, and the absorbance was 
measured at 450 nm.
In vitro studies
Cell culture 
Human THP-1 and U937 monocytes were grown in RPMI medium containing 10% heat-
inactivated FCS and 1% P/S for 10-15 passages. They were differentiated into macro-
phages after 2 days incubation by adding 100 ng/ml phorbol-12-myristate-13-acetate 
(PMA). After 2 days, PMA was removed by washing with phosphate-buffered saline (PBS) 
and macrophages were kept in complete medium without PMA for 2 additional days and 
then used for experiments. Human Peripheral blood mononuclear cells (PBMCs) were 
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isolated from whole blood by using BD Vacutainer Cell Preparation Tubes according to 
the manufacturer’s instructions. Isolated PBMCs were plated in complete medium RPMI, 
10% heat inactivated FCS, 1% P/S. After 2 h cells were washed and remaining attached 
cells were differentiated into macrophages in completed medium, containing 100 ng/
ml macrophage colony stimulating factor (M-CSF), for 5 subsequent days. During dif-
ferentiation medium was not refreshed.
Incubations 
THP-1 cells were incubated with the TLR agonists (Sigma, Fluka, Brunwich, and InvivoGen) 
lipopolysaccharide (LPS, TLR4; 100 ng/ml or 1 µg/ml), S-(2,3-bispalmitoyloxypropyl)-Cys-
Gly-Asp-Pro-Lys-His-Pro-Lys-Ser-Phe, Pam2CGDPKHPKSF (Fibroblast-stimulating Lipopep-
tide; FSL-1, TLR2 and TLR6; 1 μg/ml), tri-acylated lipopeptide Pam3-Cys-Ser-Lys4 (Pam3, 
TLR1 and TLR2; 1 μg/mL), Polyinosinic-polycytidylic acid (polyI:C, TLR3; 2 μg/ml), Muramyl 
dipeptide (MDP, NOD2; 10 μg/ml), Flagellin (Flag, TLR5; 10 ng/ml) and/or FFA-donor in-
tralipid (2 mM; Fresenius Kabi) for the indicated time periods at 37°C. After incubation, 
medium was aspired and cells were washed. Cellular ANGPTL4 mRNA was determined by 
qPCR (forward primer CACAGCCTGCAGACACAACTC; reverse primer GGAGGCCAAACTG-
GCTTTGC) and ANGPTL4 protein in the medium was determined by ELISA as detailed 
above.
statistical analysis
Data are expressed as mean ± standard deviation or as median (interquartile range) if 
the assumption of normality was not met. Categorical data are presented as frequencies 
(%). Comparisons between continuous variables were assessed by independent t-test 
or one-way ANOVA, followed by Bonferroni’s post hoc test for multiple comparisons, 
(Table 1, figure 1). Comparisons between categorical data were performed with Chi-
square tests (with the level of significance adjusted for the number of comparisons, 
Table 1). The correlation between clinical characteristics and ANGPTL4 was tested by 
Spearman’s correlation coefficients (figure 2) and multivariable regression  analysis 
with logarithmically transformed ANGPTL4 values. Statistical analysis was performed 
using SPSS for Windows (version 17.0; SPSS, Chicago, Illinois, USA). Plots were created 
with GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, USA). P<0.05 was considered 
statistically significant.
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rEsulTs
Characteristics of the human study population
To evaluate whether low grade inflammation is associated with plasma ANGPTL4 levels 
in humans, we compared Controls (n=95) with subjects with MetS-I (n=106), MetS+I 
(n=66), and with T2DM patients (n=68).
The mean age of all male subjects combined (n=335) was 56.9±6.0 years and mean 
waist circumference was 105±10 cm. Clinical characteristics of the study population are 
described in Table 1. Groups matched for age and waist circumference did not differ 
with regard to FFA and family history of cardiovascular disease. Fasting glucose and 
triglyceride levels were higher, and HDL-cholesterol levels were lower in MetS-I, MetS+I 
and T2DM compared to Controls. Blood pressure was higher in MetS-I and MetS+I com-
pared to Controls and T2DM. Subjects with T2DM used more statins and had lower total 
cholesterol compared to MetS-I, MetS+I and Controls. Furthermore subjects with MetS+I 
smoked more frequently then controls and subjects with T2DM. Low grade inflamma-
tion measured as CRP was highest in MetS+I [5.55 (4.11-8.02) mg/l, p<0.001 compared to 
all groups], followed by T2DM [3.60 (2.43-5.95) mg/l], MetS-I [1.96 (0.92-2.37) mg/l] and 
Controls [1.43 (0.76-2.85) mg/l].









Age, years 56.5 ± 7.4 56.8 ± 5.2 57.5 ± 5.5 56.8 ± 5.3
Current smoking, n (%) 17 (18) ‡ 29 (27) 26 (39)*§ 11 (16) ‡
Family history of CVD, n (%) 19 (20) 21 (20) 14 (21) 13 (19)
Statin use, n (%) 8 (8)§ 8 (8)§ 4 (6)§ 32 (47)* † ‡
Waist circumference, cm 103 ± 9 105 ± 10 107± 9 104 ± 10
Systolic blood pressure, mmHg 133 ± 18†‡ 146 ± 20*§ 145 ± 18*§ 130 ± 12†‡
Diastolic blood pressure, mmHg 82 ± 12†‡ 88 ± 10*§ 87 ± 11* 82 ± 8†
Glucose, mmol/l 5.14 ± 0.47†‡§ 5.79 ± 0.82*§ 5.80 ± 0.86*§ 8.44 ± 1.92*†‡  
Free fatty acids, mmol/l 0.62 (0.47-0.79) 0.58 (0.43-0.73) 0.58 (0.44-0.75) 0.58 (0.45-0.75)
Total cholesterol, mmol/l 5.63 ± 0.98§ 5.59 ± 1.01§ 5.57 ± 1.11§ 4.66 ± 0.93*†‡
HDL-cholesterol, mmol/l 1.24 (1.11-1.41)†‡§ 1.02 (0.89-1.22)* 1.02(0.85-1.19)* 1.11 (0.93-1.39)*
Triglycerides, mmol/l 1.09 (0.84-1.38)†‡§ 1.82 (1.31-2.45)* 1.83(1.15-2.40)* 1.50 (0.90-2.20)*
CRP, mg/l 1.43 (0.76-2.85)‡§ 1.96 (0.92-2.37)‡§ 5.55 (4.11-8.02)* †§ 3.60 (2.43-5.95)* †‡
ANGPTL4, ng/ml 3.7 (2.8-5.2)†‡§ 4.6(3.3-6.5)*‡§ 6.0 (3.8-7.7)*† 6.4 (5.2-8.2)*†
Values represent mean ± standard deviation or median (inter quartile range) unless indicated otherwise. 
Abbreviations: ANGPTL4, angiopoietin-like protein 4; CRP, C-reactive protein; CVD, cardiovascular disease; 
HDL, high-density lipoprotein; MetS-I, metabolic syndrome without inflammation; MetS+I, metabolic syn-
drome with inflammation; T2DM, type 2 diabetes mellitus. Significant as compared to *healthy controls, 
†MetS-I, ‡MetS+I, §T2DM (P<0.05). 
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Plasma aNGPTl4 levels
The median plasma ANGPTL4 in the total study population was 5.00 (3.50-6.80) ng/
ml and ranged from 0.90 to 43.30 ng/ml. The distribution of ANGPTL4 was skewed to 
the right. figure 1 shows the plasma ANGPTL4 levels in Controls, MetS-I, MetS+I and 
T2DM. Plasma ANGPTL4 was higher in T2DM [6.4 (5.2-8.2) ng/ml, p<0.001], in MetS+I [6.0 
(3.8-7.7) ng/ml, p<0.001] and MetS-I [4.6 (3.3-6.5) ng/ml, p=0.006], than in Controls [3.7 
(2.8-5.2) ng/ml]. In addition, higher ANGPTL4 was found in T2DM compared to MetS-I 
(p<0.001) (Table 1). 
relationship between plasma angptl4, metabolic parameters and low grade 
inflammation
Although groups were matched for waist circumference, in all subjects combined plasma 
ANGPTL4 positively correlated with waist circumference (r=0.195, p<0.001) and fasting 
glucose (r=0.322, p<0.001). Plasma ANGPTL4 negatively correlated with HDL-cholesterol 
(r=-0.143, p=0.009) and total cholesterol (r=-0.223, p<0.001). Plasma ANGPTL4 did not 
correlate with age (p=0.457), triglycerides (p=0.055) or FFA (p=0.226).
figure 1. Plasma angiopoietin-like protein 4 (ANGPTL4) in healthy controls (Controls), patients with meta-
bolic syndrome without (MetS-I) and with low grade inflammation (MetS+I) and patients with type 2 diabe-
tes mellitus (T2DM). Plasma was taken from Controls, patients with MetS-I, MetS+I and T2DM, and plasma 
ANGPTL4 levels were determined. As compared with plasma ANGPTL4 levels [median (IQR)] in Controls 
[3.7 (2.8-5.2) ng/ml], ANGPTL4 levels are increased in patients with MetS-I [4.6 (3.3-6.5) ng/ml, p=0.006], 
patients with MetS+I [6.0 (3.8-7.7) ng/ml, p<0.001] and patients with T2DM [6.4 (5.2-8.2) ng/ml, p<0.001]. 
Furthermore, ANGPTL4 was increased in T2DM2 compared with MetS-I (p<0.001). Significant as compared 
with Controls. *P<0.001, #P<0.05.
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Plasma ANGPTL4 showed a positive correlation with CRP (r=0.295, p<0.001) (figure 
2). Multiple regression analysis revealed that the association between ANGPTL4 and CRP 
was independent of age, waist circumference, glucose, HDL-cholesterol, triglycerides, 
total cholesterol, FFA and smoking (ß =0.142, p=0.010).
inflammation-dependent aNGPTl4 expression in human macrophages
Since the above described correlations do not necessarily implicate causal relationships, 
we performed mechanistic studies in vitro to get more insight into potential causality 
between inflammation and ANGPTL4 expression. To demonstrate that ANGPTL4 expres-
sion is sensitive to stimulation by inflammatory stimuli, we treated macrophages with 
various PRR agonists and determined ANGPTL4 expression (figure 3). We used human 
THP-1 macrophages because: 1) they are human macrophages, 2) they secrete sufficient 
amounts of ANGPTL4 to allow quantification in the cell medium.
In human THP-1 macrophages ANGPTL4 mRNA expression (figure 3a) and ANGPTL4 
protein secretion (figure 3b) were strongly increased by the TLR4 agonist LPS and the 
TLR3 agonist poly(I:C). Consistent with these data, LPS also increased ANGPTL4 mRNA 
expression in human U937 macrophages and human monocyte-derived macrophages 
(figure 3C). Intralipid, a source of FFA that induces foam cell formation, also increased 
ANGPTL4 mRNA (figure 3d) and ANGPTL4 protein (figure 3E) expression in THP-1 
figure 2. Correlation between plasma C reactive protein (CRP) and angiopoietin-like protein 4 (ANGPTL4). 
Plasma was taken from healthy controls, patients with metabolic syndrome without and with low grade 
inflammation and patients with type 2 diabetes mellitus, and plasma ANGPTL4 levels as well as CRP levels 
were determined. Plasma CRP correlates positively with plasma ANGPTL4 (r=0.295, P<0.001).
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figure 3. Inflammatory stimuli increase angiopoietin-like protein 4 (ANGPTL4) gene and protein expres-
sion in human macrophages. (A) Human THP-1 macrophages were incubated with various Toll-like recep-
tor (TLR) agonists for 12 h, and changes in expression of ANGPTL4, Gdf15 and Cxcl2 were determined. 
(B) Human THP-1 macrophages were incubated with various TLR agonists for 24 h, and ANGPTL4 protein 
levels in medium were assessed. (C) Human U937 macrophages were incubated with LPS (100 ng/ml; 4 h) 
and ANGPTL4 mRNA expression was determined; human monocyte-derived macrophages were incubated 
with LPS (1 µg/ml; 24 h) and ANGPTL4 mRNA expression was determined. (D, E) THP-1 macrophages were 
incubated with LPS, intralipid, or both for 24 h and ANGPTL4 mRNA expression (D) or protein secretion (E) 
were determined. Values are means ± SEM (n=3-6). Differences as compared to controls were evaluated by 
Student’s t-test. *P<0.05. 
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macrophages, but no clear synergy was observed between Intralipid and LPS towards 
induction of ANGPTL4. Taken together, these data show that inflammatory stimuli caus-
ing macrophage activation and macrophage foam cell formation markedly increase 
ANGPTL4 expression in human macrophages.
disCussioN
The main findings of our cross-sectional human study are: 1) patients with MetS and 
T2DM show increased plasma ANGPTL4 levels compared to Controls, 2) MetS patients 
with low grade inflammation show higher levels of ANGPTL4 compared to MetS patients 
without inflammation, 3) plasma CRP, as a marker of low grade inflammation, positively 
correlates with plasma ANGPTL4, independent of age, waist circumference, glucose and 
lipid variables.
Thus far, the expression of ANGPTL4 in numerous tissues including adipose tissue and 
liver was thought to be mainly regulated by PPARs. Consistent with a role of PPARs, fatty 
acids increase ANGPTL4 expression in vitro in numerous cell types (1,6-8). Furthermore, in 
vivo modulation of plasma FFA levels also modulates plasma ANGPTL4 levels (9,10), with 
a positive correlation observed between the change in FFA levels and change in ANG-
PTL4 levels (10). In our previous study, we postulated that patients with T2DM may have 
higher ANGPTL4 levels than healthy subjects due to elevated plasma FFA (10). Although 
in the present paper we do observe increased plasma ANGPTL4 levels in T2DM patients 
compared to controls, plasma FFA levels were not different between both groups. In 
addition, plasma ANGPTL4 levels were elevated in subjects with MetS compared to 
controls, whereas their plasma FFA levels did not differ from the healthy controls. In fact, 
in this cross-sectional study we were unable to detect a correlation between plasma FFA 
levels and plasma ANGPTL4 levels, which is likely related to the matching on visceral 
obesity and the subsequent limited variation in FFA between groups.
Therefore, we hypothesized that additional factors such as inflammation may contrib-
ute to the increased ANGPTL4 levels in subjects with MetS and T2DM. Indeed, we did 
observe a progressive increase in the plasma ANGPTL4 in males according to inflamma-
tory status (healthy controls < subjects with MetS without inflammation < subjects with 
MetS with low grade inflammation and subjects with T2DM). Furthermore, in all groups 
combined, plasma ANGPTL4 showed a positive correlation with CRP, an established 
marker for low grade inflammation.
To get more insight into the causal relationship between inflammation and ANGPTL4 
expression we treated human macrophages with various PRR ligands. Macrophages were 
used because of their sensitivity to inflammatory stimuli, not because they are suspected 
to be solely responsible for the changes in plasma ANGPTL4 levels observed in vivo. Of 
Nathanja Tjeerderma - binnenwerk v7b.indd   75 08-09-15   11:35
76 Chapter 3
all ligands tested, agonists for TLR3 (i.e. poly(I:C)) and TLR4 (i.e. LPS) consistently induced 
the expression and release of ANGPTL4 in different types of human macrophages. It 
remains unclear which intracellular pathway activated by TLR activation is responsible 
for induction of ANGPTL4. Also, it is unsure whether FFA, known to activate PRRs such 
as TLR4 in adipocytes and macrophages (11,12), may increase ANGPTL4 expression via 
TLR4 activation. It should be noted that the similarity in plasma FFA levels between 
the various groups despite major differences in plasma ANGPTL4 levels, suggests that 
plasma FFA are not a major determinant of ANGPTL4 in the population studied. Since 
CRP itself is a marker rather than a mediator of inflammation (18), the nature of the 
inflammatory stimuli that cause an increase in plasma ANGPTL4 in humans evidently 
still has to be identified. Also, it would be of interest to study the response of ANGPTL4 
to inflammatory stimuli in other cell types, including human adipocytes.
We hypothesized that the inflammation-induced increase in plasma ANGPTL4 in 
subjects with MetS and T2DM may induce further dyslipidemia. Indeed, taken all groups 
together, we observed a modest negative correlation between ANGPTL4 and plasma 
HDL-cholesterol (r=-0.143; p<0.009). Some limitations do apply to our study. First of 
all, we previously showed that the ANGPTL4 ELISA measures full length ANGPTL4 and 
the C-terminal truncated fragment of ANGPTL4 but not the N-terminal truncated frag-
ment. Only full length and the N-terminal fragment of ANGPTL4 influence plasma lipids. 
It is unclear to what extent the plasma concentrations of C-terminal and full-length 
ANGPTL4 reflect the concentration of N-terminal ANGPTL4. The mechanism underlying 
the relationship between inflammation and plasma ANGPTL4 levels is unknown as yet, 
and probably involves causal stimuli other than CRP that merely represents a marker 
of inflammation. Further studies into the causal relationships are thus required. Also, 
it is unclear why CRP is lower in T2DM compared to subjects with MetS with low grade 
inflammation. It should be noted that well-controlled diabetic patients with an HbA1c 
between 6.5-8.5%, a BMI between 25-32 kg/m2, blood pressure < 150/85 mmHg and no 
history of diabetes related complications were included, who were treated with drugs 
such as statins with pleotropic anti-inflammatory effects. Furthermore, higher CRP in 
subjects with MetS with low grade inflammation may be explained by a higher percent-
age of smokers in that group. Also, from the current study set up it is unclear whether 
the relationship between ANGPTL4 and CRP in humans is solely explained by activation 
of macrophages. Other cell types and tissues may also be involved.
In conclusion, we provide a novel link between inflammation and ANGPTL4. An in-
creased inflammatory state in subjects with MetS and T2DM was associated with higher 
plasma ANGPTL4 levels. Additionally, a positive correlation was observed between 
plasma CRP and ANGPTL4. Although in vitro studies confirmed that PRR ligands increase 
ANGPTL4 expression, further studies into the precise mechanisms underlying the rela-
tionship between inflammation and ANGPTL4 in humans are warranted.
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To assess the short-term effects of a standardized oral glucose load on regional aortic 
pulse wave velocity (PWV) using two-directional in-plane velocity encoded magnetic 
resonance imaging (MRI). 
Materials and Methods
A randomized, controlled intervention was performed in 16 male subjects 
(mean±standard deviation: age: 59±7 years, body mass index: 28±3 kg/m2) with im-
paired fasting glucose. The intervention consisted of an oral glucose load (75 grams of 
carbohydrates in 300 ml water) at one study day and water (300 ml) at the other study 
day. PWV was measured using multislice two-directional in-plane velocity-encoded MRI. 
results
PWV in the proximal aorta at 1 hour post-glucose load decreased compared to PWV 1 
hour post-water (delta PWV: -1.0±2.6 vs. 0.6±2.0 m/s, P=0.02). Eight responding subjects 
showed a significant decrease in PWV of the proximal aorta after the glucose load and 
revealed a lower blood pressure and were significant less obese (P=0.037) compared to 
non-responders. There was no significant change in PWV of the distal aorta at 1 hour 
post-load comparing both intervention groups. 
Conclusion
A standardized oral glucose load induces a decrease of the proximal, but not of the 
distal, aortic PWV. Regional response of aortic PWV may be associated with features of 
the metabolic syndrome.
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iNTroduCTioN
Insulin plays an important role in hemodynamic regulation by modulating vascular tone. 
Nitric oxide (NO) release from the endothelium may be implicated in this process and 
induces vasodilation (1). The effect of insulin on vascular tone may be region-specific 
for various vascular beds and locations.  In vitro the contribution of NO to endothelium 
dependent vasodilation is significantly larger in central arteries than in distal microves-
sels (2). Furthermore, Westerbacke et al. demonstrated a decrease in large peripheral 
arterial stiffness in healthy subjects after infusion of physiologic insulin concentrations 
(3). They assessed vascular response from a change in augmentation index, which was 
assessed by applanation tonometry of the radial artery. 
Aortic pulse wave velocity (PWV) is a surrogate marker for central arterial stiffness and 
a prognostic marker for cardiovascular disease (4). PWV is most frequently measured 
by tonometry and echo Doppler.  In contrast to these traditional methods, magnetic 
resonance imaging (MRI) in combination with velocity-encoding enables regional as-
sessment of the PWV in multiple locations in the aorta due to its accuracy in determin-
ing the true path length of the propagating wave in the aorta. Moreover, MRI-based 
estimates of regional aortic PWV  have been well validated against intra-arterial pressure 
measurements as the gold standard (5). 
Our hypothesis is that a glucose load may induce local changes in aortic stiffness 
mediated by increases in plasma insulin and possibly NO release. Accordingly, the pur-
pose of our study was to assess the short-term effects of a standardized glucose load on 
regional aortic PWV using the two-directional in-plane velocity encoded MRI technique. 
MaTErials aNd METhods
subjects
Sixteen men (mean±SD: age: 59±7 years, BMI: 28±3 kg/m2) for the current study were re-
cruited from general health care practices. All volunteers participated in cardiovascular 
screening and fulfilled the criteria for impaired fasting glucose [IFG; fasting glucose ≥5.6 
mmol/L and <7 mmol/L(6)]. The screening visit consisted of a medical history, physical 
examination and laboratory screening in the fasted state (including plasma glucose, 
lipids, creatinine, alanine aminotransferase, aspartate aminotransferase). Inclusion 
criteria were: males aged between 18 and 75 years. Exclusion criteria were: previously 
diagnosed diabetes mellitus, any chronic disease, history of cardiovascular disease, use 
of any of the following medication: antihypertensives, glucose lowering medication, 
statins or fibrates, blood pressure >160/100 mmHg [grade 2 or 3 hypertension according 
to guidelines of European Society of Hypertension and European Society of Cardiology 
Nathanja Tjeerderma - binnenwerk v7b.indd   81 08-09-15   11:35
82 Chapter 4
(7)], smoking or any contra-indication for MRI. Hypertension was defined as systolic and/
or diastolic blood pressure of greater than or equal to 140 mmHg and/or greater than 
90 mmHg. 
This study was executed in accordance with the principles of the Declaration of Hel-
sinki, it was approved by the local medical ethics committee and after the nature of 
procedures had been explained all participants signed informed consent.
study design 
This randomized, controlled intervention study consisted of two study days, with at least 
one week between the study days. The intervention consisted of a single oral drink with 
300 ml water with 75 grams of carbohydrates (Dextropur, Dextro Energy GmbH&Ko. 
KG, Germany) on one day and the other study day the intervention consisted of 300 
ml water only. The sequence of both interventions was randomly assigned. Participants 
were instructed to refrain from alcohol and caffeine and to avoid exercise during 24 
hours before both study days. Subjects consumed the evening before both study days 
the same standard meal, consisting of on average 480 kcal (37 energy percent (En%) 
carbohydrates, 44 En% fat). After a twelve hours overnight fast, participants were admit-
ted at the research unit of the university hospital. After measurement of weight and 
blood pressure, an intravenous cannula was inserted and a first blood sample was taken. 
Subsequently, participants were transferred to the MRI scanner for the first MRI scan 
(see below for scan protocol) in a temperature-controlled room. After the first MRI scan 
subjects received the glucose or control drink. Blood samples were drawn 30, 60, 90 and 
120 minutes after ingestion of the drink. PWV measurements were repeated at 60 and 
120 minutes after the ingestion of the drink. 
blood sampling and analysis
Blood samples were collected in serum-gel and potassium-EDTA tubes (Sarstedt 
Monovette®, Sarstedt, Germany). The EDTA tubes were immediately put on ice after 
sampling. All samples were centrifuged (3540g at 4°C, during 20 minutes) and stored in 
aliquots at -80 °C until analysis. Samples were measured in one assay run. Plasma glucose 
was measured on a Modular P800 chemistry analyzer of Roche Diagnostics (Mannheim, 
Germany, total CV: 1.4%). Serum insulin was measured using an Immulite 2500 analyzer 
of Siemens Diagnostics (Breda, The Netherlands, total CV 4.7%). The Homeostasis Model 
Assessment-Insulin Resistance Model (HOMA2 calculator 2.2.2 2007; www.dtu.ox.ad.uk) 
was used to calculate insulin resistance.
Pulse wave velocity 
Participants were studied in supine position using a 1.5 Tesla whole-body MR scanner 
(Gyroscan ACS/ NT15, Philips, Best, The Netherlands). The body coil and a five element 
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cardiac receiver coil were used for data acquisition. PWV was determined using mul-
tislice, two-directional in-plane velocity-encoded (VE) MRI. This technique has recently 
been described in detail and will be summarized here (5). PWV is calculated by the ratio 
of the distance along the aortic center line (∆x) and the transit-time of the propagating 
systolic pulse wave between two measurement sites (∆t). A volume slab consisting of 
three slices was acquired to image the ascending aorta, aortic arch and the descending 
aorta in double-oblique sagittal orientation, using a steady-state free-precession se-
quence. Scan parameters included: field-of-view (FOV): 450×270 mm2, slice thickness of 
10 mm, echo time (TE) of 1.4 ms, repetition time (TR) of 2.9 ms, flip angle of 50 degrees. 
Bidirectional in-plane VE MRI was acquired in anterior-posterior (AP) and feet-head 
direction (FH) with free breathing and retrospective ECG-gating using the orientation of 
the 3-slice volume slab. Scan parameters included: velocity sensitivity of 150 cm/s, TE of 
2.4 ms, TR of 4.3 ms, flip angle of 10 degrees, number of signal averages of 2.
In the three-slice volume slab, the aorta was manually segmented, from the aortic 
root to the descending aorta at the level of the 2nd lumbar vertebrae. Segmentations 
were performed by one observer (with 3 years of experience in cardiac MRI) supervised 
by a senior researcher (with 15 years of experience in cardiac MRI). Image analysis was 
performed using in-house developed MASS software (Leiden University Medical Center, 
Leiden, the Netherlands). Perpendicular to the automatically defined center line of the 
aorta, 200 sample chords were equidistantly distributed. From each sample chord, the 
maximal aortic flow velocity in the direction parallel to the centerline was calculated 
for each cardiac phase, resulting in 200 time-velocity curves (schematic represented 
in figure 1). From all 200 time-velocity curves, the time-to-half-peak was automati-
cally determined, using difference between maximum and minimum aortic flow velocity 
along the systolic upslope. The length of the aorta was manually determined by placing 
a poly-line along the center line of the aorta in the three-slice volume slab. Regional 
PWV was determined from the inverse slope, calculated by linear regression between 
the positions along the centerline versus the transit-time relation.
We calculated the PWV proximal aorta (from ascending aorta to proximal descending 
aorta, both defined in a plane transecting the aorta at the level of the pulmonary trunk), 
distal aorta (below proximal aorta to the level of the 2nd lumbar vertebrae) and the total 
PWV (proximal aorta and distal aorta summed). A change in PWV relative to baseline 
measurement was considered significant if change in PWV exceeded 2x coefficient of 
variance (COV) in PWV-assessment. The COV of this method was determined previously 
from repeated in-plane PWV-measurements (5) and was 10% for aortic PWV of the proxi-
mal and 12%  for aortic PWV of the distal aorta. 
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figure 1. Pulse wave velocity (PWV) assessment by multislice two-directional inplane velocity-encoded 
Magnetic Resonance Imaging (MRI). The aorta was manually segmented along the ascending aorta from 
the level of the pulmonary trunk to the descending aorta at the level of the second lumbar vertebrae (A) 
and contours were copied to the velocity images (B represents feet-head encoded velocity). The 200 sample 
chords were equidistantly distributed along the centerline and for each chord, the maximal aortic flow 
velocity along the centerline of the aorta was determined for each cardiac phase, resulting in 200 time-
velocity curves (C). The arrival times of each of the 200 wave forms are plotted against the position along 
the centerline and PWV is determined from the inverse slope by linear regression between arrival time and 
position. 
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statistical analyses
Data are expressed as mean ± standard deviation (SD). Comparisons of the change in 
PWV between the two interventions were performed with a paired samples t-test for 
continues variables and a Chi-Square test was used to compare the number of subjects 
with a change in aortic PWV. A p-value <0.05 was considered statistically significant. 
Statistical analyses were performed using SPSS (SPSS Inc.Chicago, Illinois, USA). Graphs 
were created using GraphPad Prism 5.01 (GraphPad Software, Inc., La Jolla, USA).
rEsulTs
Sixteen men were included (age: 59±7 years, body mass index: 28±3 kg/m2). Baseline 
characteristics of the study population are presented in Table 1. 
Glucose and insulin concentrations significantly increased over time after the glucose 
load (figure 2a&b, P<0.05) compared to the water load.
Aortic PWV was not different between both study days at baseline (aortic PWV before 
the glucose load vs. water: proximal aorta 8.0±3.0 vs. 7.0± 2.2 m/s, P>0.05; distal aorta 
9.8±4.7 vs. 9.2±3.1 m/s, P>0.05 and total aorta 8.8±1.9 vs. 8.2±1.7 m/s, P>0.05). 
The change (delta) in aortic PWV at one hour after the intervention was calculated as 
aortic PWV at 1 hour minus aortic PWV at baseline. Delta aortic PWV at two hours was 
calculated in a similar way. Delta PWV in the proximal aorta at one hour after the glucose 
load was significantly lower compared to the delta PWV one hour after the control load 
Table 1. Characteristics of the study population at screening
N 16
Age (years) 59±7
Waist circumference (cm) 101±9
Body mass index (kg/m2) 28.0±2.9
Serum glucose at screening (mmol/l) 5.6±0.4
HbA1c (%) 5.4±0.3
Plasma cholesterol (mmol/L) 6.6±1.0
HDL cholesterol (mmol/L) 1.5±0.3
Cholesterol/ HDL ratio 4.7±1.0
Plasma triglycerides (mmol/L) 1.9±1.3
Heart rate (beats/min) 63±10
Systolic blood pressure (mmHg) 136±11
Diastolic blood pressure (mmHg) 91±6
Hypertension, n (%) 11 (69)
Values are means ± standard deviation unless otherwise stated. HDL = high density lipoprotein. Hyperten-
sion = blood pressure ≥ 140/90 mmHg 
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(delta PWV proximal aorta 1 hour after the glucose load -1.0±2.6 vs. water 0.6±2.0 m/s, 
P=0.02). The delta PWV of the proximal aorta was not significantly different at two hours 
after the glucose or control load. 
The glucose load did not affect the change in aortic PWV of the distal and the total 
aorta at respectively 1 and 2 hours. (Table 2 delta PWV distal aorta one hour after the 
glucose load: -0.4±1.9 vs. water -0.1±1.7 m/s P>0.05; resp. after two hours glucose load 
-0.7±2.1 vs. water 0.1±2.3 m/s P>0.05; delta PWV total aorta: one hour after the glucose 
load -0.8± 1.7 vs. water -0.3 ±1.5 m/s P>0.05 resp. after two hours glucose load 0.2±1.8 
vs. water 0.0±1.0 m/s P>0.05).
figure 2. Plasma glucose and insulin concentrations during 120 min after a standardized oral glucose and 
water load. Plasma glucose concentrations (left panel) and plasma insulin concentrations (right panel) dur-
ing 120 min after a 75 gram glucose load with 300 mL water (closed circles with continuous line) versus 300 
mL water only (water, open circles with dotted line). The *P<0.05 compared with baseline in general linear 
model for repeated measures with Bonferroni post hoc test, † P<0.05 compared with 30 min in general 
linear model for repeated measures with Bonferroni post hoc test. 
Table 2. Delta aortic PWV one and two hours after the glucose load vs. water






P  between groups
Delta PWV proximal aorta m/s
1 hour -1.0±2.6 +0.6±2.0 0.02
2 hours +0.2±2.6 -0.8±1.8 0.13
Delta PWV distal aorta m/s
1 hour -0.4±1.9 -0.1±1.7 0.7
2 hours -0.7±2.1 +0.1±2.3 0.5
Delta PWV total  aorta m/s 
1 hour -0.8±1.7 +0.2±1.8 0.5
2 hours -0.3±1.5 +0.003±0.98 0.8
Values are means ± standard deviation. PWV = pulse wave velocity
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A significant change in proximal aortic PWV defined as a decrease in PWV exceed-
ing 2xCOV was observed in eight subjects one hour after the glucose load, whereas 
a decrease was found in one subject under the control conditions (P<0.05, figure 3). 
For the distal aorta one hour after the intervention there was no significant difference 
in the number of subjects with a decrease in aortic PWV comparing the glucose vs. 
the water load (glucose n=3 vs. water n=1, P>0.05, figure 3). Subjects who showed 
a response by a decrease in proximal aortic PWV at one hour after the glucose load 
were significantly less obese as defined by waist circumference (98±6 cm) compared to 
subjects with no change in proximal aortic PWV (104±3 cm, p=0.037). Blood pressure 
was lower (133±10 vs. 140±13 mmHg, P>0.05) but like other baseline characteristics did 
not differ significantly between groups. Furthermore there were no differences in the 
number of subjects with an increase or decrease in aortic PWV at two hours comparing 
the two interventions.
Changes in PWV did not correlate with measures of insulin resistance including delta 
glucose, delta insulin, area under the curve and HOMA-IR.
disCussioN 
The aim of the current study was to investigate the short-term effect of a standardized 
glucose load on region-specific aortic pulse wave velocity measured by two-directional 
in-plane velocity encoded MRI. The main finding of our study is that a standardized oral 
glucose load decreases aortic PWV significantly within one hour compared to water. 
Secondly this decrease in MR assessed aortic stiffness was region-specific, because it 
was observed only in the proximal, but not in the distal aorta. Finally, the subjects who 
showed a response in proximal aortic stiffness were less obese and had lower blood 
figure 3. Change in pulse wave velocity (PWV) in proximal aorta after a standardized oral glucose or water 
load. Number of subjects with no change, decrease or increase in PWV assessed in the proximal aorta dur-
ing first hour after a 75-g glucose load with 300 mL (black bar) versus 300 mL water only (gray bar). † P<0.05 
between groups
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pressure than the non-responders, possibly indicating a link between response and 
features of the metabolic syndrome.
Our results (i.e. a decline in arterial stiffness induced by an elevated glucose concen-
tration) are in line with Westerbacka et al. (3) who demonstrated a decrease in central 
arterial stiffness in nine healthy males within one hour after infusion of insulin during 
a euglycemic clamp study. However, vascular response was assessed by augmentation 
index with the use of applanation tonometry recorded from the periphery (radial artery). 
The current study is the first to demonstrate the effect of a glucose load on regional 
aortic stiffness assessed by MRI measured PWV.
Interestingly, Kawano et al. (8) observed a decrease in endothelium-dependent vaso-
dilation of the brachial artery in response to a standardized glucose load, measured as 
flow mediated vasodilation after sublingual nitroglycerin. Furthermore, Lambert et al. 
(9) observed no acute effects on carotid compliance of combined hyperglycemia and 
hyperinsulinemia on carotid compliance. Apparently, different measurement techniques 
and the measurement at different peripheral locations may yield dissimilar results.
 Furthermore, most studies have not controlled for recent food intake, although rec-
ommendations suggest that subjects refrain from smoking, eating and drinking bever-
ages containing caffeine before measurement of arterial stiffness. The measurements in 
our study were performed in controlled postabsorptive conditions with standardized 
intake and physical activity 24h before assessing PWV. Furthermore we used a well-char-
acterized, non-smoking population without medication use and co-morbidities. Male 
volunteers were chosen to exclude the confounding effect of changes in reproductive 
hormone level. Each subject served as his own control, which enabled paired statistical 
analysis, which is able to detect small intra-individual effects. 
The observed decrease in arterial stiffness was region-specific: it was observed in the 
ascending aorta and aortic arch, but not in the distal aorta. Various vascular beds and 
locations may react differently to the effect of insulin and other vasoactive influences. In 
vitro the contribution of NO dependent vasodilation is larger in central arteries than in 
distal microvessels (2). This may be explained by a smaller contribution of endothelium 
derived hyperpolarizing factor (i.e. molecules involved in the regulation of vascular 
tone,  defined as the response that persists in the presence of combined inhibition of NO 
and prostacyclin) in larger arteries which was shown in an experimental study in human 
arteries (10). Consistent with variation in vascular reactivity to mediators of vasodila-
tion, regional variation in the elastin versus collagen ratio exists within the aorta, with 
the highest ratio in the proximal segment of the aorta compared to the distal segment 
(11-13). Therefore, it is possible that the effect of postprandial hyperinsulinemia would 
have less impact on the distal segment. As the distal segment contains more collagen 
it is more affected by processes like aging and cross-linking by advanced glycation end 
products and this segment may be resistant to the vasodilatory effect of insulin.
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The lack of response in some male volunteers may be related to their higher blood 
pressure and significant larger waist circumference. Impaired NO synthesis has been 
reported in conditions like the metabolic syndrome which diagnosis is based on the 
presence of conditions including central obesity and hypertension (14). In addition an 
impaired insulin-induced decrease in arterial stiffness was shown in human obesity (15). 
This observation was somewhat unexpected in this rather small series of subjects, 
but provides the basis for further hypothesizing that there may a link between regional 
vascular response and insulin-resistance which is a key component of obesity-related 
disorders like the metabolic syndrome. Further studies are required to evaluate this 
possible mechanism. 
Our study had several limitations. First arterial stiffness was measured in men who 
fulfilled the criteria for impaired fasting glucose. These volunteers were accessible 
for research as this group participated in cardiovascular risk screening. Although this 
middle-aged group did not have a history of cardiovascular disease, nor used blood 
pressure or lipid lowering medication, more than 50% of the volunteers were diagnosed 
with hypertension and they were at risk for diabetes. Therefore, the findings of this study 
cannot be generalized to healthy men as this may lead to an underestimation of the 
physiological effect of a glucose load on aortic stiffness. Finally, a post glucose load 
decline in PWV may potentially have occurred at different time points than those that 
were chosen for testing. However, the time required for MRI measurements imposed a 
practical limitation on the number of subsequent tests that could be performed after 
the glucose load 
Arterial PWV, especially of the aorta, has emerged as an important independent pre-
dictor of cardiovascular mortality (4,16). Aortic stiffness will increase the workload of the 
heart resulting in a higher risk of left ventricular hypertrophy and cardiac failure. Aortic 
arch PWV is associated with cardiac and cerebral damage (17). Furthermore stiffening 
of the aorta leads to higher pulsatile pressure traveling to microvascular beds in the 
kidneys and brain (18). Regional abnormalities in the vascular actions of insulin may be 
of relevance in the pathogenesis of macro- and microvascular disease in insulin resistant 
states like the metabolic syndrome and type 2 diabetes. Further research is needed to in-
vestigate determinants of the aortic PWV in both healthy and insulin resistant subjects. 
In conclusion, a standardized oral glucose load elicits an acute transient decrease of the 
PWV in the proximal, but not in the distal aorta and this regional response may be as-
sociated with features of the metabolic syndrome. Therefore these results indicate that 
two-directional in-plane velocity-encoded MRI enables evaluation of region-specific 
changes of PWV in response to a glucose load.
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Type 1 diabetes mellitus (T1DM) is associated with brain damage, such as white matter 
hyperintensities and early development of cerebral atrophy, and impaired cognitive 
functioning. Metabolic factors, like hyperglycemia, and vascular complications have 
been proposed to affect the brain in T1DM. Cortical grey matter and the thalamus and 
hippocampus, two subcortical structures, are affected in patients with T1DM. No stud-
ies have yet investigated the effects on other subcortical grey matter structures. Our 
objective was to assess, with the advanced magnetic resonance (MR) imaging technique 
voxel-based morphometry (VBM), whether volumes of the basal ganglia differ between 
patients with longstanding T1DM and healthy controls. 
Methods
Sixty-two patients with T1DM and 62 age and gender matched healthy controls under-
went MR imaging of the brain. Volumes of the basal ganglia, amygdala, hippocampus 
and thalamus were assessed with VBM. 
results
T1DM patients showed volume loss of all of these grey matter areas, except for the 
amygdala. Furthermore, after correcting for potential confounding factors, the thala-
mus, hippocampus and putamen were still significantly smaller. 
Conclusions
Using MR VBM technique, volume loss of the basal ganglia, hippocampus and thalamus 
is observed in patients with type 1 diabetes compared to controls.
Nathanja Tjeerderma - binnenwerk v7b.indd   92 08-09-15   11:35
Effects of type 1 diabetes on grey matter volume 93
iNTroduCTioN
Type 1 diabetes mellitus (T1DM) is associated with micro- and macrovascular complica-
tions (1,2). It has become increasingly clear that T1DM also affects the brain (3,4). Several 
structural brain abnormalities such as white matter hyperintensities, brain infarctions 
and the early development of cerebral atrophy (5-7) have been observed by magnetic 
resonance imaging (MRI). Cross sectional studies have demonstrated that generalized 
white and grey matter volume loss in patients with T1DM is associated with cognitive 
functioning and even dementia (8). Both hyperglycemia and vascular complications 
have been proposed as underlying mechanisms in T1DM associated declined cogni-
tive functioning and volume loss, but the pathogenesis is complex and incompletely 
understood (7,9-11).
Although previous studies have shown that T1DM is associated with grey matter 
density changes in general (7) and focal cortical regions and the left thalamus (12,13) 
and hippocampus (14,15), there are no data on the volumes of subcortical structures 
including the basal ganglia and amygdala in T1DM. Since the thalamus and the hip-
pocampus are subcortical structures, we hypothesized that other subcortical structures, 
like the basal ganglia and the amygdala could also be affected in patients with T1DM.
Voxel-based morphometry (VBM) is a relatively novel and sophisticated analysis tech-
nique which enables to test for regional differences in brain volume. VBM enables to 
identify subtle grey matter alterations (16). As regional specific reductions in grey matter 
density in areas responsible for language processing and memory have been found in 
T1DM (12) we set out to perform in depth grey matter studies in T1DM, using VBM. We 
hypothesized that subcortical structures differ between patients with longstanding 
T1DM and healthy controls. 
Methods
Study participants
Patients with T1DM were recruited from the local outpatient clinic between February 
2008 and January 2010. For inclusion, patients had to be older than 18 years and di-
agnosed with T1DM. A total of 62 patients (34 men, 28 women; mean age 51.6 ± 12.4 
years) gave written informed consent to participate in the study. Healthy volunteers 
were recruited by advertisement in local newspaper. Sixty-two age and gender matched 
controls were enrolled in the study. Exclusion criteria for all participants were congenital 
aortic/heart disease, evidence of aortic valve stenosis or insufficiency, a history of stroke 
and general contraindications to MRI, like claustrophobia or a pacemaker. T1DM was 
defined according to WHO criteria (17).
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Medical data were obtained in all participants by standardized interviews and physi-
cal and laboratory examinations. Duration of T1DM in years was estimated as the time 
passed between the reported age of diagnosis and the MRI examination. Blood pressure 
and heart rate were measured using a semiautomated sphygmomanometer (Dinamap, 
Critikon, Tampa, Fla, USA). 
Hypertension was defined as: systolic blood pressure > 140 mmHg and/or diastolic 
blood pressure > 90 mmHg, on repeated physical examination before antihypertensive 
therapy was instituted and according to the criteria of the European Society of Hyper-
tension (18), or a blood pressure > 140/90 mmHg at time of MR imaging. Furthermore, 
smoking status (i.e. non-smoker or current smoker), body mass index (BMI) and high-
density lipoprotein (HDL), total cholesterol, triglycerides, creatinine, glycated hemoglo-
bin (HbA1C) in T1DM and fasting glucose in controls were determined. Renal function 
defined as estimated glomerular filtration (GFR) rate was calculated with the Modifica-
tion of Diet in Renal Disease (MDRD) equation: 186 * (serum creatinine µmol/L / 88,4)-1.154 
x (age)-0.203 (x 0,742 if female)). Retinopathy was diagnosed based on fundoscopy.
This study was approved by the local medical ethics committee and was conducted 
according to the principles in the Declaration of Helsinki. 
MRI protocol 
All brain MRIs were performed on a 3.0 Tesla (Achieva; Philips Medical Systems, Best, 
The Netherlands). Brain MRI consisted of a 3 dimensional T1 (3D T1) sequence for brain 
volume assessment. 3D T1 acquisition parameters were: repetition time (TR) 9.8 ms, 
echo time (TE) 4.6 ms, flip angle (FA) 8º, field of view (FOV) 224 mm, 192x152 acquisition 
matrix, 256x256 reconstruction matrix, slice thickness 1.2 mm, 120 slices, no slice gap). 
MRI post processing 
All MRI scans were analyzed using different tools of FSL (FMRIB Software Library) (19). 
Whole brain volume, grey and white matter volumes were calculated using the FSL-tool 
SIENAX (Structural Image Evaluation, using Normalization, of Atrophy) (20,21). SIENAX 
starts by extracting brain and skull images from the single whole-head input data  (22). 
The brain image is then affine-registered to MNI152 space (19), using the skull image to 
determine the registration scaling. This is primarily done in order to obtain the volumet-
ric scaling factor, to be used as a normalization for head size. Next, tissue-type segmen-
tation with partial volume estimation is performed to calculate total volume of brain 
tissue, including separate estimates of volumes of grey matter and white matter (23). To 
determine the volume of the subcortical twin structures nucleus accumbens, amygdala, 
caudate nucleus, hippocampus, pallidum, putamen and thalamus FMRIB’s Integrated 
Registration and Segmentation Tool (FIRST) was used. FIRST starts by registering all im-
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ages to MNI152 templates. Secondly it fits models for all different structures (meshes) to 
the images and finally applies boundary correction for the volumetric output.
A visual inspection of all registrations was performed and all final segmentations were 
visually inspected for accuracy. 
Statistical analysis
Statistical analysis was performed by using SPSS (SPSS, Chicago, Illinois, USA), version 
20. To compare clinical characteristics between T1DM and age and gender matched 
controls paired samples t-test for continuous variables with a normal distribution and 
nonparametric tests for non-normally distributed variables were used. Furthermore the 
McNemar test for dichotomous variables was used. Continuous variables are expressed 
as mean ± standard deviation (sd) or if non-normally distributed as median (interquartile 
range) and categorical variables were presented as frequencies and percentages.
The left and right volumes of the subcortical structures including the basal ganglia, 
the hippocampus and thalamus were added up and divided by 2 in order to obtain 
mean volumes. 
Multivariate linear regression analyses were performed to assess the independent 
contribution of T1DM to the volumes of subcortical structures, by controlling for the 
following confounders: age, gender, GFR, smoking, BMI, hypertension, HDL-cholesterol 
and triglycerides. The β-regression coefficients and p-values are reported. Significance 
was reached when p<0.05 (two-tailed).
rEsulTs
Three-dimensional T1-weighted MRI of the brain was performed in 62 patients with 
T1DM and 62 age and gender matched volunteers (52±12 years, 55% male). Mean T1DM 
duration was 27.4±12.7 years, all patients used insulin and diabetic retinopathy was 
present in 47 (76%) diabetic patients. The clinical characteristics of the study popula-
tion are shown in Table 1. There were no differences between groups with respect to 
smoking, body mass index and triglycerides. Cholesterol was lower and HDL higher in 
patients with T1DM compared to controls (p= 0.011 respectively 0.006). Twenty eight 
(45%) T1DM patients and 1 control subject used lipid lowering medication. Patients 
with T1DM were more often diagnosed with hypertension (37% vs 5%, p<0.001) and 
used more often blood pressure lowering drugs (34 % vs 2 %, p<0.001). Renal function 
estimated by eGFR was higher in T1DM (92.3 ±19.4 ml/min/1.732) compared to healthy 
volunteers (82.4±12.4 ml/min/1.732, p<0.001).
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Magnetic resonance imaging of the brain
Brain grey and white matter volumes were smaller in T1DM (Table 2). Both the thala-
mus (p<0.001) and the hippocampus (p=0.003) were significantly smaller in T1DM.  Of 
the basal ganglia, volumes of the nucleus accumbens (p=0.044), the globus pallidus 
(=0.013), the putamen (p<0.001) and the nucleus caudate (p=0.044) were smaller in 
patients with T1DM compared to healthy volunteers. The amygdala was the only struc-
ture of the grey matter areas explored in this study which did not differ in size between 
groups (p=0.984).
After correcting for the potential confounding factors age, gender, GFR, smoking, BMI, 
hypertension, HDL-cholesterol and triglycerides, the volumes of the thalamus (p=0.034), 
hippocampus (p=0.010) and putamen (p=0.002) remained significantly smaller in T1DM 
(Table 2). HbA1c was not associated with volumes of any of the grey matter areas.
Table 1. Clinical characteristics
Type 1 diabetes mellitus (n=62) Healthy controls  (n=62) P value
Male sex, n (%) 34 (54.8) 34 (54.8) 1.000
Age, years 52 ± 12 52 ± 13 0.381
Type 1 diabetes duration, years 27.4 ± 12.7 -
Hypertension, n (%) 23 (37.1) 3 (4.8) <0.001a
Current smoker, n (%) 8 (12.9) 8 (12.9) 1.000
Body mass index, kg/m2 25.3 ± 3.3 25.4 ± 3.4 0.791
ACE inhibitors, n (%)  10 (16.1) 0 (0) 0.004a 
AT2 antagonist, n (%)  11 (17.7) 0 (0) 0.125
Ca antagonist, n (%)  5 (8.1) 0 (0) 0.125
Diuretics, n (%)  7 (11.5) 0 (0) 0.016a
B blocker, n (%)  6 (9.7) 1 (1.6) 0.125
Use of statin, n (%) 28 (45.2) 1 (1.6) <0.001a 
Retinopathy, n (%) 47 (77) -
HbA1c, % 7.7 ± 1.1 - -
HbA1c, mmol/mol 60.9 ± 11.7  
Fasting plasma glucose, mmol/l - 5.22 ± 0.86 -
Creatinine, mmol/l 74.8 ± 12.4 81.6 ± 11.8 0.001a 
Estimated GFR (MDRD), ml/min 92.3 ± 19.4 82.4 ± 12.4 <0.001a 
Total cholesterol, mmol/l 4.85 ± 0.95 5.33 ± 1.30 0.011a 
HDL cholesterol, mmol/l 4.80 (4.29-5.40) 5.32 (4.56-6.36) 0.013a 
Triglycerides, mmol/l (median) 1.16 (0.79-1.39) 1.12 (0.82-1.55) 0.504
Data are means ± sd, number (%) or median (interquartile range). HbA1c: glycated hemoglobin; GFR: glo-
merular filtration rate, HDL: high density lipoprotein. Data were compared by paired samples t-test. a P<0.05.
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disCussioN
The main purpose of the current study was to investigate with VBM technique whether 
the volumes of the hippocampus, thalamus, amygdala and basal ganglia, differed 
between patients with longstanding T1DM and healthy controls. The main finding of 
this study is that T1DM patients showed volume loss of all of these grey matter areas, 
except for the amygdala. Secondly our results show that after correcting for potential 
confounding factors, the thalamus, hippocampus and putamen were still significantly 
smaller in patients with T1DM. 
Previous studies on hippocampal and thalamic volumes in T1DM have been per-
formed (12,14,15,24). However, to our knowledge this is the first study to investigate in 
depth volume loss in grey matter areas other than the hippocampus and thalamus, in 
T1DM with VBM. Earlier studies on grey matter in T1DM showed equivocal results with 
respect to the hippocampus and thalamus (12,14,15,24). However, three of these studies 
were performed on MR scanners with lower field strengths 1.0T (15) and 1.5T (12,14), as 
compared to our 3.0T MR scanner. In addition two of these studies did not use VBM to 
calculate the hippocampal volumes (14,15). 
In our study the amygdala was the only structure with preserved volume in T1DM pa-
tients which is in contrast to a study performed in patients with type 2 diabetes mellitus 
(25). The amygdala has an important role in the reaction to hypoglycemia (26). Although 
the mechanism behind the differential volume remains unclear, the preservation of the 
Table 2. Magnetic resonance imaging characteristics of patients with type 1 diabetes mellitus and healthy 
controls
Diabetes mellitus (n=62) Healthy controls (n=62) P value
Volume, cm3 Volume, cm3
Nucleus accumbens 0.46 ± 0.13 0.50 ± 0.10 0.043a 
Globus pallidus 1.92 ± 0.25 2.02 ± 0.20 0.013a 
Amygdala 1.38 ± 0.23  1.38 ± 0.21 0.984
Putamen 4.77 ± 0.47 5.17 ± 0.57 <0.001a 
Nucleus caudate 3.57 ± 0.41 3.70 ± 0.44 0.044a 
Thalamus 7.53 ± 0.87 7.98 ± 0.77 <0.001a 
Hippocampus 3.96 ± 0.40 4.17 ± 0.41 0.003a 
Whole brain
Grey matter 7.09 ± 0.45 ´ 102 7.34 ± 0.43 ´ 102 <0.001a
White matter 7.04 ± 0.47 ´ 102  7.24 ± 0.46 ´ 102 0.014a 
Grey + white matter 14.14 ± 0.72 ´ 102 14.57 ± 0.74 ´ 102 <0.001a
Values are means ± sd unless otherwise indicated. Volumes are corrected for head size. Grey matter, volume 
of normalized grey matter; White matter, volume of normalized white matter; Grey + white matter, volume 
of white and grey matter. Data were compared by paired samples t-test. a P<0.05.
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volume of the amygdala could be related to its important function in the hypoglycemia 
awareness.
The underlying mechanisms for grey matter changes in T1DM are incompletely un-
derstood. There are several hypotheses on the pathological mechanisms causing these 
brain alterations. Both hyper- and hypoglycemia have been proposed to be involved. 
Hypoglycemic events are associated with less grey matter density (4,12,27). Furthermore 
hyperglycemia, expressed as a higher HbA1C, was suggested to contribute to lower grey 
matter density in the left hippocampus (12), which was not confirmed in our study. In 
addition, accelerated formation and accumulation of advanced glycation end products 
have also been suggested to contribute to brain alterations and brain damage in T1DM 
(13,28,29). It has also been proposed that diabetes mellitus contributes to accelerated 
aging of the brain, which can lead to microvascular abnormalities (5,13). Furthermore, 
prior studies suggest that higher blood pressure or hypertension also negatively affect 
grey matter (30-33). However, in our study, effects of T1DM on specific grey matter 
structures remained significant after correction for hypertension. The intriguing finding 
that T1DM differentially affects specific grey matter areas is challenging but difficult to 
explain. Potential differences in the susceptibility of the thalamus, hippocampus and 
putamen and other grey matter structures to T1DM related factors may be involved. 
In conclusion using VBM technique, we found differential volume loss of the hippo-
campus, thalamus and basal ganglia in patients with T1DM, which was independent 
of potential confounding factors. The clinical significance and underlying mechanisms 
remain to be elucidated.  
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To assess the association between aortic pulse wave velocity (PWV), as a marker of arte-
rial stiffness and diffusion tensor imaging (DTI) of brain white matter integrity in patients 
with type 1 diabetes using advanced magnetic resonance imaging (MRI) technology. 
Methods
Forty-one patients with type 1 diabetes (23 men, mean age 44±12 years, mean diabetes 
duration 24±13 years) were included. Aortic PWV was assessed using through-plane ve-
locity-encoded MRI. Brain DTI measurements were performed on 3 Tesla MRI. Fractional 
anisotropy (FA) and apparent diffusion coefficient (ADC) were calculated for white and 
grey matter integrity. Pearson correlation and multivariable linear regression analyses 
including cardiovascular risk factors as covariates were assessed.
results
Multivariable linear regression analyses revealed that aortic PWV is independently as-
sociated with white matter integrity FA (Beta= -0.777, p=0.008) in patients with type 1 
diabetes. This effect was independent of age, gender, mean arterial pressure, body mass 
index, smoking, duration of diabetes and glycated hemoglobin levels. Aortic PWV was 
not significantly related to grey matter integrity.
Conclusions
Our data suggest that aortic stiffness is independently associated with reduced white 
matter integrity in patients with type 1 diabetes. 
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iNTroduCTioN
Type 1 diabetes is a common chronic metabolic disorder, which is associated with di-
verse comorbidity. Although diabetes mellitus is not primarily a brain disease it may be 
associated with cerebral atrophy, white matter hyperintensities and infarctions as well 
as decreased cognitive functioning [1-3]. 
Besides well-recognized risk factors in patients with type 1 diabetes, like chronic 
hyperglycemia and alterations in insulin metabolism, vascular risk factors are thought to 
contribute to the occurrence of brain abnormalities. Aortic stiffening may play a central 
role in the development of brain injury. Of note, previous studies have shown that aortic 
stiffness is associated with generalized white matter atrophy and cerebral small vessel 
disease in type 1 diabetes [4, 5]. Aortic stiffness may contribute to microvascular brain 
injury by exposing the small vessels to the high pressure fluctuations and flow in the 
cerebral circulation [6]. The brain is vulnerable in particular to high pressure fluctuations, 
because it is perfused at high volume flow and has very low vascular resistance. Pulse 
wave velocity (PWV) is a widely used surrogate marker for arterial stiffness. It is defined 
as the propagation speed of the systolic flow wave front traveling along the aorta, re-
flecting the elastic properties of the aortic vessel wall. PWV is estimated by dividing the 
distance between anatomical locations over the aorta by the time difference between 
the arrival of flow waves at the two locations. Higher PWV (m/s) corresponds to higher 
arterial stiffness [7].
Diffusion tensor imaging (DTI) is a validated technique of brain imaging, which, in con-
trast to conventional methods, enables measurement of white matter microstructure [8]. 
DTI is based on diffusivity of water, providing two parameters of tissue integrity, namely 
the apparent diffusion coefficient (ADC) which reflects the magnitude of diffusion and 
fractional anisotropy (FA) which is a measure of the directionality of the diffusion and 
flow of water molecules in the brain tissue. Early detection of tissue injury reflected by 
an increase ADC and reduction in FA has been observed in normal aging and cerebral 
small vessel disease [1]. Moreover, Kodl et al. showed white matter microstructural defi-
cits in patients with longstanding type 1 diabetes using this technique [8]. 
Interestingly, increased pulse pressure, an indicator of arterial stiffness, was found to 
be associated with lower FA in healthy volunteers [9]. There are no previous publications 
that explored the possible relationship between aortic stiffness and DTI of the brain 
in patients with type 1 diabetes using well-validated MRI techniques. Accordingly the 
purpose of this study was to assess the association between aortic pulse wave velocity, 
and DTI of brain white matter integrity in patients with type 1 diabetes using advanced 
MRI technology. 




This study was approved by the local medical ethics committee and all subjects gave 
written informed consent. Between February 2008 and January 2010 consecutive pa-
tients with type 1 diabetes were recruited from the local outpatient clinic. Characteristics 
of the study population are detailed in Table 1. Forty-one patients with type 1 diabetes 
(23 men and 18 women) were included with a mean age of 44±12 years. Mean dura-
tion of the type 1 diabetes was 24±13 years. All patients were treated with insulin. One 
patient was using an ACE-inhibitor in combination with an angiotensin II-antagonist for 
the presence of albuminuria. None of the other patients with type 1 diabetes were using 
blood pressure lowering medication. Statins were used by 11 (26%) patients. 
Information about the characteristics of type 1 diabetes was obtained by standard-
ized interviews and physical and laboratory examinations. Exclusion criteria for all 
participants were congenital aortic/heart disease, a clinical history of hypertension or 
cardiovascular disease, evidence of aortic valve stenosis or insufficiency, any other sys-
temic disease than diabetes and general contraindications to MRI. At MRI examination 
duration of diabetes in years was estimated from self-reported year of diagnosis. Blood 
pressure and heart rate were measured using a semiautomated sphygmomanometer 
(Dinamap, Critikon, Tampa, Fla, USA) after MR imaging. Pulse pressure was defined as 
systolic blood pressure minus diastolic blood pressure. Mean arterial pressure (MAP) 
was estimated by adding up one-third of the pulse pressure to diastolic blood pressure. 
Body mass index and smoking status (nonsmoker or current smoker) were determined. 
High-density lipoprotein (HDL), total cholesterol, triglycerides, creatinine and glycated 
hemoglobin (HbA1C) were also determined. 
This patient group was partly included in a previous study describing the predictive 
value of cerebral blood flow and aortic stiffness on generalized white matter brain atro-
phy in type 1 diabetes [4].
Mri protocol
MR imaging of the aorta and brain were performed at the same day. Aortic imaging was 
performed, as previously described, using a 1.5T MRI scanner (NT 15 Gyroscan Intera; 
Philips Medical Systems, Best, the Netherlands) [10]. In short: a scout image of the aorta 
was acquired using a five-element phased array cardiac surface coil. Aortic PWV was 
assessed according to the transit-time method from two one-directional through-plane 
velocity-encoded MRI acquisitions with high-temporal resolution performed in the aorta 
at two predefined levels: at the level of the pulmonary trunk in the ascending and in 
the abdominal descending aorta [10]. Scan parameters were: repetition time (TR) 5.0ms, 
echo time (TE) 2.9ms, flip angle (FA) 20º, field of view (FOV) 300mm, 128×115 acquisition 
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matrix, slice thickness 8mm, with maximal number of phases reconstructed ensuring 
high (6-10ms) effective temporal resolution. Aortic velocity maps were analyzed using 
the in-house developed FLOW software package. 
Table 1. Clinical characteristics and MR findings of patients with type 1 diabetes
Patients with type 1 diabetes
(n=41)
Clinical characteristics
 Age, years 44 ± 12
 Male gender, n (%) 23 (55)
 Body mass index, kg/m2 25.3 ± 2.9
 Systolic blood pressure, mmHg 128 ± 19
 Diastolic blood pressure, mmHg 73 ± 10
 Pulse pressure, mmHg 55 ± 14
 Mean arterial pressure, mmHg 91 ± 12
 Heart rate, beats/min 66  ± 10
 Current smoker, n (%) 6 (15%)
 Alcohol use yes, n (%) 23 (56%)
Laboratory markers
 HbA1c, % 7.6  ± 1.0
 HDL-cholesterol, mmol/l 1.7 ± 0.5
 Total cholesterol, mmol/l 4.8  ± 1.0
 Triglycerides, mmol/l 1.2 ± 0.6
 Creatinine, umol/l 75 ± 11
MRI findings
 Aortic PWV, m/s (median, IQR) 6.2 (5.2-7.6)
 Stroke volume, ml/heart beat (median, IQR) 87 (81-105)
 Periventricular WMHs, n (%) 7 (17)
 Subcortical WMHs, n (%) 2 (5)
 Grey matter brain volume, mL 574 ± 60
 Grey matter FA 0.171 ± 0.008
 Grey matter ADC 0.00042 ± 0.00002
 White matter brain volume, mL 564 ± 69
 White matter FA 0.344 ± 0.017
 White matter ADC 0.00036 ± 0.00001
 Total brain volume, mL 1139 ± 121
 Total brain FA 0.252 ± 0.010
 Total brain ADC 0.00040 ± 0.00001
Data are presented as mean and standard deviations unless otherwise stated. BMI: body mass index; 
HbA1c: Glycated hemoglobin, HDL: high-density lipoprotein, PWV: pulse wave velocity, IQR: inter quartile 
range, FA: fractional anisotropy, ADC: apparent diffusion coefficient.
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The aortic PWV is defined by the propagation of the systolic flow wave front, and was 
determined by the distance between the aortic measurement sites and the transit-time 
of the systolic flow wave front (figure 1). This transit-time is assessed by the time dif-
ference in arrival of the systolic flow wave front at each level, automatically assessed by 
definition of the intersection between the horizontal diastolic flow and the upslope of 
the flow wave, modeled by linear regression of all data points between 20% and 80% of 
the range of flow values along the slope. The aortic path length between the measure-
ments sites was measured by manually drawing a centerline in the aorta as defined in 
the aortic scout view, using the in-house developed software package MASS (Medis, 
Leiden, the Netherlands). Aortic vessel wall contour segmentation was performed by a 
researcher unaware of the subjects’ conditions and obtained data with brain MRI. figure 
2 shows the flow chart for the processing data. 
For the assessment of systolic LV function, the LV was imaged in short-axis orientation 
as previously described [11] by using a retrospectively-gated breath-hold segmented 
gradient-echo sequence with steady-state free-precession. Ten to twelve consecutive 
slices of 10mm thickness and without gap were obtained with one signal average and 
40 reconstructed phases. Scan parameters: echo time TE 1.7 ms, repetition time TR 3.3 
ms, flip angle 50°, acquisition matrix 256×194, acquisition voxel size 1.7×1.7×10mm3. 
figure 1. Aortic pulse wave velocity assessment. The left panel shows an oblique sagittal scout view of the 
aorta. Velocity mapping was obtained at the level of the pulmonary trunk and in the abdominal descend-
ing aorta. The aortic path length (rx) between both levels was measured, indicated by the polyline follow-
ing the centerline of the aorta. The right panel illustrates the flow curves in the ascending (red line) and 
descending (blue line) aorta. The transit time of arrival of the pulse wave (Δ) was divided by the aortic path 
length (Δ) to calculate aortic PWV (in meters per second).
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Using the software package MASS, end systolic and end diastolic LV volumes were 
obtained using manual contour defi nition of the endocardial borders in these multi-
slice and multi-phase datasets. Left ventricular end-systolic and end-diastolic volume, 
cardiac output and stroke volume were assessed [12].
All brain MRIs were performed on a 3.0 Tesla (Achieva; Philips Medical Systems, Best, 
The Netherlands). Brain MRI consisted of a 3 dimensional T1 (3D T1) sequence for brain 
volume assessment. DTI was performed to assess fractional anisotropy (FA) and apparent 
diff usion coeffi  cient (ADC). 3D T1 acquisition parameters were: TR 9.8ms, TE 4.6 ms, FA 8º, 
FOV 224mm, 192×152 acquisition matrix, 256×256 reconstruction matrix, slice thickness 
1.2mm, 120 slices, no slice gap). For DTI, a single-shot echo-planar sequence was applied 
with 32 measurement directions having the following scan parameters: TR 10,004ms, TE 
56ms, FOV 220×220×128 with an acquisition matrix of 112×110, 2.00mm slice thickness, 
transversal slice orientation, slice gap = 0, FA 90°, single reconstruction voxel dimensions 
were 1.96×1.96×2.00mm, number of slices = 64, B factor = 1,000, halfscan factor = 0.61. 
Parallel imaging (SENSE) was used with a reduction factor of 2, NSA = 1 and fat suppres-
sion was applied. DTI acquisition time was 6.55min.
Mri post processing
Evaluation of cerebral small vessel disease was evaluated on a spin-echo T2-weighted 
and fl uid-attenuated inversion recovery (FLAIR) sequences. White matter hyperintensi-
brain tissue volume was estimated with SIENAX [16, 17].
This program extracts brain and skull images from the single
whole-head input data [18]. The brain images were then
affine-registered to MNI152 space, using the skull images to
determine the registration scaling with seven degrees of
freedom (FSL-FLIRT). FSL’s FAST was used to create GM
and WM tissue segmentations. A visual inspection of all
registrations was performed and of the final segmentations
20 % were selected at random and visually inspected for
accuracy. ADC and FA reconstructions were performed di-
rectly after data acquisition using software provide by the
manufacturer (Philips Medical Systems, Best, the
Netherlands). To correct for possible partial volume effects
in ADC and FA data, especially from CSF, an eroded mask of
GM and WM segmentations was created by removing one
voxel in plane for all above named VOIs. FA and ADC
reconstructions were then registered to the eroded whole
brain, WM and GM volumes, using the same transformation
matrix obtained from the original linear registration of the T1-
w volume to MNI space. Finally, mean ADC and FA values
were calculated for (eroded) whole brain, (eroded) WM and
(eroded) GM. The researcher who obtained the FA and ADC
data was unaware of the subjects’ conditions and PWV data.
Statistical analysis
Statistical analysis was performedwith SPSS (SPSS, Chicago,
Illinois, USA), version 17. Continuous variables are expressed
as mean±standard deviation (sd) unless otherwise stated.
Categorical variables were presented as frequencies and per-
centages. Aortic PWV and stroke data were non-normally
distributed and therefore were log-transformed for further
analyses. Regression analysis, corrected for age and gender
was used to test whether subjects with white matter
hyperintensities have a different PWV than subjects without.
The correlation between aortic PWV and between stroke
volume with brain integrity was tested by Pearson correlation
analysis. Multivariate linear regression analyses were per-
formed to adjust for confounding factors, defined as age,
Fig. 1 Aortic pulse wave
velocity assessment. The left
panel shows an oblique sagittal
scout view of the aorta. Velocity
mapping was obtained at the level
of the pulmonary trunk and in the
abdominal descending aorta. The
aortic path length (Δx) between
both levels was measured,
indicated by the polyline
following the centre line of the
aorta. The right panel illustrates
the flow curves in the ascending
(red line) and descending (blue
line) aorta. The transit time of
arrival of the pulse wave (Δt) was
divided by the aortic path length
(Δx) to calculate aortic PWV (in
meters per second)
Fig. 2 Flow chart of the processing of pulse wave velocity
Eur Radiol
figure 2.  Flow chart of the processing of pulse wave velocity
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ties (WMHs) were defined as areas of brain parenchyma with increased signal on T2-
weighted and FLAIR images without mass effect. Lacunes defined as areas of more or less 
complete focal tissue destruction  are not included in the rating of WMHs. WMHs were 
classified according to Fazekas et al. [13, 14] and subdivided into either periventricular 
or subcortical. Periventricular lesions were defined as starting directly at the ventricular 
border.  When these abnormalities extend > 1cm into the adjacent white matter, this by 
convention indicates damage to both the periventricular and deep white matter. Deep 
WMH are characterized by a rim of normal appearing tissue which separates them from 
the periventricular region. Subjects were divided into those with normal [0] vs abnormal 
[1] amounts of WMHs. Fazekas scores of 0 and 1 were considered normal, a score of 2 
was considered abnormal below the age of 75 years, and a score of 3 was considered 
abnormal in any age group. 
All T1-weighted scans were analyzed using software provided by FMRIB’s Software 
Library (FSL) [15]. Total brain tissue volume was estimated with SIENAX [16, 17]. This 
program extracts brain and skull images from the single whole-head input data [18]. 
The brain images were then affine-registered to MNI152 space, using the skull images 
to determine the registration scaling with 7 degrees of freedom (FSL-FLIRT. FSL’s FAST 
was used to create GM and WM tissue segmentations. A visual inspection of all registra-
tions was performed and of the final segmentations 20 % were selected at random and 
visually inspected for accuracy. ADC and FA reconstructions were performed direct after 
data acquisition using software provide by the manufacturer (Philips Medical Systems, 
Best, The Netherlands). To correct for possible partial volume effects in ADC and FA 
data, especially from CSF, an eroded mask of GM and WM segmentations was created 
by removing one voxel in plane for all above named VOIs. FA and ADC reconstructions 
were then registered to the eroded whole brain, WM and GM volumes, using the same 
transformation matrix obtained from the original linear registration of the T1-w volume 
to MNI space. Finally, mean ADC and FA values were calculated for (eroded) whole brain, 
(eroded) WM and (eroded) GM. The researcher who obtained the FA and ADC data was 
unaware of the subjects’ conditions and PWV data .
statistical analysis
Statistical analysis was performed with SPSS (SPSS, Chicago, Illinois, USA), version 17. 
Continuous variables are expressed as mean ± standard deviation (sd) unless otherwise 
stated. Categorical variables were presented as frequencies and percentages. Aortic 
PWV and stroke data were non-normally distributed and therefore were log-transformed 
for further analyses. Regression analysis, corrected for age and gender was used to test 
whether subjects with white matter hyperintensities have a different PWV than subjects 
without. The correlation between aortic PWV and  between stroke volume with brain 
integrity was tested by Pearson correlation analysis. Multivariate linear regression analy-
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ses were performed to adjust for confounding factors, defined as age, gender, mean 
arterial pressure, body mass index, smoking, duration of diabetes and HbA1c. These 
covariates were entered simultaneously into a multivariable linear regression model. 
The β-regression coefficients and p-values are reported. Significance was reached when 
p<0.05 (two-tailed).
rEsulTs 
aortic PWV and brain integrity
PWV did not differ between patients with or without periventricular WMHs (p=0.250) 
but was higher in subjects with subcortical WMHs (Beta 0.235, p=0.008). There were 
significant correlations between the aortic PWV and white matter integrity FA (r=-0.529, 
p <0.001) and ADC (r=0.406, p=0.009). The correlation between PWV and white matter 
FA is shown in figure 3. For grey matter integrity a significant correlation was found 
for ADC (r=0.518, p=0.001) but not for FA (r=0.016, p=0.923). Stroke volume correlated 
with grey matter integrity FA (r=0.342, p=0.029) and ADC (r=-0.368, p=0.018) and with 
white matter FA (r=0.326, p=0.038). Multivariable linear regression analyses showed 
that aortic PWV is independently associated with WM integrity expressed as FA (Beta=-
0.777, p=0.008) in patients with type 1 diabetes (Table 2). This effect was independent 
of age, gender, MAP, BMI, smoking, duration of diabetes and HbA1c levels. In a similar 
multivariable linear regression model for the prediction of grey matter (GM) integrity no 
significant effect of aortic PWV was observed. Lipid lowering drugs (used by 26% of the 
patients) may reduce arterial stiffness. Therefore further adjustment for the use of statins 
was performed but this did not yield different results for the association between PWV 
figure 3. Correlations between the log-transformed pulse wave velocity (lnPWV) and fractional anisotropy 
(FA), a DTI parameters of the white matter. 
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and WM integrity (FA Beta=-0.798, p=0.006, ADC Beta=0.555, p=0.203). No significant 
association between stroke volume and integrity was found in multivariable linear 
regression analyses.
disCussioN
The main finding of our study is the observation, that aortic stiffness is associated with 
white matter integrity independently of other potential confounders in patients with 
type 1 diabetes. 
So far few studies have reported on white matter integrity in type 1 diabetes. White 
matter microstructural deficits have been observed in patients with type 2 diabetes 
[19, 20] independent of age and blood pressure levels. Kodl et al. showed white mat-
ter microstructural deficits expressed as reduced FA in 25 patients with longstanding 
type 1 diabetes, as compared to 25 age and gender matched healthy volunteers [8]. The 
patients in our study have a similar age and a somewhat shorter duration of diabetes 
(24±13 years vs. 30±11 years).
As hypothesized we found that arterial stiffness was associated with white matter 
microstructure expressed as reduced FA in patients with type 1 diabetes. The associa-
tion with PWV was not found for ADC. Possibly this may be due to the fact that ADC 
reflects general diffusional properties, therefore being a more heterogeneous white 
matter measure than FA, which reflects organizational aspects. Crucial in this analysis 
was to incorporate age as a covariate as it is known that measures of diffusion such 
as FA and ADC, as well as arterial stiffness are dependent on age [19, 21]. Aortic PWV 
Table 2. Results of multivariable linear regression analyses performed in patients with type 1 diabetes 
(n=41) to assess independent predictors of WM and GM integrity  
White matter integrity Grey matter integrity
ADC FA ADC FA
Beta p-value Beta p-value Beta p-value Beta p-value
Age, years -0.068 0.859 0.111 0.731 0.252 0.444 -0.157 0.700
Female gender (n=19) -0.166 0.418 0.123 0.474 -0.230 0.192 0.091 0.676
Mean arterial pressure, mmHg -0.048 0.830 0.064 0.731 -0.245 0.202 0.044 0.850
Body mass index, kg/m2 0.079 0.666 -0.057 0.712 0.039 0.804 -0.100 0.607
Current smoker -0.037 0.831 0.149 0.319 -0.015 0.922 0.253 0.182
Duration of diabetes, years -0.078 0.753 -0.058 0.781 0.313 0.146 -0.052 0.844
HbA1c, % -0.112 0.600 -0.011 0.949 -0.166 0.363 -0.203 0.357
Aortic PWV, m/s 0.532 0.111 -0.777 0.008* 0.270 0.338 -0.098 0.778
ADC: apparent diffusion coefficient, FA: fractional anisotropy, HbA1c: Glycated hemoglobin, PWV: pulse 
wave velocity. * p-value < 0.05.
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is a surrogate marker for arterial stiffness and has been shown to be an independent 
predictor for stroke, cerebral small vessel disease [5, 6, 20, 21] and might be a predictor 
for cognitive decline [22]. Furthermore in type 1 diabetes aortic PWV measured with 
MRI has been demonstrated a predictor of white but not grey matter atrophy [4]. In line 
with this study we could not show an independent association for aortic PWV with grey 
matter integrity. 
It is known that the blood flow in the white matter is substantially lower compared to 
the blood flow in grey matter. White matter may be more susceptible to subtle pressure 
fluctuations than grey matter, because of the vulnerable end-arterioles penetrating the 
white matter [23]. It has been hypothesized that in particular “watershed” areas of the 
brain may be sensitive to arterial stiffness [24]. In line, PWV has been associated with 
processing speed and memory, cognitive functions represented in these watershed 
locations [25]. To the best of our knowledge we are the first to show an association 
between PWV and white matter integrity in patients with type 1 diabetes as evaluated 
by MRI techniques. In agreement with our study, a relation between pulse pressure, 
another marker of arterial stiffness, and white matter deficits has been observed [9]. 
However that relationship was studied in healthy normotensive subjects. Furthermore 
aortic PWV is considered to be a more accurate method for assessing arterial stiffness 
than the measurement of pulse pressure made in the peripheral vessels which does not 
always accurately reflect the actual central pulse pressure and which may be unreliable 
in older subjects. 
In diabetes mellitus both glucose toxicity and abnormal insulin metabolism have been 
suggested to contribute to brain pathology [26, 27]. Up to now few studies investigated 
the relationship between clinical parameters of disease severity and microstructural 
white matter changes in diabetes. In patients with type 2 diabetes disease duration 
rather than HbA1C was related to DTI assessed white matter changes when investigated 
simultaneously [19]. Interestingly we did not observe associations between white mat-
ter microstructure and clinical parameters such as disease duration or HbA1c. This is 
in contrast to an earlier study that identified a significant relationship between FA and 
HbA1c and between FA and disease duration in type 1 diabetes. However in that study 
no adjustments for age were performed. Furthermore those authors did not report on 
blood pressure while we investigated patients with type 1 diabetes without a history of 
hypertension. Since high blood pressure was shown to be associated with a decrease in 
FA [28] and is frequently occurring in diabetes it is not clear to which degree this may 
have influenced these previous results. 
MR-DTI is a technique that allows early detection of white matter damage even in 
regions that appear normal on conventional anatomical images. Despite a limited 
understanding the exact pathophysiology, DTI changes could be of clinical relevance. 
In children DTI assessed structural integrity is associated with higher IQ and loss of 
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integrity in normal aging is associated with cognitive decline [29, 30]. In addition in 
patients with type 1 diabetes white matter deficits were associated with performance on 
neurocognitive tests [8]. In order to develop targeted treatments to prevent brain dam-
age it is important to understand the underlying mechanisms that cause subtle brain 
alterations. Our findings support the role of vascular mechanisms leading to a decline in 
white matter microstructure in type 1 diabetes, which adds to current knowledge. 
Smoking is known to increase arterial stiffness [31-33] consequently we adjusted for 
smoking in the linear regression analyses. Alcohol consumption may have a divergent 
effect on arterial stiffness and may also directly affect the brain, however as the number 
of alcohol units were not registered we were not able to explore the effect of alcohol. 
Furthermore this was an explorative study and associations already detected in this small 
patient group need to be confirmed in a larger population. Given the cross-sectional 
design of this study no insight into the changes over time or a causal relationship be-
tween aortic PWV and white matter damage can be determined. Another limitation of 
our study is that we did not include cognitive testing in the current study. Longitudinal 
studies are needed to assess the impact of our findings on cognitive decline and to as-
sess the prognostic and therapeutic implications.
In conclusion we found that aortic stiffness is independently associated with reduced 
white matter integrity in patients with type 1 diabetes, which suggests a vascular 
contribution to early subtle microstructural deficits. Future prospective studies are 
needed to improve knowledge of the prognostic and therapeutic implications of these 
microstructural changes.
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To assess the association between magnetic resonance (MR) imaging assessed regional 
aortic PWV and renal function within the normal range in patients with hypertension. 
Materials and Methods
In this cross-sectional study, 96 patients with hypertension and preserved renal func-
tion and 44 healthy volunteers (mean age 46±13 years  and 44±15 years) were included. 
Renal function was expressed as estimated glomerular filtration rate (eGFR). PWV was 
assessed in the total, proximal and distal part of the aorta by velocity-encoded MR imag-
ing. 
results 
An increased PWV for both aortic segments as well as for the total aorta was found in 
patients with hypertension compared to healthy volunteers [PWVtotal 6.5 vs 5.5 m/s, 
PWVproximal 6.1 vs 5.6 m/s, PWVdistal 6.6 vs 5.4 m/s, p≤0.028 and 0.03]. The ratio between 
PWVdistal:PWVproximal was not significantly different between groups. There was a statisti-
cally significant correlation between eGFR and aortic PWV in both patients with hyper-
tension (r= -0.380, p<0.001) and healthy volunteers (r= -0.383, p=0.010). The decrease in 
eGFR per increase in PWV of the total aorta was not significantly different between both 
groups (p=0.783), however patients with hypertension showed a higher aortic PWV for 
each given eGFR (p=0.047). 
Conclusion 
Changes in renal function within the normal range are inversely related to increased 
proximal and distal aortic stiffness even in the absence of disproportional stiffening. This 
relationship is present before the onset of proteinuria and macrovascular complications. 
These results stress the close link between aortic stiffness and the microcirculation. 
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iNTroduCTioN 
Arterial stiffness measured as pulse wave velocity (PWV) is an independent predictor of 
cardiovascular disease in hypertension as well as chronic renal disease (1). Hypertension 
is an important determinant of aortic wall stiffening due to the continuous and repeti-
tive pulsatile stress acting on the arterial wall which causes fracturing of the elastin and 
collagen network. A close link between arterial stiffness and microvascular renal disease 
exists and this relation appears to be bidirectional. Renal dysfunction may contribute to 
stiffening by numerous mechanisms including vascular calcification, activation of the 
renin-angiotensin-aldosteron system, chronic inflammation and endothelial dysfuncion 
(2). 
Contrawise arterial stiffening of the aortic wall may promote renal microvascular 
damage. Accordant with local variation in structure, arterial stiffening from aging or 
hypertension varies along the arterial tree, with increased stiffening of the central elastic 
arteries compared to more muscular distal arteries. Disproportionate arterial stiffening 
may accelerate transmission of excessive pulsatile energy toward the microcirculation 
(3). As a result the hypertensive microcirculation may not be exposed to the same pul-
satile energy than in normotension. In particular end-organs with high-flow and low 
vascular resistance, such as the brain and kidneys, are predisposed to the damaging 
effects of pressure pulsatility. 
Recently disproportionate stiffening of the proximal aorta compared to the carotid 
arteries was shown to be associated with microvascular structural brain damage (4,5). 
Interestingly this was associated with a reduction in blood flow volume towards the 
brain. It was hypothesized that vascular resistance in response to elevated pulse pressure 
will reduce mean blood flow. The resulting mismatch may contribute to microvascular 
damage in the brain. Likewise, age or hypertension related decline in renal function may 
be explained. Evidence supporting the hypothesis that aortic stiffness may contribute 
to lower glomerular filtration rate by transferring excessive flow pulsatility into the renal 
microcirculation was provided by the AGES study. In this study the relation between 
aortic PWV was mediated by higher renal artery pulsatility index and lower arterial 
volume to the renal cortex (6). 
However like most clinical studies which relate arterial stiffness to abnormalities in 
kidney function, generalization of the results was limited by the studied population. 
Nearly all studies have been performed in eldery subjects, subjects with end-stage renal 
disease or mild renal dysfunction. In patients with hypertension arterial stiffening as 
well as impaired renal function often co-exist. Therefore, whether increased PWV in 
patients with hypertension is directly related to high blood pressure or depends pri-
mary on co-existing renal dysfunction remains to be elucidated. Moreover there are no 
previous publications that explored the possible relationship between regional aortic 
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stiffening and renal function within the normal range in patients with hypertension. 
Magnetic resonance imaging (MRI) in combination with velocity-encoding (VE) is a 
well-validated technique that enables assessment of PWV in specific segments of the 
aorta. Our hypothesis is that increased aortic stiffness contributes to lower glomerular 
filtration rate in  the normal range by transferring elevated pulse pressure and is possibly 
mediated by disproportional aortic stiffening. Accordingly, the purpose of this study 
was to assess the relation between regional aortic PWV and renal function in the normal 
range in patients with hypertension using VE-MRI. 
METhods
study participants
For this study a total 96 consecutive patients with hypertension were recruited from 
the outpatient clinic of the Leiden University Medical Center. Healthy volunteers (n=44) 
without a history or clinical evidence of diabetes mellitus, hypertension or cardiovas-
cular disease were recruited by advertisement in local newspapers. Exclusion criteria 
consisted of aortic valve stenosis or insufficiency, Marfan syndrome, aortic coarctation 
or any aortic disease, established cardiovascular disease, pregnancy and standard MRI 
contra-indications. All subjects signed informed consent after a detailed description of 
the procedure. For this study 15 patients were excluded because of impaired renal func-
tion defined as an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.732 
and no proteinuria (<300 mg/24h urine). Part of this patient group was included in a 
previous study describing the relation between aortic stiffness, left ventricular mass and 
lacunar brain infarcts in hypertension (7). 
Blood pressure was measured after MRI using a semi-automated sphygmomanometer 
(Dinamap, Critikon, Tampa, FL, USA). Hypertension was diagnosed after repeated blood 
pressure measurements in sitting position according to the guidelines of the European 
Society of Hypertension (8). Duration of hypertension was estimated as time (in years) 
from year of magnetic resonance (MR) imaging examination minus self-reported year of 
diagnosis. Pulse pressure was defined as systolic blood pressure minus diastolic blood 
pressure. Body mass index (BMI) was determined, smoking status was obtained and 
participants were divided into current smokers and non-smokers. Information about 
diabetes mellitus and the current use of medication was obtained from medical history 
and medical status of the outpatient clinic. After an overnight fast and within two weeks 
before MR imaging a blood sample was drawn for determination of creatinine, glucose 
and lipid profiles (total cholesterol, high density lipoprotein and triglycerides). 
The Modification of Diet in Renal Diseases (MDRD) equation was used to calculate 
renal function which provides an accurate GFR estimate using serum creatinine (9). The 
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study was conducted according to the principles in the Declaration of Helsinki and the 
study was approved by the local medical ethics committee.
Mr imaging 
A 1.5 Tesla MRI (NT 15 Gyroscan Intera; Philips Medical Systems, Best, the Netherlands) 
was used for the evaluation of aortic stiffness using a previously described protocol (10). 
In short, on multi-oriented scout images of the aorta, two imaging planes were planned 
perpendicular to the aorta: one to the ascending aorta at the level of the pulmonary 
trunk, transecting both the ascending and proximal descending aorta, and one at the 
level of the abdominal descending aorta 7.5 cm beneath the diaphragm (figure 1). At 
these planes, one-directional through-plane velocity-encoded (VE) MRI with retrospec-
tive ECG-gating was used. Maximal velocity sensitivity for the first plane was set at 150 
cm/s, and for the second plane 100 cm/s. At each cross-section of the aorta, blood flow 
velocity-time curves were assessed by velocity mapping. Aortic PWV was calculated as 
the aortic path length between consecutive sampling sites (i.e., at ascending, proximal 
descending and abdominal aorta) divided by the time duration for the systolic flow 
velocity wave to propagate between sampling sites (figure 1). The time point of wave 
figure 1. Assessment of aortic pulse wave velocity 
On the left, an oblique saggital scout view of the proximal and distal aorta is shown. Two imaging planes 
were planned perpendicular to the aorta: one to the ascending aorta at the level of the pulmonary trunk, 
transecting both the ascending and proximal descending aorta, and one at the level of the abdominal 
descending aorta 7.5cm beneath the diaphragm. The aortic path length (Δx1 for the ascending aorta, Δx2 
for the abdominal aorta) between these levels was measured indicating by the red line following the cen-
terline of the aorta. On the right, the flow curves in ascending and abdominal aorta are illustrated. The 
horizontal dashed lines represent the horizontal diastolic flow at the corresponding site in the aorta. The 
line following the upstroke is determined by linear regression of all data point between 20% and 80% of 
the range of values along the slope. Time point of intersection was considered being the arrival time of 
the pulse wave. Aortic PWV was calculated as the aortic path length between consecutive sampling sites 
divided by the time duration for the systolic flow velocity wave to propagate between sampling sites.
Nathanja Tjeerderma - binnenwerk v7b.indd   119 08-09-15   11:35
120 Chapter 7
arrival was assessed from automated detection of the foot of the pulse wave, from the 
transection of two lines: one modeling the horizontal diastolic flow from the last 250 ms 
of the velocity-time curve and one modeling the upslope of the wave by linear regres-
sion of all data point between 20% and 80% of the range of values along the slope 
(11). From these data PWV for the proximal aorta (ascending and proximal descending 
aorta), PWV for the distal aorta (descending and abdominal aorta) and total aorta was 
calculated. Data were analyzed with MASS/Flow (Leiden University Medical Center, 
Leiden, the Netherlands). Analyses were performed by one researcher (A.B. with 1 year 
of experience in cardiac MR imaging) and supervised by a senior researcher (J.J.M.W. 
with 13 years of experience in cardiac MR imaging).
statistical analysis
An independent samples t-test for continues variables, Mann-Whitney U test for non-
normally distributed variables and Chi-square test for dichotomous variables were used 
to compare clinical characteristics between patients with hypertension and healthy 
volunteers. Since aortic PWV was non-normally distributed (Kolmogorov-Smirnov 
p<0.001), the correlation between aortic PWV and renal function was tested by Spear-
man correlation and a log transformation of aortic PWV values was used for regression. 
Multivariable regression with forward entry analysis for eGFR was carried out to study 
the relation between aortic PWV and the effect of hypertension. To test whether the re-
lationship between eGFR and aortic PWV differed between patients with hypertension 
and healthy volunteers an interaction term for the presence of hypertension was used. 
Furthermore, the possible confounding effect of age, diabetes mellitus, blood pressure, 
BMI, smoking, hypertension duration, medication using eGFR values uncorrected for 
age was tested. P value < 0.05 was considered statistically significant. SPSS for Windows 
(version 16.0; SPSS, Chicago, Illinois, USA) was used for statistical analysis.
rEsulTs
Clinical, laboratory and MRI derived parameters of hypertensive patients (mean age: 
46±13 years) and healthy volunteers (mean age: 44±15 years) are summarized in Table 
1. Blood pressure and pulse pressure were significantly higher in patients with hyper-
tension compared to healthy volunteers despite the use of antihypertensive drugs. 
Calcium channel blockers were used in 35% of the patients, renin-angiotensin system 
inhibitors (angiotensin receptor blockers, angiotensin converting enzyme inhibitors or 
rennin inhibitors) in 58% of the patients, adrenergic receptor blockers (alpha-1 or beta-
blockers) in 39% of the patients, diuretics and other compounds in 31% respectively 2% 
of the hypertensive patients. Ten (10%) hypertensive patients were also diagnosed with 
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type 2 diabetes mellitus. Two of them were treated with insulin, others were treated 
with lifestyle advice (n=3) or oral glucose lowering medication (n=5). Furthermore HDL-
cholesterol levels were significantly lower [1.39 (1.16-1.78) vs. 1.59 (1.36-1.81) mmol/l, 
p=0.039] in hypertensive patients compared to healthy volunteers. Renal function did 
not differ between groups. 
aortic pulse wave velocity and renal function
PWV was significantly higher in patients with hypertension compared to healthy vol-
unteers for both segments of the aorta as well as for the total aortic PWV. PWV-ratio 
(PWVdistal : PWVproximal) was not significantly different between groups. 
Statistically significant correlations between total aortic PWV and eGFR both in 
patients with hypertension (r= -0.380, p<0.001, corresponding regression line: eGFR=-
21xln(aortic PWV) + 125) and in healthy controls (r= -0.383, p=0.010, corresponding 
regression line: eGFR=-18xln(aortic PWV) + 115) were observed, which are shown in 
figure 2. Accordingly significant correlations between PWV of the proximal and distal 
aorta and eGFR were found (Table 2). Patients with hypertension showed a higher 






Male gender, n (%) 41(42) 23(52) 0.292
Age (years) 46±13 44±15 0.664
Hypertension duration (years) 7±(8) - -
Current smoker, n (%) 17(18) 4(10) 0.178
Body mass index (kg/m2) 25.8±4.0 26.7±8.3 0.481
Systolic blood pressure (mmHg) 152±25 131±15 <0.001*
Diastolic blood pressure (mmHg) 89 ±14 81±10 <0.001*
Pulse pressure (mmHg) 63±20 50±11 <0.001*
Total cholesterol (mmol/l) 5.90±1.14 5.35±1.19 0.220
Triglycerides (mmol/l), median IQR 1.38 (1.02-1.95) 1.19 (0.84-1.69) 0.059
HDL cholesterol (mmol/l), median IQR 1.39 (1.16-1.78) 1.59 (1.36-1.81) 0.039*
Fasting glucose (mmol/l) 5.5±1.4 4.9±0.6 0.008
Estimated GFR (ml/min/1.732) 85±16 83±12 0.527
Aortic stiffness













PWV-ratio (PWVdistal :PWVproximal) 1.0 (0.8-1.3) 0.9 (0.8-1.1) 0.064
Data are presented as mean and standard deviation unless otherwise stated. HDL = high-density lipopro-
tein, GFR = glomerular filtration rate *P<0.05
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PWV of the total aorta compared to healthy volunteers for each given eGFR (p=0.047). 
No significant difference between groups in PWV of the proximal (p=0.208) and distal 
(p=0.065) aorta was observed for each given eGFR (Table 2). Interaction analyses 
showed that the inverse association between renal function and total aortic PWV was 
not significantly different between patients with hypertension and healthy volunteers 
(p=0.783). Therefore, the decrease in eGFR per increase PWV of the total aorta did not 
differ between patients and healthy volunteers. The inverse association between total 
aortic PWV and eGFR was independent of age, diabetes mellitus, blood pressure, BMI, 
smoking status and hypertension duration (p=0.042, Beta=-0.279)
disCussioN
The three main findings of the present cross-sectional study are 1. Patients with hyper-
tension show increased MR assessed regional aortic stiffness of the proximal and distal 
aorta; 2. Changes in renal function within the normal range are inversely related to arte-
rial stiffness even in the absence of disproportionate stiffening; 3. This relation is similar 
in hypertension and healthy volunteers and present before the onset of decreased eGFR, 
proteinuria and macrovascular complications. 
figure 2. Correlations between aortic PWV and eGFR both in patients with hypertension (r= -0.380, 
p<0.001, corresponding regression line; eGFR=-21×ln(aortic PWV) + 125) and in healthy controls (r= -0.383, 
p=0.010, corresponding regression line; eGFR=-18×ln(aortic PWV) + 115) were observed.
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The existing link between chronic kidney disease and arterial stiffness is a widely 
known phenomenon (2,12) however, so far few studies have reported on arterial stiff-
ness and renal function in the normal range. Mourad et al. observed an independent 
association between PWV and kidney function in 1290 subjects with normal or elevated 
blood pressure (13). In line, the Hoorn study found a significant independent associa-
tion between arterial stiffness measured as distensibility of the common carotid artery, 
and renal function (14). However, the associations in these studies were solely found 
in the lowest tertile of creatinine clearance or in populations including subjects with 
mild impaired renal function. Schillacie et al. were the first to demonstrate a relationship 
between aortic PWV and GFR within the normal range (serum creatinine < 120 umol/l) in 
305 treatment naive hypertensive patients (15). Compared to our study, those patients 
had a shorter hypertension history and were older with a mean age of 49 years. Because 
both renal function and arterial stiffness are dependent on age it is relevant to determine 
whether this relation still exists in younger subjects. Furthermore, all previous studies 
used echo Doppler or applanation tonometry to determine global arterial wall stiffness 
of the aorta. These modalities are limited by the inability to register the true length of 
the aorta and need geometric assumptions to estimate PWV. MR as imaging modality 
has been validated and applied to study regional aortic PWV and with this technique we 
are the first to describe a relation between renal function within the normal range and 
regional aortic PWV in hypertensive patients. In contrast to others, our results were not 
Table 2. Linear regression analysis
eGFR
(ml/min/1.73m2)























































The table illustrates the linear regression analysis eGFR= A x ln (aortic PWV) + B for patients with hyperten-
sion and healthy volunteers. Multiple regression analysis showed an increased PWV of the total aorta in 
patients with hypertension compared to healthy volunteers for each given eGFR (p#=0.047) was found. The 
rate of decrease of eGFR per increase in total aortic PWV was not statistically significantly different between 
patients with hypertension and healthy volunteers (p*=0.783)
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confounded by kidney disease as we selected a population with normal renal function 
and absence of proteinuria. 
Our findings stress the feasibility of velocity-encoded MRI for evaluation of regional 
aortic stiffness. Intriguingly, although increased PWV was present for both segments 
of the aorta, we did not find increased proximal compared to distal aortic stiffening 
in patients with hypertension. Because central stiffening is believed to occur mainly 
beyond the fifth decade (16) this may be attributed to our young study population (only 
17% older than 60 years). In addition, PWV values were only mildly elevated compared 
to healthy volunteers and appeared to be within the range of reported values from 
intra-arterial pressure measurements which is regarded as the gold standard. With this 
technique PWV increased from 4-5m/s in the ascending aorta to 5-6m/s in the abdomi-
nal aorta (17) in subjects without hypertensive disease (mean age 42 years).  
Disproportionate aortic stiffening in aging and hypertension may promote transmis-
sion of pulsatile energy towards the microcirculation and expose end organs to potential 
damaging effects of high pulse pressure. Possibly the absence of renal damage in our 
subjects might be explained by the absence of disproportionate stiffening rather than 
stiffening per se. In addition, it is conceivable that the kidney is adapting in response to 
arterial stiffness and increased pulse pressure. Renal function may then be preserved 
at the cost of microvascular remodeling or altered activation of the renin angiotensin-
aldosteron system. In support of this hypothesis, studies in community-based samples 
have demonstrated altered microvascular structure and function in the presence of aor-
tic stiffness (18). Recently in an elderly population cohort, the association between PWV 
and GFR was mediated in part by higher renal artery pulsatility index and higher renal 
vascular resistance (6). On the other hand, microvascular renal damage is not necessary 
reflected by decreased GFR. By example, microalbuminuria provides additional informa-
tion next to GFR values and is believed to reflect endothelial dysfunction. Moreover, it 
is well known that any formula for estimating GFR has a low precision for assessing GFR 
and tends to be less accurate in subjects with relatively normal renal function (19). MR 
assessed PWV may then be a possible early marker of microvascular renal damage which 
is not yet detected by GFR. 
Our study has some limitations. First, the inclusion of patients treated with various drugs 
might have affected the results. Angiotensin converting inhibitors and blockers of the 
renin-angiotensin system in particular, may lower PWV (8,20,21) and slow onset of kid-
ney disease. Although appropriate statistical analysis was used to adjust for medication 
effects, this may lead to an underestimation of the association between PWV and GFR 
and the true association is likely to be even stronger than observed. In addition, because 
of the cross-sectional nature of this study we cannot determine the changes over time 
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and further studies are needed to establish whether increased PWV is a marker of future 
decline in renal function. 
In conclusion, the present study shows that changes in renal function within the nor-
mal range are inversely related to increased arterial stiffness even in the absence of 
disproportional stiffening. This relationship is similar in patients with hypertension and 
healthy volunteers and present before the onset of decreased eGFR, proteinuria and 
macrovascular complications. These results stress the close link between aortic stiffness 
and the microcirculation. Future studies are needed to elucidate the implications of 
early arterial stiffening in hypertension on long-term renal function. 
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The metabolic syndrome (MetS) is a well-known entity related to cardiovascular disease 
and type 2 diabetes. Many subjects with MetS are affected by central obesity. Random-
ized clinical trials have demonstrated that lifestyle changes exert beneficial effects on 
obesity and other MetS-components. However these trials have been performed under 
highly controlled conditions and the generalizability across persons, settings and out-
comes may be limited. 
aim 
The purpose of this study was to evaluate the feasibility and the effect of the imple-
mentation of a lifestyle intervention (inclusive of possible blood pressure treatment) in 
subjects with the MetS in a primary health care setting. The effect was assessed using a 
regression discontinuity design.
Methods 
In four primary health care centers 2079 of all 2942 invited non-diabetic subjects 
between 40 and 70 years of age (response rate = 71%) responded to their general physi-
cian’s request for screening. Subjects with the MetS but without diabetes (n=686) were 
identified from the total group, using a screening protocol. Insulin resistance (HOMA-IR 
≥ 2) was used as defining factor for lifestyle intervention. A regression discontinuity de-
sign was used to estimate the effect of the lifestyle intervention. Subjects with the MetS 
and HOMA-IR ≥ 2 were offered a lifestyle program.  Subjects with MetS and HOMA-IR 
< 2, the non-intervention group,  received a letter containing a set of lifestyle advices 
(amongst which also possible referral for blood pressure treatment). In the regression 
discontinuity design posttest scores were regressed on pretest scores with group as 
a covariate. For the effect on visceral obesity, glucose, lipid levels and blood pressure 
HOMA-IR was added as a second covariate.
results 
Seventy-eight subjects were included in the lifestyle intervention program and 311 
subjects were included in the non-intervention group. The intervention reduced vis-
ceral obesity [waist circumference -2.99 cm (95% CI -4.72, -1.26)] and lowered systolic 
blood pressure [- 7.28 mmHg (95% CI -12.78, -1.79)] compared to the non-intervention 
group. This blood pressure lowering effect was also present amongst the persons who 
did not receive any new blood pressure lowering medication.  Insulin resistance  did 
not significantly change in subjects whom received lifestyle intervention [adjusted for 
pre-HOMA-IR values the intervention group had a 1.17 times (95%CI 0.99-1.39) higher 
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post-HOMA-IR. Furthermore no significant change in subjects with lifestyle intervention 
compared to the non-intervention group was found for diastolic blood pressure [1.85 
mmHg (95% CI -4.96, 1.25) lower], glucose [0.06 mmol/l (95% CI -0.23, 0.12)lower], HDL-
cholesterol [0.99 (95% CI 0.94, 1.03) times lower and triglycerides levels [0.99 mmol/l 
(95% CI 1.03 (95% CI 0.89, 1.12) times lower]. 
Conclusions 
A lifestyle and dietary intervention, with the added possibility of blood pressure 
treatment, can be implemented in a primary care setting using existing facilities and 
was found to effectively reduce visceral obesity and lower systolic blood pressure in 
MetS-subjects. Therefore this study may provide an effective strategy for clinical health 
systems to meet the growing challenge of obesity and cardiovascular disease. 
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iNTroduCTioN
The World Health Organization estimates that more than 1 billion adults worldwide are 
overweight (1). Excess weight, particularly abdominal or central obesity is related to the 
metabolic syndrome (MetS). The MetS increases the risk to develop cardiovascular dis-
ease and type 2 diabetes mellitus. Two large meta-analyses have shown that the risk for 
cardiovascular disease (CVD) is increased approximately 2 fold in MetS (2;3). As central 
obesity is a key factor in the development of insulin resistance and MetS, appropriate 
management of central obesity is regarded as an important initial step to reduce the 
burden of CVD.
Randomized clinical trials (RCT’s) have demonstrated that lifestyle interventions, 
including dietary modification and increased physical activity, exert beneficial effects 
on each of the individual components of the MetS (4-6). 
RCT’s are regarded as the ‘gold standard’ for clinical research designs. Still, RCT’s are 
limited in their generalizability across persons, settings, treatments and outcomes. Most 
clinical trials have been performed with highly selected participants under highly con-
trolled conditions which is different from the situation of daily practice. Therefore the ef-
fectiveness of measures taken in everyday practice with relatively unselected participants 
under flexible conditions may be different from the results obtained using RCTs. 
In a primary care setting performing a RCT is not always possible, especially when 
evaluating the efficacy of an intervention in a “real” world setting is the objective (7). 
The regression discontinuity design is the most suitable alternative when randomiza-
tion is not feasible or acceptable. In the regression discontinuity design, assignment 
of individual subjects or groups to intervention is determined by the use of a “cut-off” 
score measured at baseline. Through regression adjustment for the assignment score an 
unbiased estimate of the intervention effect can be obtained.
The purpose of this study was to evaluate the feasibility and the effect of the imple-
mentation of a lifestyle intervention in non-diabetic MetS-subjects in primary health 




This prospective study was conducted between February 2006 and August 2010, in 
four primary health care centers in Rijswijk, the Netherlands. The study protocol was 
approved by the review board of South West Holland and performed in accordance 
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with the Declaration of Helsinki. During 2006-2008 all non-diabetic subjects between 
40-70 years of age of four general practitioners were identified using computer assisted 
screening. Exclusion criteria were diabetes mellitus, unstable medical condition, major 
psychiatric comorbidity or a history of drug or alcohol abuse. A total of 2942 subjects 
were considered eligible and invited to the practices by letter. Invitation letters were 
sent in order of month of birth. A second letter was sent for non-responding subjects. 
Screening was carried out on 2079 subjects (response rate = 71%) after written informed 
consent. Subjects with the MetS (for criteria see below) were selected and invited to 
participate in this study. Subjects with the MetS with low levels of insulin resistance 
(HOMA-IR < 2) received health care advice by letter. This is not strictly a control group as 
used in randomized clinical trial and therefore this group will be referred to as the non-
intervention group in the remainder of this manuscript. Subjects with the MetS with 
high levels of insulin resistance (HOMA-IR > 2) received lifestyle intervention. Subjects 
with new diagnosed type 2 diabetes defined by a glucose ≥ 7 mmol/l at screening were 
excluded for both arms of the study. All subjects gave informed consent. 
Measurements and definitions
During the screening visit, medical history including use of medication was taken, if 
necessary additional information was retrieved from the medical record. Subsequently, 
waist circumference was measured in standing position, midway between the lower limit 
of the rib cage and the iliac crest using a Seca 200 circumference measuring tape (Seca 
Gmbh, Hamburg, Germany). Brachial arterial blood pressure was measured twice in the 
left arm with an automatic digital BP monitor (Omron M7, Hoofddorp, The Netherlands) 
while subjects were relaxed in a seating position for at least five minutes. The average 
of the two readings was used to calculate systolic blood pressure and diastolic blood 
pressure. A third measurement was taken if the difference between the two readings 
exceeded 10 mmHg and the average of the second and third measurement was used. 
Venous blood samples were taken after a 12-h overnight fast and included glucose, 
insulin, triglycerides, and HDL-cholesterol levels. Blood samples were analyzed at the 
central laboratory facilities of the general physicians at Rijswijk in collaboration with the 
department of Clinical Chemistry at Reinier de Graaf Hospital in Delft, The Netherlands. 
Measurements were performed according to ISO 15189 standard procedures. Glucose 
levels were determined by colorimetric enzymatic methods on an Architect c8000 ana-
lyzer. Insulin was measured using an immunometric chemoluminescentic immunoassay 
(Immulite 2000). 
The MetS was defined using the IDF criteria (8). Therefore two or more of the following 
criteria in addition to an increased waist circumference (male ≥ 94 cm, female ≥ 80 cm), 
had to be present:  triglycerides ≥ 1.7 mmol/l (≥ 150 mg/dl), HDL-cholesterol < 1.03 
mmol/l (< 40 mg/dl) in male and < 1.29 mmol/l (< 50 mg/dl) in female, fasting glucose 
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≥ 5.6 mmol/l (150 mg/dl), blood pressure ≥ 130/85 mmHg or the use of blood pressure 
lowering medication. Insulin resistance was calculated using the Homeostasis Model 
Assessment-Insulin Resistance Model (HOMA-IR), according to the published algorithm 
(9).
health care advice by letter
After the screening the non-intervention group i.e. MetS-subjects with low levels of 
insulin resistance (HOMA-IR < 2) received a letter with information regarding their car-
diovascular risk and a set of lifestyle advices about general health. Recommendations 
regarding nutrition (i.e. to eat daily 200 gram vegetables and two pieces of fruit, to eat 
fish at least twice a week and to consume little or no added salt) and exercise (i.e. to 
engage in physical activity of moderate intensity for at least 30 minutes 5 times a week 
were given. If applicable quit-smoking advice was given and subjects with hypertension 
(blood pressure ≥ 140/90 mmHg) or dyslipidemia in combination with a high cardiovas-
cular risk (10) were advised to visit their general practitioner for further treatment. These 
subjects were treated according national guidelines regarding cardiovascular risk. 
lifestyle intervention
The intervention consisted of a lifestyle program and was adapted on the step one ap-
proach of type 2 diabetes mellitus treatment in the Netherlands (11). In this approach an 
individual lifestyle and dietary intervention counseling is given to subjects according to 
these guidelines. A nurse practitioner with 3 years of experience in diabetes counseling 
provided four sessions; immediately after screening and after three, six and nine months. 
The goals of the intervention program were to achieve and maintain a weight reduc-
tion of at least 5% of initial body weight through consumption of a healthy low calorie, 
low fat diet and to engage in physical activity of moderate intensity for at least 30 
minutes 5 times a week. Counseling consisted of planning, motivation and explanation 
of activating aspects of the registered lifestyle patterns including exercise and smoking. 
Dietary counseling emphasized the content fibers, fish and vegetable intake. An upper 
limit of calorie intake of 2100 kCal was advised. If weight loss was not observed after 
three months, special emphasis was given aiming at a reduction in weight of at least 
3-5%. As for the non-intervention group, medical treatment prescribed by a primary 
physician was allowed according to national guidelines for hypertension, cardiovascular 
prevention and diabetes. Prescription of glucose lowering medication was not permitted 
during the program. Weight and blood pressure were measured at each visit. Subjects 
with a high blood pressure (≥ 140/90) were treated according to guidelines (10). 
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follow up measurements 
A fasting blood sample was drawn for measurement of glucose, insulin, triglycerides, 
and HDL-cholesterol levels after the last visit to the nurse practitioners in subjects in the 
intervention group. In subjects of the non-intervention group a fasting blood sample 
and measurements of blood pressure and waist circumference were repeated nine 
months after subjects received health care advice by letter.
study outcomes
The predefined outcomes were the change in 9 months HOMA-IR, visceral obesity, 
glucose, cholesterol levels and blood pressure. 
statistical analysis 
Data are expressed as mean ± standard deviation or median (interquartile range), unless 
stated otherwise. To compare clinical characteristics between the intervention and the 
non-intervention group at baseline independent samples t-test for continuous variables 
and a Mann-Whitney for non-parametric continues variables were used. For the compar-
ison between dichotomous variables a Chi-Square test was performed. A paired t-test 
or Wilcoxon-matched-paired test was used to compare outcomes before and after the 
intervention. Because HDL-cholesterol, triglycerides and HOMA-IR were non-normally 
distributed a log transformation of these values was used in regression analysis. A P 
value < 0.05 was considered statistically significant. We used SPSS for Windows (version 
18.0; SPSS, Chicago, Illinois, USA) for statistical analysis.
Comparing pre- and post-measurements in the intervention group is hampered by re-
gression to the mean, because the intervention group was selected based on high base-
line HOMA-IR values. Therefore we also performed a regression discontinuity design, in 
which assignment of subjects to (lifestyle) intervention is solely determined by the use 
of a “cut-off” score measured at baseline. The intervention effect is not indicated by a 
difference between the posttest averages of groups but rather by a change in the pre-
post relationship at the cutoff point. Through regression adjustment for the assignment 
score an unbiased estimate of the intervention effect can be obtained. Treatment effects 
in regression discontinuity design are estimated  by fitting least squares regression lines 
regressing posttest scores on pretest scores with group as a covariate and if needed, an 
interaction term between group and pretest score (12).
Several possible results of regression discontinuity analyses are illustrated in figure 
1. All subjects are assigned to treatment or standard care based on the pre-test cut-off 
score of 2 in this fictitious situation. The first graph in figure 1 illustrates a case in which 
there is no treatment effect (model a). This is indicated by the regression line that runs 
straight through the data-points on both sides of the cut-off. The second graph (model 
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b) shows the classic regression discontinuity design. The treatment exerts a positive 
effect, as expressed by the  ‘discontinuity’ of the regression line at the cut-off point. The 
third graph in figure 1 demonstrates a regression discontinuity with an additional slope 
of the regression line; in the models a and b, the regression lines below and above the 
cut-off point have identical slopes but in model c interaction is allowed. 
Using the regression discontinuity design we analyzed the following outcomes: a) 
change in the 9-month HOMA-IR, glucose, waist circumference, blood pressure, the level 
of triglycerides and HDL-cholesterol. Therefore we regressed the 9-month HOMA-IR on 
baseline HOMA-IR with group as a second covariate. The regression coefficient for group 
then reflects the effect of the intervention for patients with the cut-off value of HOMA-
IR. For the effect on 9-month glucose, waist circumference, blood pressure, the level of 
triglycerides and HDL-cholesterol the assignment score (baseline HOMA-IR) was added 
as a second covariate. Interaction terms for pre-tests were added if they significantly 
improved the R2 for the 9-month outcome. Regression coefficients for log transformed 
variables were exponentiated, in this way they reflect how much larger the (geometric) 
mean in the intervention group is compared to the non-intervention group.
rEsulTs 
study participants
From all eligible and non-diabetic subjects aged 40-70 years, 2079 (71%) participated in 
the screening phase of the study. The flow scheme of the inclusion is shown in figure 2. 
Six hundred eighty-six subjects were diagnosed with the MetS and invited to participate 
in the second part of the study. Subjects with high insulin resistance levels (HOMA-IR ≥ 
2, n=144) were assigned to a 9 months lifestyle intervention program during the period 
figure 1. Possible results of regression discontinuity. Model a illustrates a case in which there is no treat-
ment effect i.e. the regression line runs straight through the data-points. Model b shows the classic regres-
sion discontinuity design. The treatment exerts a positive effect, as expressed by the ‘discontinuity’ of the 
regression line at het cut-off. Model c demonstrates an additional slope of the regression line; a model in 
which interaction was allowed. 
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February 2006 to August 2010. Of the seventy-eight subjects willing to participate, nine 
subjects withdrew informed consent and sixty-nine subjects followed the program. 
Subject willing to participate (n=78) did not differ from subjects not included in the 
intervention group (n=66) with respect to baseline characteristics, besides from a higher 
percentage of subjects with high triglycerides (65% vs 50%, p=0.049).  Subjects with 
insulin resistance levels below the cut-off were assigned to the non-intervention group 
(HOMA-IR < 2, n=543). In this group 311 subjects were willing to participate and received 
lifestyle advice by letter. Subjects with insulin resistance below the cut-off and willing to 
participate were older (56.1 vs 53.9 years, p=0.030) and less likely to be diagnosed with 
impaired fasting glucose compared to the subjects not included in the non-intervention 
group (40% vs 73%, p=0.001).  Baseline characteristics of both groups are listed in Table 
1. Overall the mean age was 56 ± 8 years. Median HOMA-IR was 2.50 (2.30 - 3.20) in the 
intervention and 1.20 (0.80 - 1.50) in the non-intervention group. Groups were compa-
rable with respect to age, gender, smoking, family history of cardiovascular disease and 
use of lipid lowering medication. By selection the metabolic syndrome was present in 
all subjects. Subjects in the intervention group more often fulfilled the criteria for low 
HDL-cholesterol (72% vs 59%, p=0.045) and elevated levels of triglycerides (65% vs 50%, 
p=0.012). Furthermore more subjects used blood pressure lowering medication (50% 
vs 34%, p=0.019) in the intervention group compared to the non-intervention group.
figure 2. Flowchart of enrollment and assignment of subjects based on a cut-off score for insulin resistance 
(HOMA-IR ≥ 2). Subjects above the cut-off score were assigned to a lifestyle intervention and subjects be-
low the cut-off score were assigned to the non-intervention group. 
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Measurements at follow up
The change in metabolic syndrome components and insulin resistance (HOMA-IR) after 
nine months of the intervention group and non-intervention group are shown in Table 2 
and 3. The subjects following the intervention protocol visited the nurse practitioner on 
average 3.5 ± 1.3 times during the 9 months treatment period. Nine subjects withdrew 
informed consent before the start of the lifestyle program and 4 subjects did not com-
plete all four sessions. These subjects were analyzed according to the intention-to-treat 
principle. During the nine months follow-up, five (6.4%) subjects of the intervention 
group and twelve (3.9%) subjects of the non-intervention group, developed type 2 dia-
betes (defined as a fasting glucose > 7 mmol/l).  A new prescription of antihypertensive 
medication, an increase in the number of antihypertensive drugs or a rise in dose was 
observed in 18 (23.1%) subjects of the intervention group and in 42 (13.5%) subjects 
of the non-intervention group. Statins were prescribed in five (6.4%) subjects during 
lifestyle intervention and in six subjects (1.9%) of the non-intervention group. 
results of the regression discontinuity design analysis 
Results are presented from linear models without interaction terms for pretests, as inter-
action terms did not improve the model significantly in any of the situations. A decline 
in waist circumference [-2.99 cm (95% CI -4.72, -1.26)] and a reduction in systolic blood 







Age (years)  55.7 (7.9) 56.1 (8.2) 0.717
Male gender, n (%) 40 (51) 176 (57) 0.399
Smoking status, n (%) 27 (35) 92 (30) 0.388
Family history of cardiovascular disease, n (%) 23 (29) 71 (23) 0.382
Lipid lowering medication, n (%) 18 (23) 60 (19) 0.455
Blood pressure lowering medication, n (%) 38 (50) 107 (34) 0.019*
Metabolic syndrome defining criteria
 Central obesity, n (%) 78 (100) 311 (100) -
 High blood pressure#, n (%) 69 (88) 266 (86) 0.503
 Low HDL-cholesterol#, n (%) 56 (72) 185 (59) 0.045*
 High triglycerides#, n (%) 51 (65) 154 (50) 0.012*
 Impaired fasting glucose#, n (%) 50 (64) 169 (54) 0.120
Abbreviations; HDL: high density lipoprotein. Values represent mean ± standard deviations or number of 
subjects (percentages). *P < 0.05. #IDF defined MetS criteria: central obesity waist circumference male ≥ 94 
cm and female ≥ 80 cm, HDL-cholesterol male < 1.03 mmol/l and female < 1.29 mmol/l, triglycerides > 1.7 
mmol/l, impaired fasting glucose > 5.6 mmol/l, blood pressure; systolic blood pressure > 130 mmol/l and/
or diastolic blood pressure > 85mmol/l and/or treatment with blood lowering medication.
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pressure [-7.28 mmHg (95% CI -12.78, -1.79)] in the intervention group compared to 
the non-intervention group was found (Table 4, figure 3-5). Looking at the subgroup 
of subjects without antihypertensive agents or in whom medication was not increased 
(76% of the intervention group and 86% of the non-intervention group 86%) similar 
results for systolic blood pressure were observed [-7.72 mmHg (95% CI -13.07, -2.36)]. 
Insulin resistance [1.170 units (95% CI 0.985, 1.388)] HOMA-IR higher in the intervention 
group, figure 5] did not significantly change compared to the non-intervention group. 
Similarly, no significant change compared to the non-intervention group was found for 
diastolic blood pressure [1.85 mmHg (95% CI -4.96, 1.25) lower], glucose [0.06 mmol/l 
(95% CI -0.23, 0.12) lower], HDL-cholesterol [0.99 (95% CI 0.94, 1.03) times lower] and 
triglycerides [0.99 mmol/l (95% CI 0.89, 1.11) times lower]. 
disCussioN
This study shows that lifestyle intervention can be successfully implemented in a primary 
health care center by nurse practitioners using the step one approach as described in the 
national dutch diabetes protocol. Thus showing the feasibility of lifestyle intervention in 
primary care. Furthermore, the intervention successfully reduced visceral obesity and 
lowered systolic blood pressure. Despite a reduction in obesity the intervention did not 
significantly affect insulin resistance levels in individuals with the metabolic syndrome.  
Table 3. Change in metabolic syndrome components and insulin resistance (HOMA-IR) of the intervention 
group and non-intervention group
Change in the intervention 
group 














0.02 ( -0.11 - 0.10 )
-0.04 ( -0.04 - 0.10)
0.00 ( -0.09 - 0.10 )
0.10 ( -0.11 - 0.15 )
0.949
0.488
Triglycerides, mmol/l 0.00 ( -0.42 - 0.32 ) 0.10 ( -0.43 - 0.32 ) 0.521
Fasting blood glucose, mmol/l 0.15 ± 0.57   0.21 ± 0.60 0.063
Systolic blood pressure, mmHg -5.8  ± 18.9 -0.3 ±  18.7 0.027*
Diastolic blood pressure, mmHg -4.2 ± 9.4 -1.4 ± 10.5 0.034*
HOMA-IR -0.50 ( -0.30  - 1.00 ) 0.00 ( -0.50 - 0.30 ) <0.001*
Abbreviations; HDL: high density lipoprotein, HOMA-IR: Homeostasis Model of Assessment – Insulin Resis-
tance. Values represent mean ± standard deviation or medians (interquartile range) of the change during 
9months follow up. *P<0.05.
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Table 4. Results of regression discontinuity design analysis 






1.170 (0.985, 1.388) times higher compared to the 
non-intervention group
0.074
Waist circumference, cm - 2.99 (-4.72, -1.26) 0.001*
LN HDL-cholesterol
HDL-cholesterol, mmol/l#
- 0.01 (-0.06, -0.03)





 -0.01 (-0.12, 0.11)
0.99 (0.89, 1.11) times higher compared to the 
non-intervention group
0.910 
Fasting blood glucose, mmol/l  -0.06 (-0.23, 0.12) 0.542 
Systolic blood pressure, mmHg -7.28 (-12.78, -1.79) 0.010*
Diastolic blood pressure, mmHg -1.85 (-4.96, 1.25) 0.240 
Abbreviations; HDL: high density lipoprotein, HOMA-IR: Homeostasis Model of Assessment – Insulin Resis-
tance. Values represent regression coefficients (95% confidence intervals) for the intervention group in a 
regression model with as independent variable the posttest and the pretest, group and assignment score 
(HOMA-IR) as covariates. #Exponentiated regression coefficient of the model with the log transformed out-
come . *P<0.05  
figure 3 (left panel) and 4 (right panel). Regression discontinuity analysis regarding the effect on waist 
circumference (Figure 3) and systolic blood pressure (Figure 4). Posttest scores were regressed on pretest 
scores with group and HOMA-IR score as additional covariates and predicted regression lines for both 
groups separately are shown. Waist circumference declined with -2.99 cm (95% CI -4.72, -1.26) in the in-
tervention group compared to the non-intervention group. Systolic blood pressure was reduced with 
-7.28 mmHg (95 CI% -12.78, -1.79) in the intervention group compared to the non-intervention group. 
Legend: • = non-intervention group, ----- ¯ = life style intervention group
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The MetS is relatively widespread in Western populations and is of considerable public 
health concern (1). In line, we observed MetS in 686 (33%) non-diabetic subjects in our 
study. International guidelines recommend lifestyle as a first line therapeutic strategy 
for reducing the risk of diabetes and cardiovascular disease (13). With growing number 
of individuals with obesity and MetS implementation of lifestyle intervention becomes 
a major public health care challenge. Lifestyle interventions that can be implemented in 
existing community health care systems may be advantageous in terms of time needed 
for implementation and health care budgets. This study underlines these possibilities by 
showing the feasibility of lifestyle intervention therapy in primary health care centers. 
The lifestyle intervention was successful in reducing visceral obesity and lowering 
blood pressure. The blood pressure lowering effect in the intervention group compared 
to the non-intervention group could not be solely attributed to drug treatment as the 
estimated reduction in blood pressure was similar in subjects without antihypertensive 
medication. Our results are in line with previous studies showing a beneficial effect on 
each of the components of the MetS (4-6). 
In contrast to these randomized controlled trials we observed relatively modest reduc-
tions in waist circumference [-2.99 (-4.72, -1.26) cm]. Furthermore we did not observe 
an effect for triglycerides, glucose and insulin resistance levels. A possible explanation 
is that a relative low intensity of intervention was used. Moreover our estimate of the 
intervention effect can be considered “conservative” since the data were analyzed ac-
cording to the intervention-to-treat principle. Additionally all subjects assigned to the 
non-intervention group also received general health advice by letter at base line and 
may have benefited from the advice. On the other hand HOMA-IR is a relatively crude 
method for the quantification of insulin resistance. HOMA-IR is based on the product 
of fasting insulin and glucose and only a basal measurement is used. Fluctuation in the 
figure 5. Regression discontinuity 
analysis regarding the effect on insu-
lin resistance measured as HOMA-IR; 
posttest scores were regressed on 
pretest scores with group and as-
signment score as a second and third 
covariate and predicted regression 
lines for both groups separately are 
shown. HOMA-IR was 1.170 (95% CI 
0.985, 1.388) higher in the interven-
tion group compared to the non-in-
tervention group. Legend:      · = non-
intervention group, ----- ¯ = lifestyle 
intervention group.
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basal overnight fasting insulin concentration is a major source of this variability which 
may explain why we did not find an effect for the relative small intervention group.
Few studies on lifestyle modification in metabolic at risk subjects have been per-
formed in the primary health care setting. In contrast with our results, the CELL Study 
Group found no effect of an intensive health care advice given by a general practitioner 
and nurses working in primary care. This study was mainly carried out in male with hy-
perlipidemia but did not necessarily include subjects with the MetS (14). In the setting 
of a rural primary practice in Germany a weight management program with two weekly 
training sessions was found to improve all metabolic abnormalities and blood pressure 
in subjects with the MetS after one year (15). Compared to our results larger reductions 
in obesity and blood pressure were observed. However the beneficial effect might be 
overestimated because the assignment to the treatment groups was not randomized. In 
a clinical research setting the DASH diet has been shown to reduce weight (16 kg) and to 
lower blood pressure (12 mmHg) in the MetS (4). Two other RCT’s carried out in subjects 
with the MetS demonstrated reductions in waist and blood pressure with a diet or ex-
ercise programs (16;17). The difference in effect of our intervention with respect to that 
obtained in these trials (4;16) can be explained by differences in methods and intensity 
of interventions applied. Trials were performed in clinical outpatient clinics from univer-
sity centers, subjects were often self-referred, more obese and weight loss is obtained 
during a longer intensive program more difficult to implement in daily practice.  
Our findings may be more generalizable to daily practice in primary health center 
settings than are those of highly controlled randomized trials with larger treatment 
effects. The successful adaptation of the intervention from the diabetes protocol and 
implementation using the preexisting structure of diabetes counseling by nurse prac-
titioners are highly encouraging to consider wider application of our approach.  In ad-
dition the employment of nurse practitioners provides the advantage of an established 
link between the patient and physician and experience already exists in management 
of co-morbidity.  
Several considerations affect interpretations drawn from our findings. First, we did not 
use a randomized clinical trial design. Second, when using existing primary health care 
facilities, limitations were encountered with the number of counseling sessions. Third, 
the study sample size was relatively small and patient engagement with the interven-
tion was less than desired but not inconsistent with other trials. Fourth, our intervention 
results apply primarily to MetS-subjects. Whether the results would be similar in obese 
persons without the MetS is likely but unknown. Furthermore, the period of evaluation 
was relatively short and this study cannot provide information about long-term efficacy 
and effectiveness. 
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The regression discontinuity design is a more appropriate approach than the often 
used pre-post design with no control group and has been proposed as a suitable tech-
nique for use in the public health domain (12). 
However several assumptions must be met before using the regression discontinuity 
design (12, 18). The first assumption is that treatment assignment around the cut-off 
point is as good as random, otherwise selection bias may be induced. As subjects in 
our study were not able to manipulate their HOMA-IR and thereby their assignment to 
the intervention or non-intervention group this assumption is likely to be met. Second, 
it is important to correctly identify the relationship between assignment measure and 
outcome variable, hereto a sensitivity analysis with a more narrow interval around the 
cut-off point can be considered. The third requirement is a large enough pre-test sample 
size to support the use of regression analysis to estimate the pre- and posttest relation-
ship. Fourth, all individuals in the study must be drawn from the same population. In our 
opinion, except for the sample size that ideally would have been larger, these criteria 
have been met – amongst others because we selected subjects from a population based 
cohort of individuals living in Rijswijk, the Netherlands. Finally it is assumed that all par-
ticipants in the treatment receive the same level and amount of intervention. During the 
intervention not all subjects (31%) followed the complete counseling program, which 
reflects the real life setting. 
In summary, our study shows the feasibility and success of lifestyle intervention for 
MetS subjects in primary health care centers. The prevention of progression of visceral 
obesity and MetS using such programs in primary care may provide an effective and 
efficient strategy for clinical health systems to meet the growing challenge of obesity 
and cardiovascular disease prevention.  
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The focus of this thesis was to evaluate biomarkers of cardiovascular end organ dam-
age in the metabolic syndrome and diabetes mellitus. Biomarkers are characteristics 
that are objectively measured and evaluated and may indicate underlying disease. We 
performed cross-sectional studies with biochemical and magnetic resonance imaging 
(MRI) techniques. In addition we studied the effect of a lifestyle intervention in a general 
population using primary health care setting. 
Chapter 1 provided a general introduction on the complex and interconnected 
underlying mechanisms for cardiovascular disease (CVD) and end organ damage. The 
relations between obesity related insulin resistance, dyslipidaemia, hypertension and 
inflammation were described. 
Chapter 2 is a systematic review and meta-analysis on the association between fast-
ing glucose, fasting insulin, the Homeostasis Model Assessment of Insulin Resistance 
(HOMA-IR) and incident CVD in individuals without diabetes. We performed the first 
meta-analysis that directly compared these markers with incident CVD. We included 
65 cohort studies and (nested) case-control studies involving 516,325 participants and 
used fixed and random-effect meta-analyses to calculate the pooled relative risk for 
coronary heart disease, stroke or combined CVD. We demonstrated that the relative risk 
of CVD was higher for an increase of one standard deviation in HOMA-IR compared to 
an increase of one standard deviation in fasting glucose or fasting insulin concentration. 
Since insulin resistance may only lead to hyperglycemia when pancreatic beta cells are 
no longer capable to compensate by increasing insulin production we suggest that it 
may be useful to add markers of insulin resistance to a cardiovascular risk prediction 
model. Insulin resistance plays an important role in the early and advanced stages 
of atherosclerosis, whereas hyperglycaemia seems exclusively to be involved in early 
stages of atherosclerosis (1). In addition, insulin resistance seems to modify the effect 
of insulin on the vascular wall; anti-atherogenic in the insulin sensitive state and pro-
atherogenic in the insulin resistant state. It was shown before that the addition of a 
fasting glucose measurement to the Framingham risk score (cardiovascular risk predic-
tion model) resulted in a slight net reclassification improvement of 1.8% (2). Whether 
the addition of HOMA-IR to a risk prediction model on top of plasma glucose levels will 
result in a more accurate reclassification of CVD risk is unknown and should be carefully 
weighted against the extra costs involved.
In Chapter 3 the role of angiopoietin-like protein 4 (ANGPTL4) in the context of inflam-
mation was explored. It has been more than a decade since ANGPTL4 was identified 
and now this protein has emerged as a central player in many aspects of energy ho-
meostasis. It is involved in a variety of functions including angiogenesis and lipoprotein 
metabolism. 
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In this study we aimed to investigate whether systemic inflammation is a determinant 
for plasma ANGPTL4 levels in subjects with metabolic syndrome and type 2 diabetes 
mellitus (T2DM). We studied four groups of male (n=334) subjects: healthy controls, sub-
jects with metabolic syndrome without systemic inflammation, subjects with metabolic 
syndrome accompanied by low grade systemic inflammation and patients with T2DM. 
Initially subjects were matched for waist circumference and age. Plasma levels of ANG-
PTL4, C-reactive protein (CRP) and metabolic parameters were determined. We observed 
that plasma ANGPTL4 increased with inflammatory status as measured by CRP (healthy 
controls < subjects with metabolic syndrome without inflammation < subjects with 
metabolic syndrome with low grade inflammation and subjects with T2DM). Therefore 
plasma ANGPLT4 levels in humans are related to systemic inflammation. Furthermore, 
in all groups combined, plasma ANGPTL4 showed a positive correlation with CRP. To get 
more insight into the causal relationship between inflammation and ANGPTL4 expres-
sion we assessed whether inflammatory stimuli (i.e. Toll-like receptor 3/4 activation) 
increased ANGPTL4 expression using human macrophages in vitro. Moreover we found 
that in vitro inflammatory stimuli increased the expression and release of ANGPTL4 
by macrophages. Thus far, the expression of ANGPTL4 in numerous tissues including 
adipose tissue and liver was thought to be mainly regulated by peroxisome prolifer-
ator-activated receptors (PPARs). Consistent with a role of PPARs, fatty acids increase 
ANGPTL4 expression (3-6). However we were unable to detect a correlation between 
plasma FFA levels and plasma ANGPTL4 levels which is likely related to the matching 
on visceral obesity. The current findings provide a novel link between inflammation and 
ANGPTL4 expression. As CRP itself is a marker rather than a mediator of inflammation, 
future research is needed to investigate which intracellular cascade causes an increase 
in ANGPTL4 expression in humans and whether the inflammation-induced increase in 
plasma ANGPTL4 is causally related with dyslipidemia. 
In a former study we showed that ANGPTL4 reduces foam cell formation and decreases 
atherosclerosis in atherosclerosis-prone APO*3-Leiden mice (7). In addition we observed 
a negative association of ANGTPL4 with MRI assessed VWT of the carotid artery in sub-
jects with the metabolic syndrome and systemic inflammation . 
Taken these results together, the stimulation of ANGPTL4 gene expression in macro-
phages is specially activated by oxLDL and as shown in chapter 3 may be activated by 
inflammatory stimuli. Therefore increased ANGTPL4 gene expression may be a protec-
tive feedback mechanism aimed at minimizing lipid overload 1) by directly inhibiting 
oxLDL uptake by macrophages and 2) by inhibiting lipid loading from triglyceride-rich 
lipoproteins and associated activation of macrophages. Further research on ANGPTL4, 
inflammation and atherosclerosis in humans is necessary to evaluate the potential of 
targeting ANGPL4 as a therapeutic strategy.
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Chapter 4 presented the results of a study on the short-term effect of a standardized 
glucose load on region-specific aortic pulse wave velocity (PWV) using MRI. PWV is a 
validated marker for aortic stiffness, which has become an important marker for CVD 
and end organ damage. MRI enables regional assessment of the PWV in multiple loca-
tions due to its accuracy in determining the true path length of the propagating wave 
in the aorta. We performed a randomized, placebo-controlled intervention in 16 male 
subjects with impaired fasting glucose. The intervention consisted of an oral glucose 
load at one study day and water at the other study day. PWV was measured using multi-
slice two-directional in-plane velocity-encoded MRI. The main finding of this study was 
that a standardized glucose load decreases aortic PWV within 1 hour compared with 
water. Furthermore the decrease was region-specific because it was observed in the 
proximal but not in the distal aorta. Therefore this study demonstrates region-specific 
changes in arterial stiffness after a glucose load. Various vascular beds and locations 
may react differently to the effect of insulin and other vasoactive influences. In vitro, the 
contribution of nitric oxide dependent vasodilation is larger in central arteries than in 
distal microvessels (8). Consistent with variation in vascular reactivity regional variation 
in the elastin versus collagen ratio exists within the aorta (9-11). Therefore it is possible 
that the effect of postprandial hyperinsulinemia would have less impact on the distal 
segment. Interestingly inter-individual differences in response to the glucose load were 
found. Subjects who did not show a significant change in PWV after the glucose load 
were significant more obese. Previously an impaired insulin-induced decrease in arterial 
stiffness was shown in human obesity (12) and impaired nitric oxide synthesis has been 
reported in conditions as the metabolic syndrome (13). Future research is needed to 
improve knowledge on possible regional effects of hyperglycaemia on aortic stiffness 
and whether they link to inter-individual variation in regional vascular response.
In Chapter 5 the impact of type 1 diabetes mellitus (T1DM) on regional grey matter 
volume of the brain was investigated using voxel-based morphometry (VBM). This rela-
tively novel and sophisticated analysis technique can be used to test for regional subtle 
grey matter alterations. In this study 62 patients with T1DM and 62 age and gender 
matched healthy controls underwent 3 T MRI of the brain. Volumes of the basal ganglia, 
amygdala hippocampus and thalamus were assessed with VBM. With this technique we 
show that in addition to cortical atrophy, T1DM differentially affects specific grey matter 
areas.  In T1DM all subcortical grey matter structures (i.e. basal ganglia, hippocampus 
and thalamus) but the amygdala showed atrophy compared to healthy control subjects. 
Previous studies performed with lower field strengths in T1DM showed decreased hip-
pocampal and thalamic volumes. Since the onset of T1DM is often in childhood, regional 
reductions may be likely to reflect changes that occur during brain development (14). 
It is interesting to speculate on the role of the amygdala in T1DM. It has a primary role 
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in controlling the cerebral regulation of stress response including the response to hy-
poglycaemia (15). Reduced activation of the amygdala has been found in subjects with 
T1DM and hypoglycaemia unawareness (16). Maintaining hypoglycaemia awareness 
and activation of the amygdala may therefore protect the amygdala from degeneration. 
However the clinical significance of this intriguing but challenging finding remains to 
be elucidated. Increasing awareness of the effects of T1DM on the brain is emerging; the 
necessity of brain research was recently incorporated into the report of unmet needs 
in diabetes research in Europe (http//www.diamap.eu). Future longitudinal studies in 
large patient populations are required to confirm these results and study underlying 
pathophysiology. 
In addition to hypo- and hyperglycemia, a proposed underlying mechanism in target 
organ damage of the brain in T1DM, includes vascular disease. Increased aortic stiffness 
may contribute to brain damage by exposing the small vessels to high pressure fluctua-
tions and flow in the circulation. 
The study described in Chapter 6 explored the association between aortic stiffness 
and diffusion tensor imaging (DTI) of the brain in T1DM. Forty-one patients with T1DM 
were studied and PWV was measured using a 1.5 T MRI scanner. DTI measurements were 
performed on 3 T MRI. This relatively new and validated MRI technique enables measure-
ment of white matter microstructure and is based on diffusivity of water. We found that 
aortic stiffness is independently associated with reduced white matter integrity. Aortic 
PWV is a surrogate marker for arterial stiffness and has been shown to be and indepen-
dent predictor for stroke and cerebral small vessel disease. To the best of our knowledge 
we are the first to show an association with white matter integrity in T1DM. These find-
ings add further evidence to the hypothesis of a vascular contribution to brain damage. 
Large artery stiffness may trigger damage and remodelling of the microcirculation of 
the brain. Integrity of white matter tracts form the structural connections between 
brain regions. Previous studies have observed deficits in white matter microstructure in 
normal aging and cerebral small vessel disease. In addition decrements in white matter 
tract integrity have been shown in T1DM (17). However the clinical and prognostic im-
plications of these microstructural changes and their relation with aortic stiffness have 
to be shown in future prospective studies. 
The role of arterial stiffening in hypertension and concomitant chronic kidney disease 
is not completely elucidated. As arterial stiffening and impaired renal function often 
co-exist in hypertension, increased arterial stiffening may be related to both. During 
the cross-sectional study described in Chapter 7 we included hypertensive patients 
with a normal estimated glomerular filtration rate, healthy volunteers and assessed the 
association between MR measured regional aortic PWV and renal function. We showed 
increased regional aortic stiffness of the proximal and distal aorta in hypertension com-
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pared to healthy volunteers. Furthermore changes in renal function within the normal 
range are inversely related to arterial stiffness even in the absence of disproportionate 
stiffening. This relation did not differ between patients with hypertension and healthy 
volunteers and is present before the onset of decreased eGFR, proteinuria and macro-
vascular complications. These results stress the close link between aortic stiffness and 
the microcirculation. Future studies are needed to elucidate the implications of early 
arterial stiffening in hypertension on long-term renal function
With growing number of individuals with obesity and metabolic syndrome the imple-
mentation of lifestyle intervention becomes a major public health care challenge. Chap-
ter 8 evaluated the feasibility and effect of the implementation of a lifestyle intervention 
(inclusive of possible blood pressure treatment) among non-diabetic subjects with the 
metabolic syndrome in four primary health care centers. Subjects with the metabolic 
syndrome and insulin resistance were included (n=78) and offered a lifestyle program. 
Subjects with the metabolic syndrome without insulin resistance (n=311) were included 
and received a letter containing a set of lifestyle advices (non-intervention group). In 
the regression discontinuity design posttest scores were regressed on pretest scores 
with group as a covariate. For the effect on visceral obesity, glucose, lipid levels and 
blood pressure insulin resistance was added as a second covariate. The study showed 
that lifestyle intervention can be implemented in a primary care setting using existing 
facilities. Using the regression discontinuity design the intervention was shown to ef-
fectively reduce visceral obesity and lower systolic blood pressure. Despite a reduction 
in obesity the intervention did not affect insulin resistance levels possibly explained by 
the relative low intensity of the intervention and the use of a relative crude method for 
quantifying insulin resistance. Relatively few studies on lifestyle modification in meta-
bolic at risk subjects have been performed in primary health care. Recently Bor et al. 
(18) explained the background theory and assumptions of the regression discontinuity 
design and introduced new possibilities for clinical practice. Although less efficient than 
a randomized controlled trial the design can be applied in existing care settings and can 
use existing data. Our findings may be more generalizable to daily practice than those 
of highly controlled randomized trials. Therefore this study may provide an effective 
strategy for clinical health care systems to meet the growing challenge of obesity and 
cardiovascular disease. Although frequently used in observational science, future stud-
ies are needed to examine the feasibility and robustness of the regression discontinuity 
design in medicine and clinical health.
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CoNClusioNs
Taken together the studies in current thesis contribute new information on biomarkers 
of end organ damage in the metabolic syndrome and diabetes. We have demonstrated 
that insulin resistance is a strong risk predictor for CVD and we provided a novel link 
between inflammation and ANGPTL4 expression. The imaging studies described in 
this thesis extend the knowledge on aortic stiffness and microvascular damage by 
showing an association with subtle microstructural deficits in T1DM. To improve our 
understanding of these microstructural deficits multicentre longitudinal studies that 
relate imaging parameters to cognitive performance are necessary. The predictive value 
of aortic stiffness would be highly interesting in this context because studies suggest an 
contributing role to microvascular damage. Furthermore regional and individual differ-
ences in response to an oral glucose load in MR assessed aortic stiffness were observed, 
which may open new future research paths possibly linking inter-individual variation in 
regional vascular response and CVD. 
However given the cross-sectional design of the studies in this thesis, the biomarkers 
described provide no insight in changes over time. Longitudinal studies are needed to 
investigate weather they predict future events beyond established risk factors.
Hopefully future studies will show the usefulness of these biomarkers that will 
possibly select obese and overweight patients at high risk for CVD. Early detection of 
cardiovascular manifestations is highly relevant to allow better-targeted interventions 
to reduce CVD morbidity and mortality. Until then, the prevention of overweight and 
obesity worldwide remains the most effective strategy in reducing metabolic dysfunc-
tion and remains perhaps the biggest challenge for health systems world wide.
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NEdErlaNdsE saMENVaTTiNG
Hart- en vaatziekten (HVZ) behoren tot de belangrijkste oorzaak van overlijden in de 
Westerse wereld, waarbij overgewicht en obesitas het risico op HVZ aanzienlijk verhogen. 
Het aantal mensen met overgewicht neemt de afgelopen jaren sterk toe. Overgewicht 
gaat vaak samen met verminderde gevoeligheid van de weefsels voor insuline (insuline 
resistentie) waarbij zich uiteindelijk diabetes mellitus (DM) kan ontwikkelen. Insuline 
resistentie, gaat in vele gevallen van overgewicht gepaard met verhoogde concentra-
ties in het bloed van glucose (hyperglykemie), vetten en cholesterol (dyslipidemie) en 
hypertensie. Deze clustering van risicofactoren voor HVZ wordt ook wel het metabool 
syndroom genoemd. In combinatie met laaggradige chronische ontsteking hebben 
deze factoren grote invloed op de ontwikkeling van cardiovasculaire eindorgaanschade.
Toegenomen vaatwandstijfheid van de aorta kan invloed hebben op de bloeddoor-
stroming van verschillende eindorganen waaronder de hersenen en nieren. Recent on-
derzoek toont aan dat toegenomen vaatwandstijfheid een belangrijke voorspeller is van 
HVZ. De elasticiteit van de aorta is namelijk van invloed op het omzetten van de polsgolf 
naar een meer constante bloedstroom. Bij een verminderde elasticiteit (en toegenomen 
vaatwandstijfheid) en daardoor een grotere polsdruk kan de perfusie van eindorganen 
worden beïnvloed. Aan de ontwikkeling van eindorgaanschade gaat jaren vooraf, dit 
biedt ruimte voor vroegtijdige preventieve interventies. Eén vijfde van de HVZ doet 
zich voor bij personen zonder traditionele risicofactoren. Het is daarom belangrijk om 
nieuwe voorspellers van HVZ en eindorgaanschade te identificeren.
In dit proefschrift worden biomarkers van cardiovasculaire eindorgaanschade bij 
patiënten met DM en het metabool syndroom beschreven. Biomarkers kunnen objectief 
gemeten en geëvalueerd worden en kunnen een onderliggende ziekte identificeren. 
Biomarkers kunnen verkregen worden via beeldvorming of middels bloedafname 
(biochemische biomarkers). In dit proefschrift zijn cross-sectionele studies met bioche-
mische en magnetic resonance imaging (MRI) technieken beschreven. Daarnaast is het 
effect van een leefstijlinterventie op risicofactoren voor HVZ in de algemene populatie 
bestudeerd.
hoofdstuk 2 is een systematisch literatuuroverzicht en meta-analyse waarin de as-
sociatie tussen de nuchtere bloedconcentraties van glucose, insuline, het Homeostasis 
Model Assessment of Insulin Resistance (HOMA-IR, een maat voor insuline resistentie) 
en de incidentie van HVZ is beschreven in personen zonder DM. Dit is de eerste meta-
analyse die deze verschillende factoren direct vergelijkt in hun relatie tot HVZ. Er zijn 
65 cohort studies en (nested) case-control studies met in totaal 516.325 proefpersonen 
geïncludeerd. Met behulp van een fixed-effect en random-effect model is het gepoolde 
relatief risico voor coronaire hartziekten, beroerte en HVZ berekend. Deze studie toont 
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aan dat in vergelijking met een toename in nuchter glucose of insuline het relatief risico 
op HVZ hoger is per standaarddeviatie toename in HOMA-IR. Bij gezonde mensen zorgt 
insuline ervoor dat te hoge glucosespiegels weer dalen, onder andere doordat insuline 
de opname van glucose in de weefsels stimuleert. Bij het ontstaan van insuline resisten-
tie kan in eerste instantie gecompenseerd worden door een verhoogde uitscheiding van 
insuline door de bètacellen van de alvleesklier. Als dit tekort schiet ontstaan verhoogde 
glucosespiegels. Echter voordat de hoge glucosespiegels ontstaan is er al sprake van 
een gestoorde balans tussen insuline en glucose. Een marker voor insuline resistentie 
kan daarom van toegevoegde waarde zijn om het cardiovasculaire risico te voorspellen. 
Tevens speelt insuline resistentie een belangrijke rol in de vroege en gevorderde stadia 
van atherosclerose. Insuline resistentie lijkt het effect van insuline op de vaatwand te 
modificeren; anti-atherogeen in het geval van insuline gevoeligheid en atherogeen in 
het geval van insuline resistentie. Eerder onderzoek laat zien dat de toevoeging van 
het nuchter glucose aan de Framingham risico score, een veel gebruikt risico predictie 
model voor HVZ, resulteerde in een netto re-classificatie van 1.8%. Of de toevoeging van 
HOMA-IR aan predictie modellen, naast glucose, inderdaad zal resulteren in een betere 
inschatting van het cardiovasculaire risico moet nog bevestigd worden en zal bij mo-
gelijk effect zorgvuldig moeten worden afgewogen tegen de met zich meebrengende 
kosten van het meten van HOMA-IR.
hoofdstuk 3 evalueert of laaggradige systemische ontsteking een determinant is voor 
plasma angiopoeietin-Like Protein 4 (ANGPTL4) concentraties bij diabetes mellitus 
type 2 (T2DM) en het metabool syndroom. In deze studie (n=334) zijn vier groepen 
bestudeerd: gezonde controles, patiënten met het metabool syndroom zonder systemi-
sche ontsteking, patiënten met het metabool syndroom met laaggradige systemische 
ontsteking en patiënten met T2DM. Initieel werden de deelnemers gegroepeerd op bui-
komvang en leeftijd. Plasma waarden van ANGPTL4, C-reactief proteïne (CRP) en andere 
metabole parameters werden bepaald. Deze studie laat zien dat ANGPTL4 toeneemt 
met stijgende inflammatoire status (gemeten met CRP) en toeneemt in de opeenvol-
gende groepen (gezonde controles < patiënten met het metabool syndroom zonder 
ontsteking < patiënten met het metabool syndroom met laaggradige systemische 
ontsteking < patiënten met T2DM). Concluderend zijn plasma ANGPTL4 levels gerela-
teerd aan systemische ontsteking. Wanneer alle personen werden gecombineerd werd 
een positieve correlatie gevonden tussen plasma ANGPTL4 en CRP. Om meer inzicht te 
krijgen in de causale relatie tussen ontsteking en ANGPTL4 expressie werd een in vitro 
experiment verricht waarbij werd onderzocht of stimuli voor ontsteking (Toll-like recep-
tor 3 / 4 activatie) ANGPTL4 expressie in menselijke macrofagen verhoogt. Deze in vitro 
inflammatoire stimuli blijken de expressie en secretie van ANGPTL4 door macrofagen 
te verhogen. Tot nu toe werd gedacht dat de expressie van ANGPTL4 in verschillende 
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weefsels hoofdzakelijk werd gereguleerd door peroxisome proliferator-activated recep-
tors (PPARs). Overeenkomstig de rol van PPARs, verhogen vrije vetzuren de expressie 
van ANGPTL4. Opmerkelijk genoeg vinden we in deze studie geen correlatie tussen vrije 
vetzuren in het plasma en plasma ANGTPL4 levels. De meest waarschijnlijke verklaring 
hiervoor is dat de studiedeelnemers en patiënten werden gegroepeerd op viscerale 
obesitas. De huidige bevindingen tonen een nieuwe relatie tussen ontsteking en de 
expressie van ANGPTL4. Toekomstig onderzoek zal nodig zijn om uit te wijzen welk 
mechanisme binnen cellen een toename van ANGPTL4 expressie in mensen veroorzaakt 
en of de ontsteking geïnduceerde toename van plasma ANGPTL4 oorzakelijk verband 
houdt met dyslipidemie.
hoofdstuk 4 toont de waarde van MRI bij het bepalen van de regionale stijfheid van 
de aorta door het meten van de pulse wave velocity (PWV). PWV is een gevalideerde 
marker van vaatwandstijfheid en een belangrijke voorspeller van eindorgaanschade en 
HVZ. MRI is in staat om PWV nauwkeurig in meerdere locaties van de aorta te meten 
doordat MRI de werkelijk afgelegde afstand van de drukgolf in de aorta kan bepalen. 
In deze studie werd door middel van een placebo-gecontroleerde interventie gekeken 
naar het effect van een orale glucose belasting op de regionale PWV. De studie laat zien 
dat een orale glucose belasting leidt tot een regionale daling in PWV; deze daling werd 
alleen geobserveerd in de proximale maar niet in de distale aorta. Mogelijk reageren 
verschillende vaatbedden verschillend op vasoactieve invloeden zoals insuline. In 
eerdere studies werd reeds beschreven dat in vitro de bijdrage van stikstofoxide (NO) af-
hankelijke vasodilatatie groter is in de centrale arteriën dan in de distale microcirculatie. 
Deze variatie in vasculaire reactiviteit is consistent met de regionale variatie in elastine 
versus collageen ratio van de aorta. Wellicht heeft postprandiale hyperinsulinemie min-
der effect op het distale deel van de aorta. Interessant in deze studie zijn de inter-indi-
viduele verschillen in de respons op de orale glucose belasting. Proefpersonen zonder 
significante verandering in PWV hadden een grotere buikomvang. Een eerdere studie 
beschreef reeds een verminderde insuline geïnduceerde daling in vaatwandstijfheid bij 
personen met overgewicht en verminderde NO synthese is beschreven bij patiënten 
met het metabool syndroom. Toekomstige onderzoek zou met name bij patiënten met 
DM de regionale effecten van hyperglykemie op verschillende segmenten van de aorta 
en de relatie met inter-individuele variatie in regionale verandering van PWV na glucose 
belasting tot onderwerp moeten hebben.
In hoofdstuk 5 worden de gevolgen van diabetes mellitus type 1 (T1DM) op het volume 
van corticale grijze stof met behulp van voxel-based morphometry (VBM) bestudeerd. 
Dit is een relatief nieuwe en geavanceerde MRI techniek waarmee subtiele grijze stof 
veranderingen vastgesteld kunnen worden. Voor deze studie ondergingen 62 patiënten 
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met T1DM en 62 op leeftijd en geslacht gegroepeerde gezonde controle personen een 
MRI van de hersenen. De volumes van de subcorticale grijze stof structuren bestaande 
uit de basale ganglia, amygdala, hippocampus en thalamus, werden onderzocht met 
VBM. Met deze techniek tonen we aan dat bij patiënten met T1DM alle subcorticale grijze 
stof structuren behalve de amygdala, atrofie vertonen. Eerdere studies toonden al een 
verminderd volume van de hippocampus en thalamus. Aangezien T1DM vaak ontstaat 
in de kindertijd is regionaal volumeverlies mogelijk een reflectie van veranderingen 
gedurende de ontwikkeling van de hersenen. Het is interessant om te speculeren over 
de rol van de amygdala in T1DM. De amygdala heeft een primaire rol in het controleren 
van de cerebrale regulatie van de stress reactie inclusief de respons op hypoglykemie. 
Verminderde activatie van de amygdala is gevonden bij patiënten met T1DM die lage 
glucose concentraties niet tijdig voelen aankomen (hypo-unawareness). Het behoud van 
een goede respons op lage glucose waarden en activatie van de amygdala zou daarom 
de amygdala mogelijk tegen degeneratie kunnen beschermen. Het klinisch belang van 
deze intrigerende bevinding moet nog worden onderzocht. De bewustwording dat DM 
ook effecten heeft op het brein neemt langzaam toe maar toekomstig onderzoek in 
grote patiëntpopulaties is vereist om resultaten te bevestigen en om de onderliggende 
pathofysiologie te onderzoeken.
Naast veranderingen in de glucosehomeostase, wordt een vasculaire component 
verondersteld in de pathogenese van hersenschade bij T1DM. Toegenomen stijfheid 
van de aorta kan invloed hebben op de perfusie van verschillende eindorganen door 
blootstelling van de microcirculatie aan hoge druk en aan druk fluctuaties. Mogelijk 
speelt toegenomen vaatwandstijfheid van de aorta een rol in het ontstaan van hersen-
schade. De studie in hoofdstuk 6 beschrijft de associatie tussen vaatwandstijfheid van 
de aorta en diffusion tension imaging (DTI) van de hersenen bij patiënten met T1DM. 
DTI is een relatief nieuwe en gevalideerde techniek die het mogelijk maakt om de mi-
crostructuur van witte stof te meten en is gebaseerd of de mate van diffusie van water. 
Bij 41 patiënten met T1DM werd de PWV van de aorta gemeten met een 1.5 T MRI. De 
beeldvorming van de hersenen werd met een 3 T MRI scanner verricht. Dit hoofdstuk 
demonstreert dat de stijfheid van de aorta onafhankelijk geassocieerd is met witte stof 
integriteit. PWV is een surrogaat marker voor arteriële stijfheid en is een onafhankelijke 
voorspeller van beroerte en microangiopathie van de hersenen. Voor zover bekend zijn 
wij de eersten die een associatie laten zien tussen witte stof integriteit en PWV in T1DM. 
Deze bevindingen suggereren dat vasculaire problematiek bijdraagt aan hersenschade. 
Stijfheid van de grote arteriën kan schade en remodelling van de microcirculatie van 
de hersenen bewerkstelligen. Witte stof banen vormen structurele verbindingen tus-
sen verschillende hersengebieden. Eerdere studies toonden schade van de witte stof 
microstructuur bij normale veroudering en microangiopathie van het brein, echter de 
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klinische en prognostische implicaties van deze microstructurele veranderingen en de 
relatie met vaatwandstijfheid van de aorta zal uit toekomstige studies moeten blijken.
De rol van arteriële vaatwandstijfheid bij hypertensie en chronische nierschade is niet 
compleet opgehelderd. Vaatwandstijfheid en verminderde nierfunctie komen vaak ge-
lijktijdig voor bij patiënten met hypertensie. Vaatwandstijfheid kan zowel bijdragen aan 
hypertensie als aan een verminderde nierfunctie. Disproportionele vaatwandstijfheid, 
dat wil zeggen een meer uitgesproken arteriële vaatwandstijfheid van het proximale 
systeem in vergelijking tot het distale systeem, kan de pulsatiele energie richting de 
microcirculatie bevorderen. Zo is microvasculaire schade van het brein geassocieerd 
met een meer verhoogde PWV van de arterie carotis ten opzichte van de PWV van 
de aorta. In hoofdstuk 7 wordt de associatie tussen regionale PWV bij patiënten met 
hypertensie en gezonde vrijwilligers met een normale geschatte nierfunctie (creatinine 
klaring) beschreven. In deze cross-sectionele studie wordt aangetoond dat zowel de 
vaatwandstijfheid van de proximale als de distale aorta was toegenomen bij patiënten 
met hypertensie. Veranderingen in de nierfunctie waren omgekeerd gerelateerd aan 
vaatwandstijfheid, zelfs in de afwezigheid van disproportionele stijfheid. Deze relatie is 
zowel bij patiënten met hypertensie als bij gezonde vrijwilligers aanwezig en verschilde 
niet tussen de twee groepen. De resultaten benadrukken de relatie tussen vaatwand-
stijfheid van de aorta en de microcirculatie. Toekomstige studies zullen de betekenis 
moeten uitwijzen van vaatwandstijfheid voor de nierfunctie op lange termijn.
Met het toenemend aantal personen met obesitas en het metabool syndroom is de 
realisering van leefstijlinterventies een uitdaging voor de gezondheidszorg. hoofdstuk 
8 evalueert de mogelijkheid en het effect van de implementatie van leefstijlinterventie 
(inclusief mogelijke bloeddrukbehandeling) bij patiënten met het metabool syndroom 
zonder T2DM in vier huisartsenpraktijken. Het effect werd geëvalueerd met behulp 
van het regressie disontinuïteitsdesign. In dit design wordt gebruik gemaakt van een 
bepaalde afkapgrens (discontinuïteit) die gebruikt wordt om een vergelijkbare behan-
deling en controlegroep te reconstrueren. Patiënten met het metabool syndroom en 
insuline resistentie (HOMA-IR ≥ 2) werd een leefstijlinterventie programma aangeboden. 
Voor de groep zonder interventie werden mensen met het metabool syndroom zonder 
insuline resistentie (HOMA-IR < 2) geïncludeerd. De interventiegroep ontving een brief 
met een aantal leefstijladviezen. Met behulp van het regressie discontinuïteit design 
werden post-test scores voorspeld met behulp van pre-test scores en groep (wel / geen 
interventie) als covariaat. De regressiecoëfficiënt voor groep reflecteert in dit design het 
effect van de interventie.
De studie demonstreert dat het mogelijk is om een leefstijlinterventie te implemen-
teren in de huisartsenpraktijk met gebruikmaking van de bestaande faciliteiten. Met 
Nathanja Tjeerderma - binnenwerk v7b.indd   163 08-09-15   11:35
164 Chapter 10
behulp van het regressie discontinuïteit design wordt aangetoond dat de interventie 
leidt tot een afname in viscerale obesitas en een daling van de systolische bloeddruk. 
Ondanks de afname in obesitas laat de interventie geen effect op insuline resistentie 
zien. Mogelijk wordt dit verklaard door de relatief lage intensiteit van de interventie 
en het gebruik van HOMA-IR als relatief grove maat voor het kwantificeren van insuline 
resistentie. Er zijn relatief weinig leefstijlmodificatie studies uitgevoerd in de huisart-
senpraktijk, terwijl de eerste lijn wel dicht bij de algemene bevolking en de dagelijkse 
praktijk staat. Recent werden de achtergrondtheorie en de aannames voor het regressie 
discontinuïteit design met de mogelijkheden voor de klinische praktijk geïntroduceerd. 
Ofschoon minder efficiënt dan een gerandomiseerd gecontroleerd onderzoek kan deze 
methode toegepast worden in de bestaande gezondheidszorg met gebruikmaking van 
bestaande data. Onze bevindingen zijn mogelijk meer generaliseerbaar naar de dage-
lijkse praktijk dan de bevindingen van gecontroleerde gerandomiseerde onderzoeken. 
Daarom kan deze studie een effectieve strategie bieden voor de gezondheidszorg om 
de groeiende uitdaging aan te gaan in de strijd tegen overgewicht en HVZ. Toekomstige 
studies moeten de mogelijkheid en robuustheid van het regressie discontinuïteit design 
in de geneeskunde en gezondheidszorg bewijzen.
Conclusies
De studies beschreven in dit proefschrift dragen bij aan nieuwe informatie over biomar-
kers en eindorgaanschade in het metabool syndroom en DM. We hebben aangetoond 
dat insuline resistentie een sterke risico voorspeller is voor HVZ en ontdekten een 
nieuwe link tussen ANGPTL4 en systemische ontsteking. De studies verricht met MRI 
dragen bij aan de kennis over vaatwandstijfheid van de aorta en microvasculaire schade 
door het tonen van de associatie met subtiele microstructurele witte stof schade bij 
patiënten met T1DM. Om kennis van deze microstructurele schade te verbeteren zijn 
multicenter studies nodig waarbij deze associatie wordt gerelateerd aan cognitief func-
tioneren. Verder tonen de studies in dit proefschrift regionale en individuele verschillen 
in de effecten van een orale glucose belasting op vaatwandstijfheid. Meer onderzoek 
zal moeten plaatsvinden naar deze interindividuele variatie in regionale respons en de 
eventuele associatie met HVZ, met name in patiënten met het metabool syndroom en 
DM.
Het cross-sectionele design van de studies in dit proefschrift maakt dat er geen inzicht 
in veranderingen in biomarkers over de tijd is. Meer longitudinale studies zijn nodig om 
te onderzoeken of deze biomarkers HVZ kunnen voorspellen boven al bekende en veel 
gebruikte risicofactoren.
Hopelijk zal toekomstig onderzoek de bruikbaarheid van deze biomarkers tonen 
zodat patiënten met obesitas en overgewicht met een verhoogd risico op HVZ beter 
en eerder geselecteerd kunnen worden. Het vroeg kunnen voorspellen van cardiovas-
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culaire schade is relevant voor interventies gericht op het reduceren van morbiditeit 
en mortaliteit. Tot die tijd blijft de preventie van overgewicht en obesitas wereldwijd 
de meest effectieve strategie in het verminderen van metabole dysfunctie en blijft dit 
misschien wel de grootste uitdaging voor gezondheidszorg systemen wereldwijd.
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